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Summary 
Patients with neck squamous cell carcinoma from unknown primary tumor (NSCCUP) 
present with lymph node metastases without evidence for a primary tumor. Most patients 
undergo an aggressive multimodal treatment, which induces severe toxicity. Primary tumors 
of NSCCUP can be hidden in the oropharynx. Human papillomavirus (HPV) is causally 
involved in a subgroup of oropharyngeal squamous cell carcinomas (OPSCC) associated 
with early lymph node metastasis and good prognosis. Detection of markers for HPV 
transformation in NSCCUP could allow focusing on the oropharynx in primary tumor search 
and could be of value for choice and extent of treatment.  
In this retrospective multicenter study analyzing 180 NSCCUP cases from Heidelberg, 
Treviso and Barcelona, a substantial proportion (16%) was driven by HPV, mainly by HPV16 
(89%). The prevalence of HPV-driven NSCCUP varied by geographical region, ranging from 
10% in Barcelona to 20% in Heidelberg, and increased with year of diagnosis from 9% during 
1988-2004 to 23% during 2005-2014 (p=0.007).  
Compared to HPV mRNA as gold standard to identify HPV-driven tumors, sensitivity and 
specificity of HPV DNA, p16INK4a overexpression or the combination of both markers in 
NSCCUP ranged from 81-100% and 89-100%, respectively, with the lowest concordance for 
p16INK4a (kappa=0.7) and the highest for the combination (kappa=0.95). HPV seropositivity 
was a promising diagnostic marker for HPV-driven NSCCUP, since the detection of HPV 
antibodies in serum from NSCCUP patients had a sensitivity of 91% and specificity of 100% 
compared to HPV mRNA detected in the metastasis (kappa=0.93).  
HPV-driven NSCCUP were molecularly different from non-HPV-driven NSCCUP, because 
they presented with a distinct DNA methylation pattern in five gene promoters and they did 
not harbor disruptive TP53 mutations, which were common in non-HPV-driven NSCCUP 
(52% vs. 0%, p=0.0002). Patients with HPV-driven, as well as HPV-seropositive NSCCUP 
had significantly better overall and progression-free survival rates (p≤0.002). Based on the 
observed survival benefit, HPV mRNA status assessment should be included in NSCCUP 
diagnosis. Besides an extended diagnostic work-up of the oropharynx in patients with HPV-
driven NSCCUP, de-intensification of radiotherapy concentrating on the oropharynx appears 
a promising therapeutic strategy, the efficacy of which should be assessed in prospective 
trials. 
Analysis of twelve pairs of HPV16-driven OPSCC and corresponding lymph node 
metastases revealed consistent presence of HPV DNA and mRNA. However, heterogeneity 
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was observed regarding HPV integration status and DNA methylation. Viral-cellular junctions 
identified in the primary tumor were present in only 43% of corresponding metastases, while 
new viral-cellular junctions were detected in 14%. Metastases had overall lower methylation 
levels in the five gene promoters included in the assessed HPV-associated methylation 
signature compared to primary tumors.   
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Zusammenfassung 
Patienten mit Plattenepithelkarzinom von unbekanntem Primärtumor im Hals (NSCCUP) 
weisen Lymphknotenmetastasen ohne Anzeichen eines Primärtumors auf. Nichtauffindbare 
Primärtumoren können im Oropharynx verborgen sein. Eine Untergruppe von Plattenepithel-
karzinomen im Oropharynx, die sich durch frühe Lymphknotenmetastasierung und eine gute 
Prognose auszeichnen, steht in kausalem Zusammenhang mit dem humanen Papillomvirus 
(HPV). Der Nachweis von HPV-Markern im NSCCUP könnte auf einen Primärtumor im 
Oropharynx hinweisen und somit eine ausführliche diagnostische Untersuchung dieser 
Region indizieren. Zudem könnte der HPV-Status ein entscheidendes Kriterium für die Wahl 
und das Ausmaß der Behandlung darstellen. Die meisten Patienten erhalten eine aggressive 
multimodale Therapie, welche schwere Nebenwirkungen hervorrufen kann. 
Von den 180 NSCCUP Fällen aus Heidelberg, Treviso und Barcelona, welche in dieser 
retrospektiven Studie untersucht wurden, erwies sich ein beträchtlicher Anteil (16%) als 
HPV-getrieben, größtenteils durch HPV16 (89%). Der Anteil an HPV-getriebenen NSCCUP 
variierte zwischen den Zentren von 10% in Barcelona bis zu 20% in Heidelberg und stieg mit 
zunehmendem Diagnosejahr an, insgesamt von 9% zwischen 1988 und 2004 bis zu 23% 
zwischen 2005 und 2014 (p=0.007). 
Gegenüber dem HPV mRNA-Status, der als Goldstandard für die Identifizierung von HPV-
getriebenen Tumoren gilt, zeigten die Marker HPV DNA und p16INK4a Überexpression, sowie 
die Kombination dieser beiden Marker eine Sensitivität von 81% bis 100% und eine Spezifität 
von 89% bis 100%. Die Übereinstimmung mit HPV mRNA war für p16INK4a am geringsten 
(kappa=0.7) und für die Kombination am höchsten (kappa=0.95). Positiver HPV-Serostatus 
war ein vielversprechender Marker für HPV-getriebene NSCCUP, weil der Nachweis von 
HPV-Antikörpern im Serum von NSCCUP Patienten eine Sensitivität von 91% und eine 
Spezifität von 100% im Vergleich zum Nachweis von HPV mRNA in der Metastase aufwies.  
HPV-getriebene NSCCUP unterschieden sich auf molekularer Ebene von nicht-HPV-
getriebenen NSCCUP, weil sie ein bestimmtes DNA Methylierungsmuster in fünf Promotoren 
bevorzugt aufwiesen, aber keine TP53 Mutationen zeigten, die in nicht-HPV-getriebenen 
NSCCUP häufig vorkamen (52% vs. 0%, p=0.0002).  
Patienten mit HPV-getriebenen,  sowie HPV-seropositiven NSCCUP zeigten ein besseres 
Gesamtüberleben und Progressions-freies Überleben (p≤0.002). Der beobachtete 
Überlebensvorteil würde die Aufnahme der HPV mRNA-Statusbestimmung in die 
Standarddiagnostik rechtfertigen. Neben einer ausführlichen Untersuchung des Oropharynx 
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ist eine De-Intensivierung der Bestrahlung eine vielversprechende therapeutische Strategie, 
deren Wirksamkeit es in prospektiven Studien zu untersuchen gilt.  
Paarweise Untersuchungen von zwölf HPV16-getriebenen Plattenepithelkarzinomen des 
Oropharynx und dazugehörigen Lymphknotenmetastasen ergab einen übereinstimmenden 
Nachweis von HPV DNA und mRNA in allen Paaren. Allerdings wurde Heterogenität 
zwischen den Primärtumoren und Metastasen hinsichtlich des Integrationsstatus der HPV 
DNA und zellulärer Methylierungsmuster beobachtet. So waren die im Primärtumor 
identifizierten Integrationsstellen nur in 43% der Metastasen nachweisbar, allerdings wurden 
in 14% der Metastasen neue Integrationsstellen detektiert. Der Methylierungsgrad war in den 
fünf Promotoren des HPV-assoziierten Methylierungsmusters in den Metastasen insgesamt 
niedriger als in den Primärtumoren. 
Introduction 
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1  Introduction 
1.1  Human papillomavirus 
1.1.1  Classification 
Papillomaviruses are small (50-60 nm diameter), non-enveloped double-stranded DNA 
viruses [1]. Among them, 210 types are known to infect the mucosa or the skin of humans 
[152, International Human Papillomavirus Reference Center], thus called mucosal or 
cutaneous human papillomaviruses (HPVs). HPVs are classified into five genera: alpha-, 
beta-, gamma-, mu- and nu-HPVs [1]. The genus alpha is subdivided into 14 species and 
contains all mucosal and some cutaneous HPV types. HPV types are defined by the 
sequence of the L1 gene that is at least 10% dissimilar from any other type [2]. Mucosal HPV 
types are further grouped into high-risk types, which are associated with cancer, and low-risk 
types that are mainly associated with genital warts and non-malignant lesions [3]. Most  
high-risk mucosal HPV types are included in species 9 (HPV16, 31, 33, 35, 52, 58) and 
species 7 (HPV18, 39, 45, 59, 68, 70) of the genus alpha [4].  
1.1.2 HPV infection and life cycle 
Mucosal HPV types infect epithelial cells, more precisely the basal cells in stratified 
squamous epithelia, in the mucosa of the anogenital region and the upper respiratory tract 
[4]. The virus binds to heparan sulfate proteoglycans present on the cell surface [5] and is 
internalized via clathrin-dependent endocytosis [6]. The HPV genome enters the nucleus, 
where it is maintained in episomal form at low copy numbers and replicates with the host cell 
[7]. Upon differentiation, HPV-infected cells leave the basal layer towards the suprabasal 
layers, where the viral genome replicates to more than 1,000 copies per cell and expression 
of late genes is initiated, finally leading to assembly and release of viral particles from the 
epithelial surface (Figure 1) [8].  
HPV is sexually transmitted through direct genital, anal and oral contacts [9]. Genital HPV 
infection is cleared by the immune system in most cases. Clearance takes on average  
8-14 months for high-risk types [10]. However, genital HPV infection with high-risk types may 
become persistent, which is associated with the risk of progression to premalignant lesions 
and finally carcinoma [10]. Upon persistent infection, the episomal HPV genome may 
integrate into the host cell. HPV integration is considered an important driver of 
carcinogenesis [11] and is reported for up to 80% of cervical carcinomas [12] and for  
0-100% of HPV16 DNA-positive oropharyngeal carcinomas [13-18]. 
Introduction 
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Figure 1: HPV life cycle and oncogenic activity. HPV infects basal cells in stratified epithelia and replicates in 
suprabasal layers. New infectious virions are released from cells at the surface. Expression of the oncogenes E6 
and E7 leads to inhibition of apoptosis and to cell cycle progression through their interaction with the tumor 
suppressors p53 and pRb, respectively. Source: [19]. 
 
 
1.1.3 Genomic organization and HPV proteins  
The circular HPV genome consists of approximately 8,000 base pairs (bp) [4] and contains 
eight open reading frames (ORFs) on the same DNA strand [1]. It is divided into three 
regions: (1) the non-coding region, termed long control region (LCR), (2) the early region 
coding for E1, E2, E4, E5, E6 and E7 proteins, and (3) the late region encoding the structural 
proteins L1 and L2 (Figure 2). The early genes are expressed from the p97 promoter located 
in the LCR, whereas the late genes are expressed from the p670 promoter located in the E7 
region [8].  
 
Figure 2: HPV16 genome organization. The HPV16 genome consists of 7904 base pairs and comprises three 
functional regions: the long control region (LCR, red), the early region (red/blue, blue) and the late region (green). 
Modified from [4]. 
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The early proteins E1, E2, E4 and E5 play important roles in viral replication (Table 1), while 
E6 and E7 act as oncoproteins to deregulate cellular functions like cell cycle, apoptosis and 
differentiation [8]. The late proteins include the major (L1) and minor (L2) capsid proteins that 
self-assemble into viral capsids consisting of 72 L1 pentamers and a variable number of  
L2 proteins [20]. 
Table 1: HPV proteins and their function (modified from [9]). 
Protein Function  References 
E1 
 
Adenosine triphosphate(ATP)-dependent helicase; binding to origin of replication; 
unwinding viral DNA 
 [21] 
 
E2 
 
Binding to LCR and recruiting E1; regulating late gene expression 
 
 
[22, 23] 
E4 
 
Expressed as fusion protein E1^E4; inducing cell cycle arrest in G2, virus assembly 
and release 
 
[24-26] 
E5 Enhancing epidermal growth factor signaling 
 
[27] 
E6 
 
Inducing degradation of the cellular tumor suppressor p53 
 
 
[28, 29] 
E7 Inducing degradation of the cellular tumor suppressor pRb 
 
[30] 
L1 
 
Major capsid protein mediating HPV entry by binding to heparan sulfate 
proteoglycans on epithelial cells  
 [5] 
 
L2 
 
Minor capsid protein mediating transfer of the HPV genome to the nucleus of the 
infected cell 
 [31] 
 
 
1.1.4 HPV carcinogenesis  
HPV has been shown to be associated with several anogenital cancers including cervical 
[32], vaginal [33], vulvar [34], anal [35] and penile [36], as well as oral cancers [9, 37, 38].  
In order to replicate in suprabasal epithelial layers consisting of differentiating cells, in which 
DNA replication is normally suppressed, HPV needs E6 and E7 to prevent the cells from 
growth arrest and to inhibit apoptosis [39]. Inhibition of apoptosis is mediated by E6, which 
induces proteasomal degradation of the cellular tumor suppressor protein p53 by forming a 
complex with the E6-associated protein (E6AP), a cellular E3 ubiquitin ligase [28, 29]. In 
addition, E6 prevents cellular senescence by activating the human telomerase reverse 
transcriptase (hTERT) through the interaction with E6AP [40, 41]. The telomerase stabilizes 
telomere length, thereby allowing indefinite proliferation. Cellular proliferation is induced by 
E7 via disruption of the cyclin-dependent kinase (CDK) inhibitors p21WAF1/CIP1 and 
p27KIP1 [42-44] and via degradation of tumor suppressors from the Rb family (pRb, p107, 
Introduction 
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p130). Binding of E7 to pRb within a cullin 2 ubiquitin ligase complex, leads to degradation of 
pRb [30, 45] and to the release of E2F transcription factors [46]. 
1.1.5 HPV detection methods  
Commonly applied methods for the detection of HPV DNA or mRNA in human tissue are 
polymerase chain reaction (PCR) and in situ hybridization (ISH). Immunohistochemistry 
(IHC) is used to detect overexpression of the surrogate marker p16INK4a, which is triggered by 
the interaction of the viral E7 protein with cellular pRb (Figure 1). Transcriptionally active 
HPV, and thus clinically relevant infection, can only be detected by targeting HPV mRNA 
[47], which is technically challenging but possible [48-50]. While PCR and ISH can be 
designed to detect several HPV types within one reaction (multiplex), only type-specific PCR 
can distinguish detected types. In contrast, ISH and IHC allow HPV detection within the 
tissue context, but their interpretation is observer-dependent.  
A meta-analysis, comparing those techniques with the detection of HPV mRNA, which is the 
gold standard to identify HPV-driven tumors in research [47, 51, 52], revealed highest pooled 
sensitivity for HPV detection by PCR (98%), followed by IHC (94%), and lowest sensitivity for 
ISH (85%) [53]. Pooled specificity is highest for ISH (88%), but lower for IHC (83%), since 
p16INK4a overexpression might be triggered by non-viral mechanisms, and for PCR (84%) due 
to the risk of cross-contamination and the high analytical sensitivity allowing the detection of 
few individual HPV-infected cells [47, 53].  
HPV detection by PCR works well in frozen tissue, but is challenging in formalin-fixed 
paraffin-embedded (FFPE) tissue, which is often available in the clinic and for retrospective 
studies, because of formalin-induced cross-linking or potential degradation of nucleic acids. 
In contrast, ISH and IHC are well suited for FFPE tissue and for routine use in the clinic, 
since those are standard or easily transferable techniques for pathology laboratories. 
Suggested algorithms to identify HPV-driven head and neck cancers in clinical settings  
are p16INK4a IHC, if positive followed by HPV PCR [51] or ISH [47]. Only double positive  
(HPV DNA/p16INK4a-positive) cases are considered HPV-driven. The combination of positivity 
by PCR and IHC increased pooled specificity to 96% with 93% sensitivity when compared to 
positivity for HPV mRNA in the meta-analysis [53]. 
For oropharyngeal tumors, an evolving diagnostic method without need of tumor tissue is the 
detection of HPV antibodies in serum or plasma, especially antibodies against the HPV16 E6 
protein, which show strong correlation with presence of HPV DNA, mRNA and p16INK4a 
overexpression in tumor tissue [54]. Using this technique, high-risk HPV infection can even 
be detected more than ten years prior to tumor diagnosis [55]. 
Introduction 
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1.2 Head and Neck Squamous Cell Carcinoma 
1.2.1 Epidemiology 
In the head and neck region, cancers arise in the oral cavity, the pharynx with its 
subdivisions nasopharynx, oropharynx and hypopharynx, in the larynx, the nasal cavity, 
paranasal sinuses and in salivary glands (Figure 3). More than 90% of head and neck 
cancers are squamous cell carcinomas (HNSCC) [56]. Head and neck cancer is the sixth 
most common cancer [57] with 686,328 estimated new cases in 2012 worldwide and 139,603 
in Europe, comprising 61,416 cancers in the lip and oral cavity, 39,921 in the larynx, 34,094 
in the oropharynx and hypopharynx and 4,172 in the nasopharynx (http://globocan.iarc.fr). 
The estimated age-standardized mortality rate is 9.0 (males) and 1.3 (females) cases per 
100,000 (http://globocan.iarc.fr). For oropharyngeal squamous cell carcinomas (OPSCC),  
a significant increase in incidence was reported in recent years for North American and 
European countries [58]. 
 
Figure 3: Head and neck cancer regions. Head and neck cancers arise in the pharynx (including nasopharynx, 
oropharynx and hypopharynx), larynx, oral and nasal cavity, paranasal sinuses and salivary glands. Source: 
https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet. 
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1.2.2 Risk factors 
Major risk factors for head and neck cancer are tobacco and alcohol consumption. A pooled 
analysis found 35% of head and neck cancers to be attributed to the consumption of both 
tobacco and alcohol, 33% to tobacco alone and 4% to alcohol consumption alone [59]. Other 
risk factors are exposition to dust or industrial toxins, sun exposition for carcinomas in the lip, 
betel nut chewing for oral cavity carcinomas, radiation for carcinomas in salivary glands, poor 
mouth hygiene and maybe even alcoholic mouth wash for OPSCC [60]. 
In an US study population, OPSCC was significantly associated with a higher number of 
lifetime genital-sex and oral-sex partners, as well as with oral HPV16 infection [61], 
suggesting sexually transmitted HPV as a risk factor. Infection with high-risk HPV is causally 
associated with a subset of OPSCC [9, 62, 63] and Epstein-Barr virus (EBV) has been linked 
to nasopharyngeal carcinoma [64]. 
1.2.3 HPV prevalence in HNSCC 
Among head and neck cancers, the highest HPV prevalence is reported for the oropharynx, 
particularly for the palatine tonsils followed by the base of tongue (53.9% and 47.8% HPV 
DNA-positive, respectively), whereas the HPV prevalence outside the oropharynx is low [65]. 
A retrospective study analyzing 281 HNSCC cases from the United Kingdom revealed  
70% HPV DNA/p16INK4a-positive OPSCC, but only 7.1% in the hypopharynx, 3.2% in the 
larynx and 4% in the oral cavity [66]. In an international study including 3,650 HNSCC cases 
from 29 countries, the HPV-driven proportion (HPV DNA/mRNA-positive) was 21.8% in the 
oropharynx, 15.1% in the unspecified pharynx, 5.9% in the nasopharynx, 3.9% in the oral 
cavity, 3.1% in the larynx and 2.4% in the hypopharynx [67]. HPV16 is the most common 
type, ranging from 51% of all HPV DNA-positive cases in the larynx up to 83% in the 
oropharynx [67].  
The HPV prevalence varies not only by cancer site, but also by geographical region. A meta-
analysis, including 148 studies with all together 12,163 HNSCC cases from 44 countries, 
revealed for the oropharynx the highest HPV DNA prevalence in North America (60.4%) and 
the lowest in South and Central America (14.9%) [65]. Within Europe, the highest HPV DNA 
prevalence is reported in Northern Europe (56.5%), followed by Central and Eastern (41.8%), 
Western (37.6%) and Southern Europe (24.2%) for the oropharynx [65]. 
1.2.4 HPV infection in the oropharynx 
The high HPV prevalence in the oropharynx is probably due to facilitated HPV infection in the  
oropharynx, in particular in the tonsillar crypts representing a favored niche for HPV. The 
normal function of the crypts is to maximize the surface of the tonsils in order to foster the 
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transport of antigens taken up via the mouth to the lymphoid tissue [68]. The reticulated 
structure of the epithelium facilitates migration of immune cells like lymphocytes and antigen-
presenting cells (Figure 4). This structure is favorable for HPV, because the virus can easily 
migrate through the epithelium to enter the basal cells, where it replicates. It may even play a 
role in cancer progression by promoting early invasion and metastasis [68].  
Another favorable characteristic of the tonsillar epithelium is the expression of the 
programmed death-ligand 1 (PD-L1) on the membrane of epithelial cells observed in benign 
tonsils [69]. PD-L1 induces immune suppression by binding to the PD-1 receptor on T cells 
and turning those from an activated into an anergic state. The PD-L1/PD-1 pathway might 
therefore be important for persistence of HPV infection and immune resistance during 
malignant progression [69]. 
 
Figure 4: Reticulated epithelium in the tonsillar crypts. In the crypts of the palatine tonsils, the squamous 
epithelium is reticulated to allow migration of lymphocytes and cells from the antigen-presenting group (APG). 
This facilitates HPV infection and entry into the basal cells. Adapted from [68]. 
 
1.2.5 Characteristics of HPV-positive HNSCC 
Epidemiological, molecular and clinical differences between HPV-positive and HPV-negative 
HNSCC have been identified [70]: Patients with HPV DNA-positive HNSCC report higher oral 
sex exposure, but they are more often nonsmokers and mild or moderate drinkers, whereas 
heavy smokers and drinkers present with HPV DNA-negative HNSCC [61, 71]. While 
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mutations in the TP53 gene encoding the p53 protein are common in HNSCC leading to loss 
of p53 function, HPV DNA-positive HNSCC mostly present with TP53 wild-type sequence 
since p53 is inactivated by the viral E6 protein [72, 73].  
Additional analysis of HPV DNA-positive HNSCC for presence of HPV mRNA revealed a 
distinct group of HPV DNA-positive/mRNA-negative HNSCC, with molecular and clinical 
characteristics that were similar to HPV DNA-negative HNSCC [74]. Gene expression 
profiles and TP53 mutation rates in those HPV DNA-positive/mRNA-negative HNSCC were 
similar to HPV DNA-negative HNSCC, while both groups were significantly different from 
HPV-driven (mRNA-positive) HNSCC [75].  
In HPV-driven HNSCC, the CDKN2A gene encoding p16INK4a is commonly upregulated 
leading to overexpression of p16INK4a [74]. A promoter methylation signature has been 
identified to be associated with HPV-driven OPSCC [76] and to correlate with better clinical 
outcome in HNSCC patients independent of the HPV status [77].  
In previous studies, HPV DNA-positive HNSCC were more radiosensitive and those patients 
had a better survival than patients with DNA-negative HNSCC [78], which was also observed 
for patients with p16INK4a-positive compared to p16INK4a-negative HNSCC [79, 80]. Based on 
this survival benefit and the distinct characteristics, it is assessed in ongoing clinical trials 
whether HPV DNA-positive and/or p16INK4a-positive OPSCC patients might benefit from  
de-intensified treatment [81]. However, HPV mRNA analysis revealed that only HPV-driven 
OPSCC patients show a better survival, while for HPV DNA-positive/mRNA-negative OPSCC 
the survival rate is as poor as for HPV DNA-negative OPSCC [49].  
1.3 Neck Squamous Cell Carcinoma from Unknown Primary Tumor 
1.3.1 Clinical presentation 
Between 2% and 9% of all head and neck cancer patients initially present with an enlarged 
neck lymph node that turns out to be a metastasis from squamous cell carcinoma, but 
frequently without detectable primary site [82]. This syndrome is termed neck squamous cell 
carcinoma from unknown primary tumor (NSCCUP). The median size of the lymph node 
metastases is 5 cm, ranging from 2-14 cm [83], but pain is reported in only 9% of patients 
[84]. In 80-90% of patients multiple lymph nodes are affected, but only in 10% on both sides 
of the neck (bilateral vs. unilateral) [85]. Most neck lymph node metastases are located in 
lymph node level II (30-50%), followed by level I and III (10-20%), and level IV and V (5-10%) 
[86] (Figure 5). 
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Figure 5: Lymph node levels of the neck. The neck lymph nodes (left) are grouped into different regions called 
levels (right). Source: http://www.headandneckcancerguide.org/adults/introduction-to-head-and-neck-cancer/ 
neck-cancer/metastatic-lymph-nodes/anatomy/. 
 
1.3.2 Diagnostics 
Diagnostic procedures for patients with NSCCUP aim at assessing the lymph node 
involvement and searching for the primary site. Pathological staging is done by neck 
dissection to assess if only a single lymph node smaller than 3 cm (nodal stage N1) or larger 
(N2a) is affected, or multiple ipsilateral (N2b), bilateral or contralateral lymph nodes (N2c), or 
lymph nodes larger than 6 cm (N3) are affected. The position of the metastases, more 
precisely the lymph node level (Figure 5), is the best indicator for the localization of the 
primary tumor. Potential primary sites represent the organs draining into the metastatic 
lymph nodes (Table 2). Most metastases are reported in level II, where they may be derived 
from carcinomas in the nasopharynx, oropharynx or larynx, whereas primary tumors from 
metastases found in the supraclavicular level V would be expected to be located outside of 
the head and neck region. 
Table 2: Location of neck lymph nodes and possible primary sites (modified from [86]). 
Level Involved neck lymph nodes Possible primary sites 
I Submandibular Mouth floor, lips, anterior part of the tongue 
II Jugulodigastric/upper jugular Nasopharynx, base of tongue, tonsils, larynx 
III Middle jugular Supraglottic larynx, inferior pyriform sinus, postcricoid region 
IV Inferior jugular Hypopharynx, subglottic larynx, thyroid, esophagus 
V Supraclavicular Lung, thyroid, breast, gastrointestinal system 
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The standard diagnostic work-up of patients with NSCCUP includes patients’ history, 
physical examination, fine-needle aspiration biopsy (FNAB), imaging modalities like 
computed tomography (CT) and/or magnetic resonance imaging (MRI), as well as 
panendoscopy of the upper aerodigestive tract with biopsies from suspicious areas and from 
the tonsils and the base of tongue, which are common primary sites [86-88]. More recently, 
CT is combined with 18F-fluorodeoxyglucose-positron emission tomography (PET/CT). Roh et 
al. revealed a significantly higher sensitivity of PET/CT vs. CT (87.5% vs. 43.7%) for the 
detection of primary tumors in 44 NSCCUP patients [89]. 
Patients benefit from localization of the primary tumor, especially in regions of favorable sub-
sets, because they may be eligible for targeted treatment [90]. Mozet et al. reported that 
primary tumors are most often located in the head and neck region (60-80%), to a lesser 
extent in the lung (15-20%) and rarely in the gastrointestinal tract [91]. A study including 236 
US patients with lymph node metastasis in level II and/or III revealed localization of 53.4% of 
the identified primary tumors in the tonsillar fossa, followed by 43.9% in the base of tongue 
[87]. Most NSCCUP patients undergo a unilateral or bilateral tonsillectomy, if not performed 
earlier because of tonsillitis, to reveal and directly resect suspicious tonsillar carcinomas. 
Contralateral or bilateral tonsillar carcinomas were identified after bilateral tonsillectomy in 
23% to 25% (4/16 and 5/22, respectively) of NSCCUP patients presenting with unilateral 
metastases [92, 93]. The true incidence of synchronous bilateral tonsillar carcinoma is likely 
to be underreported and since bilateral tonsillectomy adds only minimal morbidity, this is 
recommended for NSCCUP patients [94].  
In general, the identified primary tumors are much smaller than the lymph node metastases. 
Zengel et al. reported an average size of 1.1 cm (0.3-2.4 cm) for primary tumors in the tonsil 
and 0.8 cm (0.2-2.2 cm) in the base of tongue in contrast to large lymph node metastases 
with an average size of 3.1 cm (0.5-6.3 cm) for tonsillar and 2.7 cm (1.4-5.5 cm) for base of 
tongue carcinomas [95]. This significant difference in size might explain why the metastasis 
is diagnosed first, whereas the primary tumor sometimes cannot be detected by imaging, but 
only after taking biopsies. In about 10% of patients with NSCCUP, the primary site is 
revealed later at some time after initial diagnosis, usually within 2 years [96]. 
1.3.3 Treatment 
Since no randomized trials have been performed yet, the choice of treatment for NSCCUP 
patients is based on evidence from small non-randomized retrospective studies, on clinical 
experience from HNSCC treatment and on institutional policy [86, 97]. It is suggested to treat 
NSCCUP similar to locally advanced head and neck cancer [98]. The guidelines of the 
European Society for Medical Oncology (ESMO) recommend neck dissection and/or bilateral 
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irradiation, and for advanced stages induction chemotherapy with platinum-based 
combination or chemoradiotherapy [99]. 
In a neck dissection, potentially affected lymph nodes are removed. While a radical neck 
dissection also targets the spinal accessory nerve, internal jugular vein and 
sternocleidomastoid muscle, a modified neck dissection spares those structures to preserve 
shoulder mobility [100]. A less invasive option is selective neck dissection removing only 
certain groups of lymph nodes in restricted levels [97]. 
Postoperative radiotherapy is particularly recommended for patients with multiple lymph 
nodes affected (N2b or higher) and/or extracapsular spread (ECS), meaning that the tumor 
penetrates the lymph node capsule, to include potential primary sites in the radiation field 
[96, 100]. For patients with poor general condition or comorbidities, or in case of risk of 
causing harm to adjacent structures, primary radiotherapy might be indicated [96]. A 
retrospective analysis of 106 NSCCUP patients revealed a lower regional recurrence rate 
and reduced appearance of the primary tumor in irradiated patients (9%) compared to 
patients that did not receive irradiation (32%, p=0.006), while overall and disease-free 
survival rates were similar [101]. 
However, more extensive treatment is associated with a higher risk for acute toxicity and late 
complications (Pavlidis 2009). High-grade acute skin toxicity was reported in 45% of 
irradiated patients, mucositis in 34-43%, dysphagia (impaired ability to swallow) in 35%, and 
high-grade late neck fibrosis and xerostomia (dryness in the mouth) in 27-34% and 34-61%, 
respectively [101, 102]. Late toxicity can be significantly decreased by using intensity-
modulated radiation therapy to deliver high dose to lymph nodes, but minimized doses to 
organs at risk like salivary glands, while reaching similar overall and disease-free survival 
rates [103]. 
Additional use of chemotherapy might be indicated to reduce the risk of distant metastases. 
Patients with advanced nodal disease had less distant metastases after chemoradiotherapy 
compared to patients treated without chemotherapy (36% vs. 59%) [104]. In contrast, no 
benefit regarding overall and progression-free survival and loco-regional control, but 
significantly increased high-grade acute (59% vs. 25%) and late toxicity (47% vs. 14%) was 
reported for patients treated with concurrent chemoradiotherapy compared to radiotherapy 
[105]. 
1.3.4 Outcome and prognostic factors 
Among all patients with carcinoma from unknown primary, patients with NSCCUP represent 
a favorable sub-set with 5-year survival rates ranging from 36% to 75% [96]. It has been 
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shown that subsequent discovery of the primary tumor in NSCCUP patients is associated 
with better overall and disease-free survival with a hazard ratio of 0.13 (0.02-0.82) and 0.25 
(0.07-0.91), respectively [90]. In addition, several clinical and epidemiological parameters 
were identified as prognostic factors. Park et al. revealed the total volume and the ratio of 
metastatic lymph nodes as independent prognostic factors for disease-free survival with 
hazard ratios of 13.08 (p=0.004) and 17.28 (p<0.001), respectively [106]. Huang et al. 
identified increased nodal stage, age at diagnosis and surgical treatment compared to non-
surgical treatment as prognostic factors with hazard ratios of 5.85 (p=0.01), 1.08 (p<0.0001) 
and 0.4 (p=0.04), respectively [107]. Extracapsular spread was an independent prognostic 
factor for overall survival (p=0.013) in a long-term follow-up study including 26 NSCCUP 
patients [108]. NSCCUP patients with low p53 expression had a significantly better 5-year 
overall survival than those with high p53 expression (69% vs. 14%) [109]. But the major 
prognostic factor discussed in the literature is HPV [110]. 
1.3.5 HPV as a biomarker in NSCCUP  
The major challenges of the NSCCUP syndrome are how to find the primary site and how to 
treat the patients without knowing the origin of the metastasis and thus the site and 
aggressiveness of the tumor. Since a subset of OPSCC has been shown to be causally 
associated with HPV [9, 62, 63, 111, 112], whereas the HPV prevalence is low outside of the 
oropharynx [65-67], detection of HPV in the lymph node metastases of NSCCUP patients 
might be an indication for an occult HPV-driven oropharyngeal primary tumor [110]. 
Furthermore, NSCCUP patients with an occult HPV-driven OPSCC might have a better 
prognosis based on the survival benefit previously reported for patients with HPV-driven 
OPSCC [49]. 
Recently, we have systematically reviewed previous knowledge about the role of HPV  
in NSCCUP [113]. In the 18 evaluated studies including altogether 659 NSCCUP patients, 
the HPV prevalence defined by positivity for both HPV DNA and p16INK4a overexpression 
varied between 0% and 85%, with an average of 36% (Table 3). Seven studies showed that 
HPV may predict an oropharyngeal localization of the primary tumor [114-120].  
Univariate survival analysis was performed in eleven studies (Table 4), and revealed in  
six studies a significantly better prognosis of patients with HPV-positive compared to  
HPV-negative NSCCUP [90, 109, 115, 118, 121, 122]. However, no significant survival 
difference was found in the remaining five studies [123-127], likely due to small study 
populations. The median number of NSCCUP cases studied was 34, ranging from 10 to 68 
(Table 3). 
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Multivariate survival analysis revealed a better overall survival of patients with HPV-positive 
NSCCUP with hazard ratios between 0.29 (p=0.03, adjusted for p53, gender, age and 
smoking) and 0.71 (p=0.009, adjusted for age, smoking, alcohol and non-keratinizing 
morphology) [109, 122, 128], and a better disease-free survival with a hazard ratio of 0.29 
(p=0.03, adjusted for ECS and p53) [115], whereas one study did not reveal a significant 
difference [126]. 
Table 3: HPV prevalence in NSCCUP (modified from [113]). 
Country Cases 
 
HPV positivity (%)  Reference 
  (n)  DNA p16INK4a both    
USA 68 
 
- 95.6 - 
 
Graboyes, 2014 [129] 
Germany 63 
 
52.4* 57.1 36.5 
 
Tribius, 2012 [123] 
Denmark 60 
 
21.7* 21.7 18.3 
 
Jensen, 2014 [122] 
Germany 59 
 
   22.0*/** 22.0 22.0 
 
Vent, 2013 / Straetmans, 2014 [118, 124] 
Korea 58 
 
 53.4** 50.0 43.1 
 
Park, 2012 [115] 
Sweden 50 
 
40.0* 42.0 36.0 
 
Sivars, 2014 [109] 
USA 39 
 
 64.1** 74.1 64.1 
 
Davis, 2014 [90] 
USA 35 
 
- 74.3 - 
 
Keller, 2013 [121] 
Japan 33 
 
 18.2** 24.2 18.2 
 
Kobayashi, 2014 [117] 
USA 34 
 
- 47.1 - 
 
Perkins, 2012 [125] 
Japan 27 
 
37.0* 51.9 37.0 
 
Yasui, 2014 [119] 
Germany 26 
 
80.8* 80.8 80.8 
 
Zengel, 2012 [95] 
USA 25 
 
 28.0** 44.0 28.0 
 
Compton, 2011 [126] 
Netherlands 20 
 
    0.0*/**   0.0   0.0 
 
Straetmans, 2014 [124] 
USA 17 
 
 58.8** 58.8 58.8 
 
Demiroz, 2014 [127] 
Germany 13 
 
92.3* 84.6 84.6 
 
Weiss, 2011 [120] 
USA 13 
 
 23.1** 15.4 15.4 
 
Chenevert, 2012 [130] 
USA 10 
 
 30.0** 30.0 30.0 
 
Begum, 2007 [116] 
both=positive for HPV DNA and p16INK4a overexpression; *DNA detected by PCR; **DNA detected by ISH 
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Table 4: Survival of NSCCUP patients in relation to HPV status (modified from [113]). 
Reference HPV positivity (HPV+) Cases Survival of HPV+ vs. HPV- 
  (n)  
Tribius (2012) DNA and p16INK4a 63 not significant 
Jensen (2014) DNA and p16INK4a 60 OS HR=0.09, p=0.02; PFS HR=0.23, p=0.04 
Park (2012) 
 
DNA (OS), p16INK4a (DFS) 
 
58 
 
4-year OS 80.8% vs. 52.7%, p<0.05;  
4-year DFS 85.0% vs. 56.9%, p=0.02     
Straetmans (2014) DNA and p16INK4a 51 not significant 
Sivars (2014) 
 
p16INK4a  50 
 
5-year OS 76.2% vs. 37.9%, p=0.007;  
5-year DFS 85.7% vs. 62.1%, p=0.03 
Davis (2014) 
 
DNA and/or p16INK4a 
 
39 
 
OS (HPV-) HR=10.3, p<0.05;  
DSS (HPV-) HR=6.7, p=0.03 
Vent (2013) p16INK4a 37 5-year OS 69% vs 33%, p<0.05     
Keller (2013) 
 
p16INK4a  
 
35 
 
5-year OS 92% vs. 30%,  p<0.0001;  
5-year DSS 92% vs. 60%,  p=0.09 
Perkins (2012) p16INK4a 34 not significant 
Compton (2011) DNA and p16INK4a 25 not significant 
Demiroz (2014) DNA and p16INK4a 17 not significant 
DNA=HPV DNA positivity (PCR or ISH), HR=hazard ratio, OS=overall survival, DSS=disease-specific survival, 
DFS=disease-free survival, PFS=progression-free survival,  
 
While in the majority of studies, the combination of HPV DNA detection and p16INK4a 
overexpression was used to identify HPV-positive NSCCUP, three studies only assessed 
p16INK4a overexpression and none considered presence of HPV mRNA, which is the gold 
standard for the identification of HPV-driven tumors [47, 49]. In this review, we pointed out 
the potential of HPV as a biomarker in NSCCUP and the need for studying larger series of 
NSCCUP patients from various regions using adequate HPV detection methods to determine 
the HPV-driven proportion and to clarify the prognostic impact of HPV. 
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1.4 Aim of this thesis 
Previous studies give evidence for HPV being a promising biomarker in patients with 
NSCCUP indicating oropharyngeal localization of the occult primary tumor and a better 
prognosis, but those studies are limited by small sample size and HPV markers analyzed. 
Aim of this study was to investigate the role of HPV in NSCCUP by determining the 
proportion of HPV-driven NSCCUP in a large multicenter study. Besides enlarging the power 
by increasing the number of analyzed cases, the retrospective setting and the inclusion of 
study centers in three European countries (Germany, Italy and Spain) allowed the analysis of 
time trends, as well as regional differences in HPV prevalence. 
In order to identify cases with actively transcribed and thus clinically relevant HPV, presence 
of HPV mRNA was assessed. In addition, the HPV mRNA status was compared to presence 
of HPV DNA and p16INK4a overexpression, which are the HPV markers widely used in clinical 
settings, to evaluate the concordance between the markers and the importance of HPV 
mRNA testing in NSCCUP. Furthermore, the potential of detecting HPV antibodies in serum 
from NSCCUP patients as a novel HPV detection method was evaluated by comparing the 
HPV serostatus with the molecular HPV status in the patients’ tumor tissue.  
The HPV status was correlated with the patients’ outcome in order to assess the prognostic 
impact of HPV detected in lymph node metastases from NSCCUP patients. NSCCUP cases 
driven by HPV were compared to non-HPV-driven cases regarding epidemiological, clinical 
and molecular differences in order to assess whether they represent a biologically distinct 
entity with a distinct risk profile. On the molecular level, the TP53 mutation status was 
assessed as a prognostic marker, as well as a prognostic promoter methylation signature 
known to be associated with HPV-driven OPSCC.  
Another aim of this thesis was to assess potential heterogeneity regarding HPV status and 
HPV-associated markers between lymph node metastases and primary tumors. Therefore, 
pairs of HPV-driven OPSCC and corresponding neck lymph node metastases were 
compared, since HPV-driven metastases in NSCCUP patients are expected to be mainly 
derived from occult HPV-driven OPSCC. In particular, the stability of integrated HPV upon 
metastasis formation and an HPV-associated DNA methylation signature were investigated.  
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2 Materials 
2.1 Reagents and solvents 
Acetic acid, 100% Merck, Darmstadt 
Aceton Sigma-Aldrich, Steinheim 
Agarose NEEO ultra-quality Carl Roth, Karlsruhe 
Bromphenol blue (BPB) marker Serva Electrophoresis, Heidelberg 
Casein Sigma-Aldrich, Steinheim 
Dideoxynucleuotides (ddNTP) Carl Roth, Karlsruhe 
Eosin Carl Roth, Karlsruhe 
Ethanol, absolute Sigma-Aldrich, Steinheim 
Ethidium bromide Sigma-Aldrich, Steinheim  
Ethylenediaminetetraacetic acid (EDTA), Invitrogen, Carlsbad, CA, USA 
 pH 8.0, UltraPureTM, 0.5M  
Eukitt O. Kindler GmbH, Freiburg 
Glycerol, 100%, anhydrous Carl Roth, Karlsruhe 
Hydrochloric acid (HCl), 37% Riedel-de Häen, Seelze 
MagNA Pure DNA Tissue Lysis Buffer Roche, Applied Science, Mannheim 
MagNA Pure LC RNA Isolation Tissue Roche, Applied Science, Mannheim 
 Lysis Buffer 
Mayer’s Haemalaun Solution AppliChem GmbH, Darmstadt 
MgCl2 Thermo Fisher Scientific 
2-(N-Morpholino) ethanesulfonic acid (MES)  Sigma-Aldrich, Steinheim 
Phosphate buffered saline (PBS), powder Biochrom GmbH, Berlin   
 without Ca2+, Mg2+ 
RNase AWAY spray Thermo Fisher Scientific, Dreieich 
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Sarcosyl (N-Lauroylsarcosine), 20%  Sigma-Aldrich, Steinheim 
Sodium dodecyl sulfate (SDS) Serva Electrophoresis, Heidelberg 
Streptavidin-R-Phycoerythrin (Strep-PE) Invitrogen, Carlsbad, CA, USA  
Tetramethylammonium chloride (TMAC) Sigma-Aldrich, Steinheim 
Tris-EDTA (TE) buffer, RNase-free, 1x  Acros Organics, Geel, Belgium 
 (10 mM Tris-HCl, 1 mM EDTA, pH 8.0)  
Tris-HCl, pH 8.0, RNase-free, 1M Jena Bioscience, Jena 
Tween20®, RNase-free Serva Electrophoresis, Heidelberg 
Water, DNase/RNase-free  Invitrogen, Carlsbad, CA, USA 
xMAPTM Sheath Fluid  Luminex Corporation, Austin, TX, USA 
Xylene Fisher Scientific, Pittsburgh, PA, USA 
2.2 Buffers 
6x BPB DNA-loading buffer 
  0.25% (w/v) bromophenol blue (BPB), 30% (v/v) glycerol, H2O ad 100 ml  
Coupling wash buffer I (Luminex) 
  50 µl Tween20®, H2O ad 250 ml  
Coupling wash buffer II (Luminex) 
  2.5 ml of SDS (10%), H2O ad 250 ml  
Detection solution DNA/RNA (Luminex) 
  2M TMAC, 75mM Tris-HCl, pH 8.0, 6mM EDTA, pH 8.0, 1.5% (w/v) Sarcosyl 
DNA hybridization solution (Luminex) 
  0.15M TMAC, 75mM Tris-HCl, pH 8.0, 6mM EDTA, pH 8.0, 1.5% (w/v) Sarcosyl 
Hybridization wash buffer (Luminex) 
  0.02% Tween20®, 1x PBS, pH 7.4 
MES coupling buffer, 0.1M (Luminex) 
  4.88 g MES, H2O ad 250 ml, adjust to pH 4.5 with NaOH (5M)  
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2.3 Enzymes 
AmpliTaq Gold DNA Polymerase (5 U/µl) Thermo Fisher Scientific, Dreieich  
Proteinase K, recombinant, PCR grade Roche, Applied Science, Mannheim 
RNase-free DNase (QIAGEN) QIAGEN, Hilden 
Taq DNA Polymerase, native Thermo Fisher Scientific, Dreieich 
2.4 Antibodies 
Biotinylated goat anti-human IgG Dianova, Hamburg 
Mouse anti-human p16, Clone: G175–405 BD Pharmingen, San Jose, CA, USA 
2.5 Commercial kits and reagents 
DNA Clean & Concentrator-5 Kit Zymo Research, Freiburg 
EZ DNA Methylation Kit Zymo Research, Freiburg 
GeneJet Gel-Extraction Kit Thermo Fisher Scientific, Dreieich 
HotStarTaq Plus Master Mix Kit QIAGEN, Hilden 
LightCycler® 480 Probes Master Roche, Applied Science, Mannheim 
LightCycler® 480 RNA Master Hydrolysis Roche, Applied Science, Mannheim 
 Probe Kit  
MagNA Pure 96 Cellular RNA Large Roche, Applied Science, Mannheim 
 Volume Kit 
MagNA Pure 96 DNA and Viral NA Large  Roche, Applied Science, Mannheim  
 Volume Kit  
Multiplex PCR Kit and PCR Plus Kit  QIAGEN, Hilden 
Nextera DNA Sample Preparation Kit Illumina, San Diego, CA, USA 
OncoE6™ Oral Test Arbor Vita Corporation, Fremont, CA, USA 
OptiView DAB IHC Detection Kit Roche, Applied Science, Mannheim 
PureLink FFPE Total RNA Isolation Kit Invitrogen, Carlsbad, CA, USA 
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Qiagen Multiplex PCR Plus Kit  QIAGEN, Hilden 
QIAquick PCR Purification Kit QIAGEN, Hilden 
QuantiTect Virus Kit QIAGEN, Hilden 
2.6 Consumables 
Conductive Filtered Tips (50 µL), QIAgility  QIAGEN, Hilden 
Cover slips Thermo Fisher Scientific, Dreieich 
Disposable protective coats (Foliodress) Hartmann, Heidenheim 
Eppendorf tubes, safe-lock (1.5, 2 ml) Eppendorf, Hamburg 
Falcon-tubes (15, 50 ml) Greiner Bio One, Frickenhausen 
Filter tips (0.1-10 µl, 2-20 µl, 20-200 µl) Starlab, Hamburg 
Filter tips (200-1000 µl) nerbe plus GmbH, Winsen  
Jung Tissue Freezing Medium (Tissue Tec) Leica Microsystems, Nussloch 
LightCycler®480 Multiwell Plate 96, white  Roche, Applied Science, Mannheim 
LightCycler®480 Sealing Foil  Roche, Applied Science, Mannheim 
Litter plastic bags nerbe plus GmbH, Winsen 
Low-retention tubes Kisker GbR, Steinfurt 
Microscope slides, SuperFrost Plus Thermo Fisher Scientific, Dreieich 
Microtome Sectioning Blades, 819 Leica Microsystems, Nussloch 
Microtome Sectioning Blades, C35 Feather pfm medical, Köln 
Multiscreen 96-well wash plates  Millipore, Bedford, MA, USA 
Pipette tips for motor pipette  Biozym, Hessisch Oldendorf  
Reagent Reservoir 4870 (50 ml)  Corning Incorporated, Corning, NY, USA 
Sealing foil Steinbrenner, Wiesenbach 
SeroMapTM beads  Luminex Corporation, Austin, TX, USA 
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Tubes, graduated, flat-base, 5 ml  QIAGEN, Hilden 
PCR plates, 96-well, skirted Thermo Fisher Scientific, Dreieich  
2.7 Laboratory devices 
ABI PRISM 3730 genetic analyzer Applied Biosystems, Foster City, CA, USA 
Agarose gel electrophoresis chamber Renner, Dannstadt 
 including gel tray and combs  
Centrifuge, Heraeus Fresco 17 Thermo Fisher Scientific, Dreieich 
Centrifuge, Heraeus Megafuge 40R Thermo Fisher Scientific, Dreieich 
8-channel pipette 0.5-10 µl, 20-200 µl Brand, Roskilde, Denmark 
8-channel-motor pipette Precision®  Biozym Diagnostik, Hessisch Oldendorf 
Cryostat  Leica Microsystems, Nussloch 
Freezer -20°C, fridge 4°C Liebherr, Bulle, Switzerland 
Freezer -80°C Forma Scientific, Ohio, USA 
Gilson pipettes (2 µl, 10 µl, 20 µl, 200 µl Gilson International, Limburg 
 1000 µl)  
Ice machine Hoshizaki, Amsterdam, The Netherlands 
Incubator, Heraeus Thermo Fisher Scientific, Dreieich  
Light microscope Leica Microsystems, Nussloch 
Luminex 100/200 Analyzer Luminex Corporation, Austin, TX, USA 
MagNA Pure 96 (MP96) System Roche, Applied Science, Mannheim 
Mastercycler Eppendorf, Hamburg 
Micro wave Sharp, Osaka, Japan 
Mini centrifuge neoLab, Heidelberg 
Mini plate spinner Woodbridge, NJ, USA 
Mini-tube rotator Fisher Scientific, Pittsburgh, PA, USA 
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NanoDrop 1000 Peqlab Biotechnologie GmbH, Erlangen 
Pasteur pipettes Sigma-Aldrich, Steinheim 
pH-Meter  inoLab®, WTW, Weilheim 
Pipetboy  Integra Biosciences, Fernwald 
QIAgility QIAGEN, Hilden 
Shaker Labnet (at 37°C) Woodbridge, NJ, USA 
Shaker UNIMAX 1010  Heidolph, Schwabach 
Thermomixer heating block Eppendorf, Hamburg 
Vacuum-wash station  Millipore, Bedford, MA, USA 
VENTANA BenchMark ULTRA Roche, Applied Science, Mannheim 
Vortex Genie  Scientific Industries, Bohemia, NY, USA 
2.8 Oligonucleotides 
Primers and probes were purchased from Sigma-Aldrich (Hamburg). Sequences of primers 
and probes for the E6*I mRNA assay (Table 5) and the multiplex HPV genotyping assay 
(Table 6) are indicated in 5’ to 3’ direction. Sequences of primers and TaqMan probes used 
for the HPV DNA real-time quantitative PCR and HPV RNA pattern detection, as well as the 
probes for the multiplex HPV genotyping assay are not presented for reason of intellectual 
property protection. 
Table 5: Primers and probes used in the E6*I mRNA assay 
HPV Forward primer Backward primer Probe 
16 GTGTACTGCAAGCAACAGTTA TCCAGATGTCTTTGCTTTTCTTCA GCGACGTGAGGTGTATTAAC 
18 TGTATATTGCAAGACAGTATT GCTGGATTCAACGGTTTCTGG ACTTACAGAGGTGCCTGCG 
31 ATGAACTAAGATTGAATTGTG TTCTTCTGGACACAACGGTCT TACTGCAAAGGTGTATAACG 
33 TACAGTGCGTGGAATGCAAA TACGTCGGGACCTCCAACACG ACGATCTGAGGGCGCTGTG 
35 GTATACTGCAAACAAGAATTA ACTGGACACAGCGGTTTTTGA GCGGAGTGAGGTGTATTACA 
52 GTGCAGTGCAAAAAAGAGCTA CAGGTCGGGGTCTCCAACACT ACGAAGAGAGGGCGCTGTTC 
53 GTGTTCTGCAAGAAGGCATTG TCTGGTGTCAACGGATGTTGA AGCGTCAGAGGTGCTACAGA 
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Table 6: Primers used in the multiplex HPV genotyping assay 
Target Primer Direction Sequence 
Cellular beta-globin MS3 Forward AATATATGTGTGCTTATTTG 
 Bio-MS10 Backward AGATTAGGGAAAGTATTAGA 
HPV L1 GP5+ Forward TTTGTTACTGTGGTAGATACTAC 
 BSGP5+-2 Forward TTTGTTACTGTTGTIGATACTAC 
 BSGP5+-3 Forward TTTGTTACTGTTGTIGATACCAC 
 BSGP5+-4 Forward TTTGTTACTTGTGTIGATACTAC 
 BSGP5+-5 Forward TTTTTAACTGTTGTIGATACTAC 
 BSGP5+-6 Forward TTTGTTACTGTGGTAGACACTAC 
 BSGP5+-7 Forward TTTGTTACAGTIGTAGACACTAC 
 BSGP5+-8 Forward TTTGTTACAGTIGTAGATACCAC 
 BSGP5+-9 Forward TTTGTTACTGTGGTAGATACCAC 
 Bio-GP6+ Backward GAAAAATAAACTGTAAATCATATTC 
 Bio-BSGP6+-b Backward GAAAAATAAATTGTAAATCATACTC 
 Bio-BSGP6+-c Backward TCTGGTGTCAACGGATGTTGA 
Bio=biotinylated 
 
2.9 Software 
EndNote X7.7.1 Thomson Reuters, New York City, NY, USA 
GraphPad Prism® 6 Graphpad Software Inc, La Jolla, CA, USA 
LightCycler® 480 Roche, Applied Science, Mannheim 
Luminex 100 IS 2.3 SP1 Software Luminex Corporation, Austin, TX, USA 
Microsoft Office Microsoft Deutschland GmbH, München 
Nucleotide Blast NCBI National Center for Biotechnology Information,  
 (https://blast.ncbi.nlm.nih.gov/)  Bethesda, MD, USA 
R Studio (https://www.rstudio.com/) Boston, MA, USA  
R Version 3.2.3 (https://www.r-project.org/) R core team 
SAS 9.4, SAS Enterprise Guide 6.1 SAS Institute Inc, Cary, NC, USA 
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2.10 Patients and clinical specimen 
NSCCUP patients treated at the ENT (Ear-Nose-Throat) clinic of the University Hospital in 
Heidelberg were identified from the laboratory (head Prof. Dr. Jochen Hess) database (n=30, 
diagnosed 1990-2011) and from the Cancer Registry and Tissue Bank of the National Center 
of Tumor Diseases (NCT) (n=19, 2009-2011). Patients from Spain (1990-2012) and Northern 
Italy (1988-2014) were identified by the collaborators (Dr. Laia Alemany and Dr. Paolo 
Boscolo-Rizzo) from the databases of the Hospital de Sant Pau in Barcelona (n=59), Treviso 
Regional Hospital (n=46), Montebelluna Hospital (n=15) and Trieste Hospital (n=11).  
Patients presenting with neck lymph node metastases were eligible for the retrospective 
NSCCUP study, if no primary tumor was found during initial diagnostic work-up. The general 
work-up included physical examination, sonography of the neck and abdomen, CT (recently 
also PET/CT) and/or MRI scan of the head and neck, CT scan of the thorax, and 
panendoscopy under general anaesthesia including microlaryngoscopy, endoscopy of the 
oropharynx, hypopharynx, epipharynx, esophagus and trachea and bronchia [88]. Biopsies 
were taken from the nasopharynx and the base of tongue, and bilateral tonsillectomy was 
performed for all cases from Heidelberg and for most cases from the other centers. During 
follow-up examinations, in 13 cases a potential primary tumor was detected within three 
years after initial diagnosis.  
FFPE tissues from lymph node metastases were available from 161 patients (Table 7). 
Among them were eleven patients from Heidelberg with additional fresh-frozen biopsies 
stored at -80°C. From 19 patients from Heidelberg only frozen biopsies were available. 
NSCCUP patients from Leipzig (n=46) with at least one serum and up to 12 serial serum 
samples were identified by the collaborators from the University Hospital database (Table 7). 
FFPE blocks from 28 of those patients were available from the Pathology archive (Table 7). 
Due to limited access, all available blocks from HPV-seropositive NSCCUP (n=10) were 
selected and the maximum number of HPV-negative NSCCUP (n=18), but sectioning and 
molecular HPV analysis was performed unaware of the HPV serostatus. 
From a previous HPV16 integration study performed by Dr. Dana Holzinger and Prof. Dr. 
Elisabeth Schwarz [Holzinger et al. in preparation] all patients with HPV16-driven OPSCC 
patients and lymph node metastasis at the time of diagnosis were selected in order to assess 
pairs of primary tumors (n=12, of which eight were re-analyzed for HPV markers including 
four that were re-analyzed for HPV integration) and metastases (n=20, 1-4 per patient). From 
those, either frozen biopsies (n=19) or FFPE tissues (n=9) were provided by the NCT Tissue 
Bank (Table 7). 
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Table 7: Clinical specimen included in this thesis. 
Study center Number Specimen Patients Diagnosis 
Heidelberg, Germany 30 FFPE tissues NSCCUP 1997-2011 
Heidelberg, Germany 30 Frozen biopsies NSCCUP 1990-2011 
Barcelona, Spain 59 FFPE tissues NSCCUP 1990-2012 
Treviso, Italy 46 FFPE tissues NSCCUP 1988-2012 
Montebelluna, Italy 15 FFPE tissues NSCCUP 2003-2014 
Trieste, Italy 11 FFPE tissues NSCCUP 2003-2014 
Leipzig, Germany 46 Serum NSCCUP 2008-2016 
Leipzig, Germany 28 FFPE tissues NSCCUP 2008-2016 
Heidelberg, Germany 19 Frozen biopsies (P/M) OPSCC 1991-2008 
Heidelberg, Germany 9 FFPE tissues (M) OPSCC 1997-2008 
FFPE=formalin-fixed paraffin-embedded, P=primary tumors,  M=metastases, NSCCUP=neck squamous cell 
carcinoma from unknown primary, OPSCC=oropharyngeal squamous cell carcinoma 
 
2.11 Ethics statement 
All patients gave informed consent. The studies were approved by the local ethics 
committees (ethic votes: 421/AULSS9 in Treviso; PR077/11 in Barcelona; 201-10-12072010 
and 202-10-12072010 in Leipzig; NCT Tissue Bank project approvals in Heidelberg: 1426, 
1427, 1811, 1812, 1874, 1901, 2016, 2178 and 2200). 
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3 Methods 
3.1 Tissue sectioning 
FFPE tissue blocks were sectioned with 5 µm thickness according to the previously 
described sandwich method [49, 88, 131]. The first and the last section were stained by 
hematoxylin and eosin to verify the tumor content. In between, tissue ribbons were prepared 
for DNA and RNA extraction, followed by one section for p16INK4a staining and additional 
sections. In order to avoid cross-contamination between consecutively sectioned tissues, 
blades were used for only one tissue block, and before and after each block the microtome 
and all instruments were extensively cleaned with acetone, 70% ethanol and RNase AWAY 
spray (Thermo Fisher Scientific, Dreieich). Potential contamination was monitored by 
sectioning healthy mouse brain tissue at least once per day, which should be free of human 
beta-globin DNA and ubiquitin C mRNA in subsequent analysis.  
Tissues from all study centers were processed according to this protocol. Tissue blocks from 
the University Hospital Leipzig were provided by the Institute of Pathology for in-house 
sectioning done by me in Leipzig. Samples from Heidelberg were sectioned by collaborators 
at the NCT Tissue Bank in accordance with their regulations. For samples from Barcelona, 
sectioning and DNA extraction were performed by collaborators at the Catalan Institute of 
Oncology (ICO, Barcelona, Spain). 
From frozen biopsies, sections of 16 µm thickness yielding around 5 mg of tissue were cut, 
homogenized with pistils in liquid nitrogen and stored at -80°C prior extraction [49, 88]. As 
described for FFPE tissue, the first and the last section were prepared for hematoxylin and 
eosin staining. New blades and gloves were used for every biopsy. The cryostat was 
extensively cleaned with acetone, and mouse biopsies were included as negative controls. 
Sections for RNA extraction were prepared at a later time point using the same protocol, but 
only for HPV DNA-positive frozen biopsies (n=2) and few HPV DNA-negative controls (n=5). 
3.2 Hematoxylin and eosin staining 
Presence of tumor cells in the tissue was validated by hematoxylin and eosin (HE) staining. 
Tissue sections were stained for 10 min in Mayer’s Haemalaun Solution (AppliChem GmbH, 
Darmstadt), rinsed with tap water for 10 min, and counterstained for 10 min in eosin (Carl 
Roth, Karlsruhe). After a short rinse with aqua bidest, sections were dehydrated for short 
time in 70%, 96% and 100% ethanol, and cleared in xylol before being covered with a cover 
slip using Eukitt mounting medium (O. Kindler GmbH, Freiburg).  
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FFPE tissue sections needed to be deparaffinized by short incubation in xylol and 
rehydration in 100%, 96% and 70% ethanol prior staining with Mayer’s Haemalaun Solution. 
Tumor content was determined under the microscope. A subset and all ambiguous sections 
were evaluated by a pathologist, in addition. Cases with less than 10% tumor content were 
excluded. 
3.3 Nucleic acid extraction 
3.3.1 DNA extraction 
Genomic DNA was released from FFPE tissue sections by incubation for 16 hours at 56°C in 
200 µl proteinase K (1 mg/ml, Roche, Applied Science, Mannheim) solution consisting of  
45 mM Tris-HCl, 0.9 mM EDTA and 0.45% Tween 20 in DNase/RNase-free water [88]. 
Samples were then incubated for 10 min at 72°C to inactivate the enzyme and were 
centrifuged to separate the paraffin layer from the aqueous phase containing the DNA. In 
order to optimize the quality of DNA extracted from FFPE by reversing potential formalin-
induced cross-linking, an aliquot of extracted DNA was subsequently incubated for 20 min at 
90°C, followed by centrifugation and transfer of the aqueous phase [88]. 
From frozen biopsies, DNA was extracted by incubating the sections in 200 µl MagNA Pure 
DNA Tissue Lysis Buffer (Roche) supplemented with proteinase K (0.5 mg/ml) for 3 hours at 
55°C. The MagNA Pure 96 system (MP96, Roche) was then used to extract and elute DNA 
in 200 µl with the MP96 DNA and Viral NA Large Volume Kit and the protocol ‘DNA tissue 
Large Volume 2.0’ (Roche). Extracted DNA was stored at -20°C prior further analysis. 
3.3.2 RNA extraction 
RNA was extracted from FFPE tissue sections using the Pure-Link FFPE Total RNA Isolation 
Kit (Invitrogen, Carlsbad, CA) [88]. In addition to the manufacturer’s instructions, DNase 
(Qiagen, Hilden) was added to the columns and incubated for 15 min prior to elution in 50 µl 
DNase/RNase-free water. 
For RNA release from frozen biopsies, sections were lyzed in 300 µl MagNA Pure LC  
RNA Isolation Tissue Lysis Buffer (Roche) [88, Supplements]. Total RNA was extracted from  
200 µl of lysate supernatant and was eluted in 50 µl using the MP96 with the MP96 Cellular 
RNA Large Volume Kit and the protocol ‘Cellular RNA Large Volume’ (Roche). Extracted 
RNA was stored at -20°C prior further analysis. 
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Figure 6: Detection of HPV DNA by multiplex HPV genotyping. The multiplex HPV genotyping (MPG) assay 
allows amplification of HPV L1 DNA from 51 mucosal HPV types by polymerase chain reaction (PCR) using 
broad-spectrum general-primers (BSGP), followed by hybridization to HPV type-specific probes coupled to distinct 
fluorescently-labeled beads. Antisense 5’-biotinylated primers (bio-BSGP6+) allow detection of PCR products by 
adding Streptavidin-R-Phycoerythrin (Strep-PE), which is measured by the green laser in the Luminex analyzer. 
The red laser detects the HPV type-specific bead set. Adapted from [132]. 
 
3.4 HPV DNA detection 
3.4.1 Multiplex HPV genotyping (MPG)  
HPV DNA was amplified by PCR and detected by hybridization to probes coupled to beads 
(Luminex Corp., Austin, Texas) as previously described [88, 132-134]. For the PCR, 5 µl of 
extracted DNA was used with the Multiplex PCR Kit (Qiagen, Hilden) and a broad-spectrum 
general-primer (BSGP5+/6+) mix that generates HPV L1 amplimers of ~150 bp and allows 
simultaneous amplification of 51 mucosal HPV types (Figure 6) [133]. PCR products were 
hybridized to HPV type-specific probes coupled to distinct fluorescently-labeled bead sets. 
After staining with Streptavidin-R-Phycoerythrin (Strep-PE, Invitrogen), bound PCR products 
were detected with the green laser of the Luminex analyzer, while the bead set representing 
the HPV type was detected with the red laser (Figure 6). The net median reporter 
fluorescence intensity (MFI) was calculated for each set after measuring at least 100 beads 
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per set. Samples with net MFI >5 for any HPV type were defined HPV DNA-positive for that 
type [134]. Human beta-globin was co-amplified to validate DNA integrity. Samples were 
invalid, if neither HPV nor beta-globin was detected. 
3.4.2 HPV16 DNA real-time quantitative PCR 
A real-time quantitative PCR (qPCR) was used to assess the quality of extracted DNA by the 
number of detectable cell equivalents (human beta-globin copies) and to determine the viral 
load (HPV copies per cell). In a total volume of 10 µl, 1 µl of extracted DNA was mixed with 
beta-globin and HPV16 E6 primers (0.5 µM), probes (0.1-0.2 µM) and 5 µl of LightCycler® 
480 Probes Master (Roche) and PCR-grade water. Quantification was done based on  
beta-globin and HPV16 standard curves. Two standards were used in 10-fold dilutions:  
0.1-100 ng/µl human placenta DNA (for beta-globin) and 1-106 HPV16 copies diluted in  
50 ng/µl human placenta DNA. 
3.5 HPV RNA detection 
3.5.1 E6*I mRNA detection 
E6*I mRNA of HPV was detected by reverse transcription PCR (RT-PCR) using the 
QuantiTect Virus Kit (Qiagen) followed by hybridization to probes coupled to beads as 
previously described [48, 88]. This assay is available for twelve carcinogenic (HPV16,  
18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59; IARC Group 1 carcinogens) and eight 
probably/possibly carcinogenic HPV types (HPV26, 53, 66, 67, 68, 70, 73 and 82; IARC 
Group 2A/B carcinogens) [135].  
For the RT-PCR, 1 µl of RNA was used. Short HPV E6*I (~65 bp) amplicons were amplified 
with HPV type-specific primers, and cellular ubiquitin C (85 bp) was co-amplified to assess 
RNA integrity. Samples were valid if positive for HPV E6*I mRNA and/or ubiquitin C. HPV  
DNA-positive samples were tested for mRNA of the HPV types detected by MPG. In addition, 
all FFPE samples were tested for ubiquitin C and HPV16 mRNA and DNA-invalid samples 
with high p16INK4a expression were additionally tested for HPV18, HPV33 and HPV35 mRNA 
[88].  
3.5.2 HPV RNA pattern detection 
In frozen biopsies, three spliced HPV16 transcripts (E6*I, E1^E4 and E1C) and the cellular 
ubiquitin C transcript were assessed by reverse transcription quantitative PCR analysis  
(RT-qPCR) [136]. A triplex RT-qPCR was used to quantify E6*I, E1^E4 and ubiquitin C, while 
the low abundant E1C transcript was quantified in a separate RT-qPCR. The two assays 
were performed using 2 µl (or 4 µl for E1C) of RNA with the LightCycler® 480 RNA Master 
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Hydrolysis Probe Kit (Roche) as previously described [136]. Samples were measured in 
duplicates.  
Copy numbers per RT-qPCR were calculated based on standard curves obtained from  
10-fold dilution of in vitro-generated transcripts (1-106 copies). Samples were classified as 
HPV16 RNA pattern-positive, if E6*I was increased relative to E1^E4 (E6*I/E1^E4 
ratio>0.095) and/or if E1C was present [136]. 
3.6 p16INK4a immunohistochemistry 
The cellular protein p16INK4a was detected in FFPE sections by IHC using the mouse  
anti-human p16INK4a antibody G175–405 (BD Pharmingen, San Jose, CA, USA) with the 
VENTANA BenchMark ULTRA system and the OptiView DAB IHC Detection Kit (Roche). 
Staining was evaluated unaware of the HPV status. Results were compared with an 
independent evaluator (Dr. Dana Holzinger) and discordant cases were discussed. p16INK4a 
overexpression was defined by moderate to strong diffuse nuclear and cytoplasmic staining 
of >25% of tumor cells in the section [88, 137]. For additional assessment of the commonly 
used 70% cut-off value, cases with p16INK4a expression in >25% but ≤70% of tumor cells were 
identified. 
As internal staining control, background p16INK4a expression in non-cancerous cells present in 
lymph nodes, such as lymphocytes, was evaluated in p16INK4a-negative cases. In case of no 
visible expression (n=5), p16INK4a staining was repeated and Ki-67 staining was performed on 
additional sections. Cases without Ki-67 expression (n=3) were invalid. 
3.7 HPV16/18 E6 oncoprotein detection 
The commercially available OncoE6TM Oral Test (Arbor Vita Corporation, Fremont, CA, USA) 
was used to detect the HPV E6 oncoprotein in HPV-driven frozen biopsies. This assay is a 
lateral diffusion immunoassay with E6 protein in lysates captured by a monoclonal antibody 
fixed to the strip and followed by staining. Sections were prepared as described above. 
According to the manufacturer’s instructions, the homogenized and conditioned tissue lysate 
was loaded on a test strip. After washing and developing, a purple internal control line 
appeared on the test strip, and two additional lines only appeared, if E6 from HPV16 and/or 
HPV18 was present in the tissue. Intensity of the bands was evaluated by comparing with a 
reading guide showing bands with signal strength ranging from 1 to 5. As negative control, a 
lysate from a non-HPV-driven tonsillar carcinoma was used. 
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3.8 HPV Serology 
HPV antibodies were detected in serum samples by bead-based multiplex serology. As 
previously described, HPV antigens were expressed in Escherichia coli as glutathione  
S-transferase (GST) fusion proteins to be coupled to glutathione-casein beads [138]. Each 
HPV antigen was coupled to a distinct fluorescently-labeled bead set. The bead mixture was 
combined with diluted serum to allow binding of HPV antibodies present in the serum. All 
sera were diluted 1:100 (first experiment), while serial serum samples from HPV-seropositive 
patients were additionally tested in 1:1,000 and 1:10,000 dilution (second experiment).  
Bound antibodies were detected using a biotinylated anti-human immunoglobulin G antibody. 
After staining with Strep-PE, MFI values were determined for each antigen in each sample by 
measuring at least 100 beads per set with the Luminex analyzer [138]. Presence or absence 
of antibodies was defined based on antigen-specific cut-off values [55] (Table 8). MFI values 
>1000 were referred to as high antibody levels. Besides HPV antigens, also major capsid 
proteins VP1 from human polyomaviruses (BK virus, JC virus, Merkel cell polyomavirus) 
were included (Table 8).  
Table 8: Antigens included in serology assay. 
Organism Virus Antigens Cut-off values 1:100 (MFI) 
Papillomavirus HPV16 E6, E7, E1, E2, E4**, L1 1000, 548, 200, 679, 876, 422 
 HPV18 E6, E7, E1, E2, L1 243, 789, 200, 600, 394 
 HPV31 E6, E7, L1 890, 200, 712 
 HPV33 E6, E7, L1 253, 500, 515 
 HPV35 E6, E7, L1 250, 500, 552 
 HPV45 E6*, E7*, L1* 249, 200, 368 
 HPV52 E6*, E7*, L1* 271, 200, 547 
 HPV58 E6*, E7*, L1* 250, 200, 371 
Polyomavirus BK virus (BKV) VP1 400/250 (1:100/1000) 
 JC virus (JCV) VP1** 250 (1:1000) 
 Merkel cell polyomavirus (MCV) VP1** 250 (1:1000) 
*included only in first experiment, **included only in second experiment (HPV-seropositive patients) 
 
Single sera of patients with serial samples were excluded, if antibody patterns were evidently 
different from the other sera of the same patient. Single nucleotype polymorphism (SNP)-
genotyping [139] was performed to compare the sequence of the DNA extracted from the 
doubted serum with the DNA from tissue, if available, or from other serum samples of the 
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same patient. DNA was extracted from 40-50 µl of serum filled up with PBS to 500 µl using 
the MP96 (Roche) with the MagNA Pure 96 DNA and Viral NA Large Volume Kit and the 
protocol ‘Viral NA Universal Large Volume’ (Roche). DNA was eluted in 50 µl and sent for 
analysis (Multiplex Cell Line Authentication, service offered by Multiplexion, Heidelberg). In 
case of less than 90% DNA sequence identity, samples were assumed to be from different 
donors. 
3.9 HPV16 integration analysis 
3.9.1 TEN16 
HPV integration sites were identified in frozen biopsies from HPV16-driven OPSCC primary 
tumors (n=5) and lymph node metastases (n=14) by using the TEN16 (Tagging, Enrichment 
and Next-generation sequencing of HPV16) strategy as previously described [12]. This 
analysis was performed in collaboration with Prof. Dr. Elisabeth Schwarz (DKFZ). For 
tagging with ten distinct barcodes, nine pools with two DNA samples (25 ng each) and one 
single DNA sample were prepared. DNA fragmentation and adaptor tagging was done by 
Nextera reaction (Illumina, San Diego, CA, USA) and was followed by purification of 
fragmented DNA and blocking of free 3’-OH termini (Figure 7). HPV16 DNA was enriched by 
Multiplex PCR using an HPV forward primer mix and a barcoded Nextera adapter primer, 
followed by pooling of all reactions into a single DNA sample and DNA purification (Figure 7). 
Prior sequencing, a fragment size selection was performed by loading the sample on an 
agarose gel with the bromphenol blue (BPB) marker and cutting the part, where fragments 
with a size between 200 bp and 500 bp would be expected. DNA was extracted from the cut 
gel, followed by ethanol precipitation to reach a final DNA concentration of 2 mg in 40 µl. 
Sequencing was done by the High Throughput Sequencing Unit (DKFZ) on an Illumina 
HiSeq2000 system.  
Analysis of sequencing data included sorting into barcode groups and alignment against the 
HPV16R genome (NC_001526.3) and the human genome GRCh38 reference sequence 
using the tools provided by the National Center for Biotechnology Information (NCBI). This 
resulted in a list of candidates for viral-cellular junctions (VCJs), which were then validated by 
PCR and gel electrophoresis. 
DNA samples from sections with less than 10% tumor content had to be excluded later, as 
well as cases, in which SNP-genotyping [139] revealed different sequences in the metastasis 
versus the primary tumor, indicating that the tissues were not from the same patient 
(Multiplex Cell Line Authentication, service offered by Multiplexion). Thus, one primary tumor 
and three metastases were excluded. 
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Figure 7: TEN16 work-flow. The TEN16 (Tagging, Enrichment and Next-generation sequencing of HPV16) 
strategy allows simultaneous detection of HPV16 integration sites in multiple samples. Pooled DNA (1) is 
fragmented and tagged with a Nextera adapter (2). Enrichment of HPV16 DNA is done by PCR using a mixture of 
the Nextera adapter primer and HPV primers covering the genes E1, E2 and E5 (4). Sequencing of a single 
pooled DNA sample (5, 6) and subsequent data processing (7) revealed four categories of potential candidate 
junctions: both reads contain only HPV sequences (category 1), or only cellular sequences (category 2), or a read 
pair consisting of one HPV sequence and one cellular sequence (category 3), or the viral-cellular junction located 
within one or both reads (category 4). Candidates from category 3 and 4 were selected for validation by PCR (8). 
Primary tumors analyzed in this study (TEN16_2016), were already included in a previous study (TEN16_2013).  
Adapted from [12]. 
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3.9.2 Validation PCR 
All VCJ candidates with at least 20 read pairs were validated by viral-cellular junction PCR 
(VCJ-PCR). Cellular and HPV primers were designed using the HUSAR sequence analysis 
package (DKFZ). For each barcode, both pooled DNA samples were analyzed for all 
detected candidate VCJs (Figure 7). Purified PCR products were sent for sequencing 
(GATC, Konstanz). Positive VCJs were validated by VCJ-PCR in all DNA samples from the 
patient, including the DNA extracted from the primary tumor, from all metastases and the 
DNA prepared for the previous study (TEN16_2013). 
3.10 Methylation analysis 
DNA methylation in the promoters of the five genes ALDH1, OSR2, GATA4, GRIA4 and 
IRX4 was quantified by PCR using bisulfite converted DNA, followed by matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MassARRAY) as previously described 
[76]. This analysis was performed in collaboration with Dr. Dieter Weichenhan (DKFZ). In 
order to allow application of this method to FFPE material, new primers were designed to 
shorten the amplicons, but still cover the informative CpG units of the five gene promoters of 
interest. One amplicon each was designed for OSR2 (174 bp), GRIA4 (180 bp) and IRX4 
(158 bp) and two amplicons each for ALDH1 (119 bp and 155 bp, respectively) and GATA4 
(131 bp and 126 bp, respectively). 
Bisulfite conversion of genomic DNA was performed using the EZ DNA Methylation Kit 
(Zymo Research, Freiburg) according to the manufacturer’s instructions. All DNA samples 
with sufficient quality, implying that beta-globin was detectable by MPG, and with enough 
volume left were included. As starting material 500-1000 ng of DNA (quantified by 
PicoGreen) were used and were eluted in 2x 30 µl M-Elution Buffer. In case of lower  
DNA concentration, samples were eluted in 2x 15 µl (300-500 ng DNA) or 2x 10 µl (<300 ng). 
The five gene promoters of interest were amplified by PCR and methylation was assessed by 
MassARRAY.  
Percent methylation values were obtained for all CpG units. If methylation levels were not 
measurable in more than 66% of the CpG units in one gene, this gene was not considered in 
this particular sample. For each gene, the mean value of all CpG units was calculated, which 
was either below (low) or above (high) the pre-defined cut-off value (ALDH1: 22.7%,  
OSR2: 7.8%, GATA4: 17%, GRIA4: 16.4%, IRX4: 12%) [76]. A methylation score (MS, range 
0-5) was determined for each patient by the number of gene promoters with a methylation 
level according to a previously identified pattern (ALDH1 low, OSR2 low, GATA4 high, 
GRIA4 high, IRX4 high methylation) [76]. 
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3.11 TP53 sequencing 
TP53 mutations were searched by analyzing exons 4 to 10, the gene region where  
the majority of mutations are localized [140], in collaboration with Dr. Roberta Bertorelle 
(Institute Oncologico Veneto, Padua, Italy). All DNA samples from HPV-driven biopsies and 
non-HPV-driven biopsies matched for gender, smoking status and age at diagnosis with 
≥50% tumor content and with sufficient DNA quality (beta-globin detected by MPG) were 
included. DNA (100-200 ng) was amplified by PCR with exon-specific primers (0.2 µM, 
sequences from IARC protocol, 2010), 1.5-2.5 mM MgCl2 and AmpliTaq Gold DNA 
polymerase (1 U/sample, Thermo Fisher Scientific). After initial denaturation at 95°C for  
10 min, 40 cycles were run comprising a denaturation step (95°C for 1 min), an annealing 
step (exon-specific, 52-59°C for 90 sec) and an extension step (72°C for 90 sec), followed by 
final extension at 72°C for 7 min. PCR products (177-353 bp) were then sequenced by 
fluorescent capillary electrophoresis (ABI PRISM 3730 genetic analyzer, Applied Biosystems, 
Foster City, CA, USA) and sequences were compared with the NCBI reference sequence 
NC_000017.10. Mutations were confirmed by additional independent PCR and sequencing 
and were grouped into disruptive (stop mutations, frameshift mutations or non-conservative 
mutations occurring within the DNA binding domain) and non-disruptive mutations (all other 
mutations) as previously described [72, 75]. 
3.12 Statistics 
Patient characteristics and follow-up data obtained from clinical charts were provided by the 
NCT Cancer Registry and collaborators in Heidelberg, Treviso, Barcelona and Leipzig.  
As previously described, overall survival (OS) time was calculated from the date of diagnosis 
to date of death (event) or end of follow-up (censored) [88]. Progression-free survival (PFS) 
time was calculated from the date of diagnosis to new lymph node or distant metastasis 
(event), malignancy in the head and neck region or outside (event), death (event) or end of 
follow-up without progression (censored). The Kaplan–Meier method was used to assess 
survival distributions. Curves were compared using log-rank tests.  
To assess the effect of HPV on OS and PFS and adjust for possible confounders, 
multivariable Cox proportional hazard regression models were fitted in collaboration with  
Dr. Manuel Wiesenfarth (DKFZ). Besides HPV status, models included age at diagnosis 
(continuous), gender, N stage (categorized into 1/2a, 2b and 2c/3, according to the 
categories for OPSCC in the AJCC Cancer Staging Manual, 7th edition), extracapsular 
spread (presence vs. absence), alcohol and tobacco consumption (current or former vs. 
never) and treatment (multimodal vs. single). Only patients with complete clinical data could 
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be included. In the multicenter study, models were stratified by country and the proportional 
hazards assumption was met after modeling a time-dependent treatment effect. While 
multimodal treatment comprised postoperative radiotherapy, chemotherapy and chemo-
radiotherapy in the multicenter study, only postoperative chemoradiotherapy was comprised 
in the serology study to meet the proportional hazards assumption. In the serology study, the 
Firth’s penalized likelihood method was applied to mitigate convergence problems arising 
from the fact that none of the female patients experienced an event. 
P values below 0.05 were considered statistically significant. For statistical analyses  
R version 3.2.3 and SAS version 9.4 was used. Sensitivity of a marker to identify HPV-driven 
NSCCUP (true positive rate) and specificity, as the probability for a negative result in non-
HPV-driven NSCCUP (true negative rate), were calculated with 95% exact Clopper-Pearson 
confidence interval using an online tool (https://www.medcalc.org/calc/diagnostic_test.php). 
The degree of marker agreement was quantified by Cohen’s kappa values that were 
calculated using a second online tool (http://www.graphpad.com/quickcalcs/kappa2/). 
Figures were generated using GraphPad Prism® version 6. 
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4 Results 
4.1 Multicenter NSCCUP study  
4.1.1 Study population  
For retrospective HPV analysis, 180 NSCCUP patients from Heidelberg (n=49), Barcelona 
(n=59) and Treviso (n=72, including patients from Montebelluna and Trieste) were eligible. 
All patients presented with neck lymph node metastasis, but no primary tumor could be 
identified during initial diagnostic work-up. The median age at diagnosis was 62 years, 
ranging from 36 to 88 years, and there was strong male predominance (88%) (Table 9) [88]. 
Current or former tobacco (84%) and alcohol consumption (69%) were common, with 64% of 
patients consuming both tobacco and alcohol, but the proportion of tobacco and alcohol 
consumers decreased with increasing year of diagnosis (p=0.006 and 0.008, respectively,  
chi squared test for trend in proportion) [88]. The majority of patients presented with 
advanced nodal disease (73% stage N2b, N2c or N3) and extracapsular spread (71%).  
All cases received surgical treatment comprising neck dissection, except for two cases 
treated by primary radiotherapy. While surgery was the only treatment for 39 cases (22%),  
it was followed by chemotherapy in two cases, by radiotherapy in 52 cases (30%) and by 
combined chemoradiotherapy in 79 cases (45%). 
The median year of diagnosis was 2004 for all 180 patients and for all patients from Treviso, 
while patients from Barcelona were diagnosed earlier (median: 2002) and patients from 
Heidelberg more recently (median: 2008). Patients from Barcelona presented with a 
significantly higher N stage (39% N2c/3 vs. 26%, p=0.006) and were more frequently treated 
by chemoradiotherapy (81% vs. 41% in Heidelberg and 19% in Treviso, p<0.0001, Pearson 
chi squared test, Table 9). Regarding age, gender, extracapsular spread, tobacco and 
alcohol consumption, no significant differences between the three study centers were 
observed (Table 9).  
4.1.2 Prevalence of HPV-driven NSCCUP 
Two molecular HPV markers (HPV DNA and E6*I mRNA) and the surrogate marker p16INK4a 
were analyzed to assess the HPV status. HPV-driven cases were defined by presence of 
HPV mRNA in combination with at least one additional marker, meaning HPV DNA and/or 
p16INK4a overexpression. Based on this algorithm, 28 (15.6%) of 180 NSCCUP were HPV-
driven [88].  The prevalence of HPV-driven NSCCUP varied from 10.2% (6/59) in Barcelona 
to 16.7% (12/72) in Treviso and up to 20.4% (10/49) in Heidelberg and increased significantly 
with year of diagnosis (p=0.004, chi squared test for trend in proportion), in total from 8.5% 
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(early period: 1988-2004, n=93) to 23.0% (late period: 2005-2014, n=87; Figure 8) [88]. This 
increase was present in all three centers, although to a different extent: while in Barcelona 
only a small increase from 8.3% to 13.0% was observed, the HPV-driven proportion 
approximately tripled in Heidelberg (10.0% to 28.0%) and Treviso (8.1% to 25.7%).  
Table 9: Characteristics of NSCCUP patients from Heidelberg, Barcelona and Treviso [88]. 
  
Heidelberg 
(n=49) 
Barcelona 
(n=59) 
Treviso  
(n=72) 
Total 
(n=180) p
†
 
Gender 
 
    
 
Male 43 (88%) 52 (88%) 63 (88%) 158 (88%) 1.0 
 
Female   6 (12%)   7 (12%)   9 (13%)   22 (12%) 
 
Age, range (median) 43-85 (61) 36-81 (61) 39-88 (63) 36-88 (62) 0.7 
Sampling period 
     
 
1988-2004 20 (41%) 36 (61%) 37 (51%) 93 (52%) 0.1 
 
2005-2014 29 (59%) 23 (39%) 35 (49%) 87 (48%) 
 
Tobacco 
     
 
Ever 33 (73%) 52 (88%) 63 (88%) 148 (84%) 0.07 
 
Never 12 (27%)   7 (12%)   9 (13%)   28 (16%) 
 
 
N/A 4 
  
4 
 
Alcohol 
     
 
Ever 30 (68%) 43 (73%) 48 (67%) 121 (69%) 0.7 
 
Never 14 (32%) 16 (27%) 24 (33%)   54 (31%) 
 
 
N/A 5 
  
5 
 
N stage 
     
 
1, 2a 21 (45%) 12 (20%) 14 (19%) 47 (26%) 0.006 
 
2b 14 (30%) 24 (41%) 39 (54%) 77 (43%) 
 
 
2c, 3 12 (26%) 23 (39%) 19 (26%) 54 (30%) 
 
 
N/A 2 
  
2 
 
Extracapsular spread 
     
 
Yes 27 (63%) 43 (75%) 51 (72%) 121 (71%) 0.4 
 
No 16 (37%) 14 (25%) 20 (28%)   50 (29%) 
 
 
N/A 6 2 1 9 
 
Treatment 
   
 
 
 
Surgery only   8 (18%) 10 (17%) 21 (29%) 39 (22%) <0.001 
 
+RT 15 (34%) 0 37 (51%) 52 (30%) 
 
 +CRT 18 (41%) 47 (81%) 14 (19%) 79 (45%)  
 Other* 3 (7%) 1 (2%) 0 4 (2%)  
 
N/A 5 1 
 
6 
 
Median follow-up, years 1.7 3.3 2.9 2.5 
 
N/A=not available, +RT=postoperative radiotherapy, +CRT=postoperative chemoradiotherapy, *including 
radiotherapy only (n=2) and postoperative chemotherapy (n=2),  
†Pearson chi squared test (age categories: ≥62 vs. <62), Fisher’s exact test for treatment 
Statistically significant values are displayed in bold. 
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Figure 8: Time trend of HPV-driven NSCCUP. The proportion of HPV-driven NSCCUP diagnosed in the early 
period 1988-2004 (grey) is compared to the late period 2005-2014 (black) for all 180 cases and by center. The 
number of cases (N) analyzed in each period is depicted below the graph. Pearson chi squared test for trend in 
proportion was used to calculate the p value. Published in [88]. 
 
HPV16 was by far the most common HPV type, since 25 (89%) of 28 HPV-driven NSCCUP 
were driven by HPV16 [88]. The remaining three cases were driven by HPV18, HPV33 and 
HPV35, respectively (4% each). DNA from HPV90 was detected in one case. Since HPV90 
is not known to be a (probable) high-risk type, no assay was available for detecting HPV90 
E6*I mRNA. But this case did not show p16INK4a overexpression and was thus considered to 
be non-HPV-driven. In another non-HPV-driven case, DNA from both HPV52 and HPV53 
was detected, but no mRNA of those types and no p16INK4a overexpression was detected. 
4.1.3 HPV detection and marker concordance 
Based on the defined algorithm, all 28 HPV-driven NSCCUP were positive for HPV mRNA. In 
addition, DNA of the same HPV type was detected in all cases. P16INK4a overexpression was 
observed in 25 of the 26 HPV-driven NSCCUP with FFPE tissue available for IHC (Figure 10, 
11). One case positive for both HPV16 DNA and mRNA showed no p16INK4a staining signal in 
the tumor islands, while faint signals were detectable in the surrounding non-cancerous cells.  
In the two HPV16-driven frozen biopsies, p16INK4a expression could not be evaluated, but 
transformation-specific HPV16 RNA patterns (E6*I/E1^E4 ratio>0.095 and E1C) were 
present. In addition, the HPV16 E6 protein could be detected in lysates from these two 
biopsies with intermediate to high signal strength (2 and 4, respectively, on a scale ranging 
from 0 to 5, Appendix Figure A-1) using the commercially available OncoE6TM Oral Test 
(Arbor Vita Corporation, Fremont, CA, USA). 
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While DNA extracted from frozen biopsies was of sufficient quality, extraction from FFPE 
tissue was challenging, as 102/161 (63%) FFPE samples were DNA-invalid (beta-globin-
negative by MPG) after standard extraction. DNA extraction was improved by incubating the 
extracted DNA for 20 min at 90°C, which resulted in an increased detection of beta-globin 
copies by qPCR  (median: 1235 vs. 467 copies per µl DNA, p=0.002, paired student’s t-test; 
Figure 9). Re-testing DNA-invalid samples by MPG after this additional incubation reduced 
the total number of invalid samples to 58/161 (36%). Two cases were HPV16 DNA-positive 
after re-testing, of which one was positive but the other one was negative for HPV16 mRNA 
and p16INK4a overexpression, while the remaining 42 samples were HPV DNA-negative. 
 
Figure 9: Beta-globin detection in DNA from FFPE tissue after standard vs. improved extraction. DNA 
extracted from FFPE tissue was tested for beta-globin (BG) by quantitative real-time PCR prior to and after 
additional incubation for 20 min at 90°C. BG-negative samples are set to 0.15 to be visible on log scale. DNA 
samples were tested by MPG with valid result (black), invalid result (red) or valid result only after incubation 
(blue). Paired student’s t-test was used to calculate the p value. 
 
The proportion of DNA-invalid cases was significantly increased among the cases diagnosed 
between 1988 and 2004 (44/93, 47%) compared to those diagnosed between 2005  
and 2014 (14/87, 16%, p<0.0001, Pearson chi squared test). However, all 180 cases were  
mRNA-valid. Only three cases (diagnosed in 1993, 2002 and 2004, respectively) were 
p16INK4a-invalid, because of no visible p16INK4a expression in surrounding non-cancerous cells 
and no signal in the subsequent Ki-67 staining. Overexpression of p16INK4a was equally 
common in HPV mRNA-negative cases that were DNA-negative (7/72, 10%) or DNA-invalid 
(6/55, 11%, p=0.8, Pearson chi squared test). 
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Among the 102 cases with valid result for HPV mRNA, DNA and p16INK4a expression, all 
three markers were concordantly positive or negative in 90 (88%) cases. The discordant 
cases comprised seven cases (7%) with only p16INK4a overexpression, three cases with only 
HPV DNA detected (3%), and a single case (1%) with HPV DNA and p16INK4a overexpression 
in the absence of HPV mRNA (Figure 10).  
 
Figure 10: Marker distribution among the 37 cases positive for at least one marker with valid result for all 
markers. The 26 HPV-driven cases on the left are defined by presence (black box) of HPV mRNA with at least 
one additional marker. Not shown are the 65 cases negative for all three markers, DNA-invalid cases (n=58), and 
cases not tested for RNA (n=1) or p16INK4a (n=19, including 2 HPV-driven cases). Published in [88]. 
 
Table 10: HPV marker concordance in NSCCUP. 
  
HPV mRNA Sensitivity Specificity Cohen’s Kappa 
  N % %  
  + - (95% CI) (95% CI) (95% CI) 
HPV DNA* + 28 4 100 (88-100) 95 (88-98) 0.91 (0.82-1.00) 
 
- 0 76 
   
p16INK4a (>25%) + 25 14 96 (80-100) 89 (83-94) 0.71 (0.58-0.85) 
 
- 1 117 
   
DNA/p16INK4a (>25%)** + 25 1 96 (80-100) 99 (93-100) 0.95 (0.88-1.00) 
 
- 1 75 
   
p16INK4a (>70%) + 21 9 81 (61-93) 93 (87-97) 0.70 (0.55-0.84) 
 
- 5 122 
   
DNA/p16INK4a (>70%)** + 21 0 81 (61-93) 100 (95-100) 0.86 (0.74-0.98) 
 
- 5 76 
   
*only DNA-valid cases were considered, **positivity for both HPV DNA and p16INK4a overexpression 
CI=confidence interval  
 
When considering all cases with valid results for at least two markers, compared to HPV 
mRNA positivity as gold standard for HPV-driven cases, positivity for HPV DNA, p16INK4a 
overexpression and the combination of both had a sensitivity of 100%, 96% and 96%, and  
a specificity of 95%, 89% and 99%, respectively (Table 10). However, differences between 
the markers were not statistically significant, since 95% confidence intervals were 
overlapping (Table 10). The lowest concordance to HPV mRNA had p16INK4a overexpression 
(kappa=0.71). While in this study p16INK4a overexpression was defined by staining of more 
HPV mRNA
HPV DNA
p16INK4a
HPV-driven (n=26) non-HPV-driven (n=11)
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than 25% of tumor cells (Figure 11), in other publications 70% has been applied as cut-off 
value. When this more stringent cut-off was explored, the sensitivity of p16INK4a 
overexpression to identify HPV mRNA-positive cases was lower and specificity was slightly 
higher (81% and 93% for the 70% cut-off value vs. 96% and 89% for the 25% cut-off value, 
respectively).  
 
Figure 11: p16INK4a expression levels in FFPE tissue. FFPE tissue sections from three patients stained for 
p16INK4a (left column) and hematoxylin and eosin (HE, right column) are shown exemplarily for two HPV16  
DNA-positive and mRNA-positive NSCCUP with p16INK4a expression in >70% (ID 33) or 25%-70% (ID 70) of 
tumor cells in comparison to an HPV mRNA-negative NSCCUP without p16INK4a expression (ID 77). Weak 
p16INK4a expression in surrounding non-cancerous cells served as staining control. Images were acquired with 10x 
magnification. The scale bars in the lower right corner represent 100 µm.  
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Table 11: Clinical parameters of NSCCUP patients in relation to HPV status [88]. 
 
 
N HPV-driven non-HPV-driven p† 
 
 
 (n=28) (n=152)  
Gender 
    
Male 158 21 (75%) 137 (90%) 0.02 
Female 22   7 (25%)   15 (10%) 
 
Age, years (median) 
 
39-79 (59) 36-88 (62) 0.2 
Region 
    
Heidelberg 49 10 (36%) 39 (26%) 0.3 
Treviso 72 12 (43%) 60 (39%) 
 
Barcelona 59   6 (21%) 53 (35%) 
 
Tobacco 
    
Ever 148 18 (64%) 130 (88%) 0.002 
Never 28 10 (36%)   18 (12%) 
 
 
N/A 4  4  
Alcohol 
    
Ever 121 12 (44%) 109 (74%) 0.003 
Never 54 15 (56%)   39 (26%) 
 
 
N/A 5 1 4  
N status 
    
1, 2a 47 12 (43%) 35 (23%) 0.002 
2b 77 15 (54%) 62 (41%) 
 
2c, 3 54 1 (4%) 53 (35%) 
 
 
N/A 2  2  
Lymph node level 
    
II 36 9 (75%) 27 (47%) 0.07 
I, III, IV, V 34 3 (25%) 31 (53%) 
 
 
N/A 110 16 94  
Extracapsular spread 
    
Yes 121 18 (64%) 103 (72%) 0.4 
No 50 10 (36%) 40 (28%) 
 
 
N/A 9  9  
Treatment 
    
Surgery only 39   9 (32%) 30 (21%) 0.6 
  
+RT 52   7 (25%) 45 (31%) 
 
 
+CRT 79 12 (43%) 67 (56%)  
Other* 4   0 4 (3%) 
 
 
N/A 6  6  
N/A=not available, +RT=postoperative radiotherapy, +CRT=postoperative chemoradiotherapy, *including 
radiotherapy only (n=2) and postoperative chemotherapy (n=2),  
†Pearson chi squared test, student’s t-test for age, Fisher’s exact test for treatment 
Statistically significant values are displayed in bold. 
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4.1.4 Risk factor assessment in HPV-driven vs. non-driven NSCCUP 
Compared to patients with non-HPV-driven NSCCUP, those with HPV-driven NSCCUP were 
significantly more often females (25% vs. 10%, p=0.02), less frequently current or former 
tobacco (64% vs. 88%, p=0.002) and alcohol consumers (44% vs. 74%, p=0.003) and 
presented less frequently with far advanced nodal disease (4% vs. 35% N2c/3, p=0.002 
Pearson chi squared test, Table 11) [88].  From 70 patients from Treviso the neck lymph 
node level was known, in which the lymph node metastasis was located. Most HPV-driven 
metastases were found in level II (9/12, 75%, p=0.07), while only 47% (27/58) of the  
non-HPV-driven metastases were found in level II (Table 11). In some patients, HPV-driven 
metastases were also found in level III (n=2) and IV (n=1). Regarding study center, age at 
diagnosis, extracapsular spread and treatment, no significant differences were observed 
between patients with HPV-driven and non-HPV-driven NSCCUP (Table 11). 
4.1.5 Prognostic value of HPV 
The impact of the HPV status on survival could be evaluated for 27 patients with HPV-driven 
and 137 with non-HPV-driven NSCCUP, for which all covariate information was available. 
Patients with HPV-driven NSCCUP had a significantly better overall and progression-free 
survival (p=0.002 and p=0.0006, respectively, log-rank test; Figure 12) [88]. Progression was 
reported for only eight (30%) of the 27 HPV-driven NSCCUP compared to 99 (72%) of the 
137 non-HPV-driven NSCCUP, and only seven (26%) patients with HPV-driven NSCCUP 
died compared to 89 (65%) patients with non-HPV-driven NSCCUP.  
 
Figure 12: Survival of NSCCUP patients in relation to HPV status. Kaplan–Meier curves for overall survival 
(left) and progression-free survival (right) with 95% confidence interval (shaded areas) are compared for  
HPV-driven (HPV+, grey) versus non-HPV-driven (HPV-, black) patients. Only patients with all covariate 
information available were included (n=164). The numbers (N) at risk are depicted for each group below the 
graph. Log-rank test was used to calculate p values. Published in [88]. 
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The prognostic role of HPV was confirmed by multivariable Cox regression analysis revealing 
significant hazard ratios of 0.30 for overall survival and 0.27 for progression-free survival 
(p=0.008 and p=0.003, respectively, Wald test; Table 12), when compared patients with 
HPV-driven versus non-HPV-driven NSCCUP [88]. Besides HPV status, also multimodal 
treatment was significantly associated with better progression-free survival, but a time-
dependent effect of treatment needs to be considered. Unfavorable prognostic factors for 
both overall and progression-free survival were increased age, presence of extracapsular 
spread and advanced nodal stage with hazard ratios ranging from 1.03 to 2.69 (Table 12), 
while gender, tobacco and alcohol consumption had no significant effect on survival.  
Table 12: HPV status and clinical parameters in relation to survival [88]. 
Multivariable analysis (n=164)*: OS 
 
PFS 
  
HR (95% CI) 
 
p† 
 
HR (95% CI) 
 
p† 
HPV-driven (yes/no) 0.30 (0.12 - 0.73) 
 
0.008 
 
0.27 (0.11 - 0.65) 
 
0.003 
Gender (female/male) 0.71 (0.31 - 1.65) 
 
0.4 
 
0.48 (0.21 - 1.11) 
 
0.09 
Age at diagnosis 1.03 (1.01 - 1.06) 
 
0.003 
 
1.03 (1.01 - 1.05) 
 
0.01 
Tobacco (ever/never) 1.00 (0.48 - 2.10) 
 
1.0 
 
1.10 (0.53 - 2.26) 
 
0.8 
Alcohol (ever/never) 1.00 (0.57 - 1.75) 
 
1.0 
 
1.12 (0.66 - 1.91) 
 
0.7 
N stage 
   
 
   
     2b vs. 1,2a 2.02 (1.05 - 3.91) 
 
0.04 
 
1.71 (0.93 - 3.14) 
 
0.08 
     2c,3 vs. 1,2a 2.31 (1.16 - 4.57) 
 
0.02 
 
2.69 (1.44 - 5.04) 
 
0.002 
Extracapsular spread (yes/no) 2.61 (1.41 - 4.85) 
 
0.002 
 
2.20 (1.26 - 3.83) 
 
0.005 
Treatment (multimodal/single) 0.09 (0.01 - 1.46) 
 
0.09 
 
0.12 (0.03 - 0.43) 
 
0.001 
Treatment.Time** 2.18 (0.56 - 8.51) 
 
0.3 
 
3.20 (1.25 - 8.18) 
 
0.02 
OS=overall survival, PFS=progression-free survival, HR=hazard ratio, CI=confidence interval,  
single=surgery or radiotherapy only, multimodal=postoperative radiotherapy/chemotherapy/chemoradiotherapy  
*stratified by country, **modelling of time-dependent treatment effect, †Wald test 
Statistically significant values are displayed in bold. 
 
4.1.6 HPV in patients with initial NSCCUP 
In 13 patients, a squamous cell carcinoma was detected within three years after initial 
NSCCUP diagnosis that might represent the primary tumor (Table 13). In two of these 
patients, the initial NSCCUP was HPV-driven. Twelve tumors were detected in the head and 
neck region and one in the lung. Of the twelve patients with head and neck tumor, six (50%) 
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were only treated by neck dissection after NSCCUP diagnosis, but did not receive 
postoperative radiotherapy and/or chemotherapy. 
Most patients (n=7) had a base of tongue carcinoma, among which one patient had 
presented with an HPV35-driven NSCCUP 18 months earlier (Table 13) and also the base of 
tongue carcinoma contained HPV35 DNA and mRNA and overexpressed p16INK4a.  
In addition, serum samples were available from time of: NSCCUP diagnosis (month 0), a  
follow-up visit (month 14) and the base of tongue carcinoma diagnosis (month 18). High 
levels of HPV35 E7 antibodies (median fluorescence intensity >3000) and low to 
intermediate levels of HPV35 E6 antibodies (200-700) were present in all three sera.  
One patient with subsequently detected carcinoma in the nasopharynx had an HPV16-driven 
NSCCUP. Since nasopharyngeal carcinomas are frequently associated with Epstein-Barr-
Virus (EBV), the NSCCUP was additionally analyzed for presence of EBV DNA [141], but 
was found negative. 
Table 13: Patients with carcinoma detected within three years after NSCCUP diagnosis. 
Patient Carcinoma Time after NSCCUP Postoperative  NSCCUP 
  diagnosis (months) Treatment HPV status 
ID 161 Base of tongue 10 No No 
ID 10 Base of tongue 11 CRT No 
ID 86 Base of tongue 18 No HPV35 
ID 13 Base of tongue 26 No No 
ID 31 Base of tongue 29 CRT No 
ID 166 Base of tongue 32 No No 
ID 49 Base of tongue 35 CRT No 
ID 150 Oral cavity 1 RT No 
ID 139 Retromolar trigone (oral cavity) 12 No No 
ID 132 Pyriform sinus (hypopharynx) 12 RT No 
ID 9 Nasopharynx 14 CRT HPV16 
ID 143 Helix (ear) 24 No No 
ID 85 Lung 29 CRT No 
RT=radiotherapy, CRT=chemoradiotherapy 
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4.2 HPV serology in NSCCUP patients 
4.2.1 Study population  
Serological samples (n=134) from 48 patients presenting with NSCCUP at the University 
Hospital in Leipzig between 2008 and 2016 (median: 2011) were collected and available for 
retrospective analysis to assess the potential of HPV antibodies as a diagnostic marker for 
HPV-driven NSCCUP and as a prognostic marker in patients with HPV-driven NSCCUP.  
From three patients that had discordant HPV status by serology versus molecular  
HPV markers, DNA extracted from the serum and the metastasis was analyzed by  
SNP-genotyping [139] to ascertain that paired samples truly were derived from the same 
patient. This led to the exclusion of two patients due to sequence identity of only 57% and 
73%, respectively, indicating that serum and tissue were not from the same donor.  Thus, 
128 sera from 46 patients were included in the analyses presented here.  
The majority of patients was male (41/46, 89%), and the median age at diagnosis was  
59 years (ranging from 38 to 80) (Table 14). Tobacco and alcohol consumption were 
common (36/46, 78% and 41/46, 89%, respectively). At presentation, the majority of patients 
had advanced nodal disease (29/45, 64% N2b/2c/3) and extracapsular spread (32/42, 76%). 
Most patients (38/44, 86%) received surgical treatment, which was the only treatment in ten 
patients (23%) and was followed in six patients (14%) by radiotherapy and in 21 patients 
(48%) by chemoradiotherapy. Four patients (9%) received radiotherapy alone, one patient 
chemotherapy alone and one patient postoperative chemotherapy, while another patient 
refused treatment. One patient presented with a base of tongue carcinoma 15 months after 
surgical treatment, likely to be the primary tumor. 
The serology study population from Leipzig and the population of the multicenter study 
(Chapter 4.1.1, Table 9) were similar regarding age at diagnosis, gender, tobacco 
consumption, N stage and extracapsular spread. However, alcohol consumption was more 
common in the Leipzig study population (89% vs. 69%, p=0.006, Pearson chi squared test) 
and fewer patients from Leipzig received postoperative radiotherapy (14% vs. 30%, 
p=0.0009), but were more often treated by radiotherapy alone (9% vs. 1%). 
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Table 14: Characteristics of NSCCUP patients from Leipzig in relation to HPV serostatus. 
  
Total
 
(n=46)
 
Seropositive 
(n=13) 
Seronegative
 
(n=33) 
p† 
 
Gender
 
    
 
 Male 41 (89%) 11 (85%) 30 (91%) 0.6 
 
 Female   5 (11%)   2 (15%) 3 (9%) 
 
Age, years (median) 38-80 (59) 52-79 (66) 38-80 (58) 0.2 
Tobacco
 
    
 
 Ever 36 (78%) 6 (46%) 30 (91%) 0.003 
 
 Never 10 (21%) 7 (54%) 3 (9%) 
 
Alcohol
 
    
 
 Ever 41 (89%) 11 (85%) 30 (91%) 0.6 
 
 Never   5 (11%)   2 (15%) 3 (9%) 
 
N stage
 
    
 
 1, 2a 16 (36%)   7 (54%)   9 (28%) 0.4 
 
 2b 22 (49%)   5 (38%) 17 (53%) 
 
 
 
 2c, 3   7 (16%) 1 (8%)   6 (19%) 
 
 
 N/A 1 1   
Extracapsular spread
 
    
 
 Yes 32 (76%) 6 (55%) 26 (84%) 0.09 
 
 No 10 (24%) 5 (45%)   5 (16%) 
 
  N/A 4 2 2  
Treatment
 
    
 
 Surgery only 10 (23%) 3 (23%)   7 (23%) 0.7 
 
 +RT   6 (14%) 3 (23%)   3 (10%)  
 
 +CRT 21 (48%) 5 (38%) 16 (52%)  
 
 Other*   7 (16%) 2 (15%)   5 (16%)  
  N/A 2  2  
N/A=not available, +RT=postoperative radiotherapy, +CRT=postoperative chemoradiotherapy, *including 
radiotherapy only (n=4), chemotherapy only (n=1), postoperative chemotherapy (n=1) and one untreated case, 
†Fisher’s exact test, student’s t-test for age 
Statistically significant values are displayed in bold. 
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4.2.2 HPV antibody patterns 
Out of 46 NSCCUP patients, 13 (28%) were HPV-seropositive as defined (i) for HPV16 and 
HPV18 by high antibody levels (MFI >1000) against E6 and/or presence of antibodies 
against at least three type-concordant early antigens (E6, E7, E1, E2, E4) [54, 55] and (ii) for 
the other HPV types (HPV31, 33, 35, 45, 52, 58) by presence of type-concordant E6 and E7 
antibodies.  
Most seropositive patients were seropositive for HPV16 (10/13, 77%), single patients were 
seropositive for HPV18 and HPV33, respectively, and one patient for both HPV31 and 
HPV35. High antibody levels against HPV16 E6 were present in nine of the ten  
HPV16-seropositive patients and HPV16 E6, E7, E1 and E2 antibodies were simultaneously 
present in seven patients. One HPV16-seropositive patient lacked E6 antibodies but had 
high antibody levels against HPV16 E7, E1 and E2 (Figure 13). HPV16 E4 and L1 antibodies 
were only detectable in three (30%) and five (50%) of the HPV-seropositive cases, 
respectively (Figure 13).  
The HPV18-seropositive case had high antibody levels against HPV18 antigens E7, E1, E2 
and L1, but lacked E6 antibodies (Figure 13). One case had high antibody levels against 
HPV31 E6, E7 and L1, but also against HPV35 E6 (low) and E7 (high). The  
HPV33-seropositive case had high antibody levels against HPV33 E6 and E7, but no L1 
antibodies. 
 
Figure 13: Antibody reactivity patterns against HPV antigens in 13 HPV-seropositive NSCCUP patients at 
diagnosis. Presence (light/dark blue = low/high levels) or absence (black) of antibodies against HPV16, HPV18, 
HPV31/35 or HPV33 proteins, measured in 1:100 serum dilution and based on pre-defined cut-offs [54], is 
depicted. High antibody levels (dark blue) were defined by MFI >1000. For some HPV types some antigens were 
not available (grey) and one HPV16-seropositive serum was not tested for E4 (grey). 
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In 16 (48%) out of the 33 HPV-seronegative patients, antibodies were detected against 
single (n=10), two (n=5, type-concordant only 1) or three (n=1, not type-concordant) HPV 
antigens (Table 15). Antibodies were mainly against HPV L1 (n=13), followed by E7 (n=6), 
E2 (n=2) and E6 (n=2). 
Table 15: Individual antibody reactivity in HPV-seronegative NSCCUP patients. 
Patient HPV16 HPV18 HPV31 HPV33 HPV35 HPV45 HPV52 HPV58 N 
ID L52 L1 
 
L1 
 
L1 
   
3 
ID L29 E2, L1 
       
2 
ID L24B 
   
E7 E7 
   
2 
ID L17 
   
L1 L1 
   
2 
ID L51 
    
L1 
 
L1 
 
2 
ID L34 
     
E7 
 
L1 2 
ID L23 
 
E2 
      
1 
ID L41 
 
L1 
      
1 
ID L8 
   
E7 
    
1 
ID L33 
   
E7 
    
1 
ID L30 
    
E6 
   
1 
ID L24 
    
L1 
   
1 
ID L38 
     
E6 
  
1 
ID L36 
      
E7 
 
1 
ID L6 
       
L1 1 
ID L13 
       
L1 1 
Only HPV-seronegative patients with antibody reactivity against at least one (N≥1) HPV antigen are shown. 
 
4.2.3 Diagnostic value of HPV seropositivity 
From 28/46 (61%) NSCCUP patients with serum samples, FFPE tissues from the lymph 
node metastases were available for molecular HPV status assessment to be compared with 
the serological HPV status. Of these patients, nine were seropositive for HPV16 and one for 
both HPV31 and HPV35. The molecular HPV status was defined as described for the 
multicenter study (Chapter 4.1.2). Eleven (39%) of the 28 metastases were HPV-driven, nine 
(82%) by HPV16 and one each by HPV31 and HPV33. All HPV16-driven metastases were 
positive for HPV16 mRNA, DNA and p16INK4a overexpression and the patients were 
concordantly HPV16-seropositive (Table 16). Patients with HPV16-driven NSCCUP showed 
significantly increased antibody reactivity against the individual HPV16 antigens E6, E7, E1, 
E2 and L1 compared to patients with non-HPV16-driven NSCCUP (p≤0.002, Mann-Whitney 
U test, Figure 14). 
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Figure 14: Antibody reactivity to individual HPV16 antigens in NSCCUP patient serum at time of diagnosis 
by molecular HPV status. Serum antibody reactivity at 1:100 dilution against HPV16 antigens is depicted as 
median fluorescence intensity (MFI) for patients with HPV16-driven (HPV16+) compared to non-HPV16-driven 
(HPV16-) NSCCUP. HPV16-driven NSCCUP are defined by presence of HPV16 mRNA together with HPV DNA 
and/or p16INK4a overexpression in the lymph node metastasis. Patients were defined HPV16-seropositive (blue, 
high HPV16 E6 antibody levels and/or antibodies against ≥3 early antigens), HPV31/35-seropositive (red, E6 and 
E7 antibodies of HPV31 and HPV35) or HPV-seronegative (black). The median of MFI levels (short solid line) and 
antigen-specific cut-off values (dotted line) are depicted. P values were calculated using Mann-Whitney U test. 
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The patient (ID L40) with HPV31-driven metastasis had high antibody levels against HPV31 
E6, E7 (and also L1), but additional antibody reactivity against HPV35 E6 and E7 (Figure 
13). In another patient (ID L24B) with HPV33-driven metastasis, the serological HPV status 
was not concordant with the molecular HPV status, since this case had antibodies against 
HPV33 E7, but not against HPV33 E6 (and L1), and was thus defined HPV-seronegative 
(Table 15). 
In total, of the eleven cases with HPV-driven metastases, ten cases were seropositive for the 
same HPV type, but one case was HPV-seronegative. All 17 cases with non-HPV-driven 
metastases were HPV-seronegative, resulting in an overall sensitivity of 91% and specificity 
of 100% for identifying HPV-driven NSCCUP by HPV serology (Table 16). NSCCUP driven 
by HPV16 were identified with 100% sensitivity and specificity. 
Table 16: Concordance of HPV serostatus and molecular HPV status in 28 NSCCUP patients. 
  
HPV mRNA* Sensitivity Specificity Cohen’s Kappa 
  n % %  
  + - (95% CI) (95% CI) (95% CI) 
HPV serostatus + 10 0 91 (59-100) 100 (81-100) 0.93 (0.78-1.00) 
 
- 1 17 
   
HPV16 serostatus + 9 0 100 (66-100) 100 (82-100) 1.00 (1.00-1.00) 
 
- 0 19 
   
HPV serostatus was defined by presence of antibodies against HPV16/18 E6 (MFI >1000) and/or ≥3 early type-
concordant antigens, or against type-concordant E6 and E7 of any other HPV type. 
*Only positivity for HPV16 mRNA was considered for comparison with HPV16 serostatus.  
 
 
4.2.4 Prognostic value of HPV antibodies 
As observed for patients with HPV-driven NSCCUP in the multicenter study (Chapter 4.1.4, 
Table 11), tobacco consumption was significantly less common also among HPV-
seropositive versus HPV-seronegative NSCCUP patients (46% vs. 91%, p=0.003, Fisher’s 
exact test, Chapter 4.2.1, Table 14). HPV-seropositive patients presented with less advanced 
N stage (54% vs. 28% N1/2a) and less frequently with extracapsular spread (55% vs. 84%) 
compared to HPV-seronegative patients, while gender distribution, age at diagnosis, alcohol 
consumption and treatment were similar (Table 14).  
HPV-seropositive NSCCUP patients showed significantly better overall and progression-free 
survival compared to HPV-seronegative patients (p=0.004 and p=0.02, log-rank test; Figure 
15). Multivariable Cox regression analysis revealed for HPV-seropositivity hazard ratios of 
0.09 (p=0.001, Wald test) and 0.03 (p=0.002) for overall and progression-free survival, 
respectively (Table 17). Another prognostic factor was multimodal treatment with a hazard 
ratio of 0.09 (p=0.007) and 0.02 (p=0.0007) for overall and progression-free survival, 
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respectively. Extracapsular spread was an unfavorable prognostic factor for progression-free 
survival with a hazard ratio of 6.64 (p=0.02), while no impact on survival was observed for 
gender, age at diagnosis, tobacco and alcohol consumption and N stage (Table 17).   
 
Figure 15: Survival of NSCCUP patients from Leipzig in relation to HPV serological status. Kaplan–Meier 
curves for overall (left) and progression-free survival (right) with 95% confidence interval (shaded areas) are 
compared for HPV-seropositive (HPV+, grey) versus HPV-seronegative (HPV-, black) cases. The numbers at risk 
are depicted below the graph. P values were calculated using log-rank test. 
 
Table 17: HPV serostatus and clinical parameters in relation to survival. 
Multivariable analysis (n=39): OS 
 
PFS 
  
HR (95% CI) 
 
p† 
 
HR (95% CI) 
 
p† 
HPV serostatus (positive/negative) 0.09 (0.01 - 0.42) 
 
0.001 
 
0.03 (0.002 - 0.18) 
 
0.0002 
Gender (female/male) 0.23 (0.001 - 2.07) 
 
0.2 
 
0.26 (0.002 - 2.31) 
 
0.3 
Age at diagnosis 1.04 (0.98 - 1.13) 
 
0.2 
 
1.07 (0.99 - 1.16) 
 
0.07 
Tobacco (ever/never) 3.56 (0.60 - 24.2) 
 
0.1 
 
  0.69 (0.10 - 4.65)* 
 
0.7 
Alcohol (ever/never) 0.55 (0.10 - 4.48) 
 
0.5 
 
1.64 (0.22 - 21.7) 
 
0.7 
N stage 
   
 
   
     2b vs. 1,2a 3.24 (0.92 - 14.3) 
 
0.07 
 
1.25 (0.40 - 4.15) 
 
0.7 
     2c,3 vs. 1,2a 0.37 (0.05 - 2.13) 
 
0.3 
 
0.54 (0.10 - 2.61) 
 
0.4 
Extracapsular spread (yes/no) 2.46 (0.52 - 22.4) 
 
0.3 
 
6.64 (1.32 - 79.3) 
 
0.02 
Treatment (multimodal/other**) 0.09 (0.01 - 0.53) 
 
0.007 
  
0.02 (0.001 - 0.22) 
 
0.0007 
Firth’s penalized likelihood method has been applied to mitigate convergence problems due to the fact that none 
of the female patients experienced an event. Statistically significant values are displayed in bold. 
OS=overall survival, PFS=progression-free survival, HR=hazard ratio, CI=confidence interval, multimodal= 
postoperative chemoradiotherapy, *PH assumption violated, **including one untreated case, †Wald test 
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4.2.5 HPV antibody levels in follow-up sera from seropositive NSCCUP 
From five HPV-seropositive (3x HPV16, 1x HPV18 and 1x HPV33) NSCCUP patients 
between two and nine serial serum samples were available for follow-up periods of at least 
eight months and up to 60 months after treatment. HPV antibody levels in patients with  
HPV-driven OPSCC and NSCCUP are often very high and are thereby frequently in 
saturation, when measured at the routine 1:100 serum dilution. To better assess potential 
changes in antibody levels, all sera from HPV-seropositive patients with serial serum 
samples were additionally measured at 1:1,000 and 1:10,000 serum dilutions. 
During follow-up, all patients remained HPV-seropositive, and HPV antibodies were still 
detectable at 1:10,000 serum dilution even five years after neck dissection (Figure 16). HPV 
antibody levels decreased within about one year irrespective of the HPV antigen, whereas 
antibody levels against the control antigens from the polyomaviruses BK (BKV), JC (JCV) 
and Merkel cell polyomavirus (MCV) did not (Figure 16). While in one patient (ID L7)  
HPV16 E6 and E7 antibody levels within eight months showed a reduction by 83% and 74%, 
respectively, in another case (ID L49) HPV18 E7, E1 and E2 antibody levels decreased by 
only 16%, 31% and 16%, respectively. In two further patients with longer follow-up, the main 
decrease in HPV antibody levels was observed within the first 18 months, ranging from 25% 
(ID L18, E2) to 52% (ID L16, E7), while within the following 18 months antibody levels 
decreased only by additional 14% and 10%, respectively.  
One patient (ID L5) with HPV16-driven NSCCUP, who received surgical treatment but 
declined chemoradiotherapy, was diagnosed with an HPV16-driven base of tongue 
carcinoma 15 months after NSCCUP diagnosis. In this case, HPV16 antibody levels also 
decreased initially after surgical removal of the lymph node metastasis by 18% (E1), 34% 
(E6) and 36% (E7 and E2). However, relapse with new lymph node metastasis at month 29 
was associated with an antibody level increase relative to the level measured immediately 
after surgical removal of the base of tongue carcinoma, not for E6 but for all three other 
HPV16 antigens (17% for E2, 19% for E1 and 57% for E7), reaching similar levels as 
measured at the time of NSCCUP diagnosis (81% for E2, 101% for E1 and 121% for E7) 
(Figure 16). In the following 18 months, antibody levels again decreased to 40%-50% (E6, 
E2, E1) or 85% (E7).   
Results 
64 
 
 
Figure 16: Antibody levels in follow-up sera from NSCCUP patients. HPV serum antibody levels of  
HPV-seropositive NSCCUP patients with up to nine follow-up sera collected within six years after neck dissection 
(time=0) measured at 1:1,000 (HPV16/18 E7 and E1, HPV33 E6) or 1:10,000 (HPV16 E6 and E2, HPV18 E2, 
HPV33 E7) serum dilution are depicted as normalized median fluorescence intensity (MFI) with 1 representing the 
value immediately after treatment (dotted line), and 0.5 a reduction of 50%. For sera collected within two 
consecutive days, the average value is depicted. Levels of JC virus (JCV), BK virus (BKV) and Merkel cell 
polyomavirus (MCV) control antigens were added (1:1,000, grey). Only antigens that were seropositive at time=0 
are shown. HPV16 E4 and L1 were excluded due to rather low antibody reactivity (Figure 13) and weakest 
association with HPV-driven NSCCUP (Figure 14). The dashed vertical lines indicate subsequent discovery of the 
primary tumor (at month 15) and relapse (at month 29).  
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4.3 TP53 mutations in NSCCUP 
4.3.1 TP53 mutation frequency 
In order to investigate potential additional molecular differences between HPV-driven and 
non-HPV-driven NSCCUP, presence of tumor suppressor TP53 mutations was assessed in 
lymph node metastases from 70 NSCCUP patients from Heidelberg, Barcelona and Treviso 
by amplification and sequencing of the TP53 exons 4-8, which encode the DNA binding 
domain of p53. Exons 9 and 10 were additionally assessed in 57 patients. 
Amplification and sequencing was successful for 397 (86%) of the 464 assessed exons.  
The success rate per exon ranged from 77% for exon 4 to 91% for exons 6 and 9 (Table 18). 
All seven exons (4-10) were successfully sequenced in 42 patients, and exons 4-8 in  
45 patients. Of the 397 sequenced exons, 19 (5%) were mutated. The mutation frequency 
per exon varied between 0% for exon 9 and 10% for exon 7 (Table 18).  
Only single TP53 mutations were detected in 19 patients (Table 19), but since in five of these 
patients one or two exons each could not be sequenced, additional mutations cannot be 
excluded. Out of the 19 identified TP53 mutations, 16 (84%) were disruptive, comprising 
missense mutations (n=7) that were all located within the DNA binding domain (amino acids 
102-292), frameshift mutations (n=4, three resulting in missense mutations at a later amino 
acid position), as well as nonsense mutations (n=5, four within the DNA binding domain, 
Table 19). 
Table 18: Mutation frequency per TP53 exon in NSCCUP tumor DNA. 
TP53  exon N N (%) N % mutated of 
 assessed sequenced mutated N sequenced 
4 70   54 (77) 4 7 
5 70   61 (87) 3 5 
6 70   64 (91) 4 6 
7 70   61 (87) 6 10 
8 70   59 (84) 1 2 
9 57   52 (91) 0 0 
10 57   46 (81) 1 2 
Overall 464 397 (86) 19 5 
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Table 19: TP53 mutations detected in NSCCUP tumor DNA. 
TP53 exon cDNA description Protein description Effect Database report 
4 c.182delA p.D61fs frameshift  
4 c.214_215delCGinsT p.R72fs*50 frameshift/missense  
4 c.245_246insTG p.P82fs*41 frameshift/missense Cosmic 
4 c.366G>A p.V122V synonymous  
5 c.451C>A p.P151T missense IARC, Cosmic 
5 c.455_456insC p.P152fs*34 frameshift/missense  
5 c.535C>A p.H179N missense IARC, Cosmic 
6 c.584T>A p.I195N missense IARC, Cosmic 
6 c.585_586CC>TT p.R196* nonsense IARC, Cosmic 
6 c.586C>T p.R196* nonsense IARC, Cosmic 
6 c.660T>A p.Y220* nonsense IARC, Cosmic 
7 c.705C>T p.N235N synonymous  
7 c.707A>G p.Y236C missense IARC, Cosmic 
7 c.708C>A p.Y236* nonsense IARC, Cosmic 
7 c.712T>A p.C238S missense IARC, Cosmic 
7 c.743G>A p.R248Q missense IARC, Cosmic 
7 c.753C>T p.I251I synonymous  
8 c.833C>T p.P278L missense IARC, Cosmic 
10 c.1024C>T p.R342* nonsense IARC, Cosmic 
del=deletion; ins=insertion; fs=frameshift; *stop codon position;  
IARC database: http://p53.iarc.fr/; Cosmic database: http://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TP53 
 
4.3.2 TP53 mutations in relation to HPV status 
NSCCUP patients with disruptive TP53 mutation in any exon (n=16) were compared to 
patients without disruptive mutation but with complete sequence of exon 4-9 (n=32) 
regarding HPV status and clinical parameters. None of the 17 patients with HPV-driven 
NSCCUP presented with disruptive TP53 mutation, but one patient had a non-disruptive 
mutation in exon 4. In contrast, disruptive mutations were found in 16/31 (52%) patients with 
non-HPV-driven NSCCUP (p=0.0002, Fisher’s exact test). 
Patients with non-HPV-driven NSCCUP without disruptive TP53 mutation presented with less 
extracapsular spread, but with significantly advanced N stage compared to patients with 
HPV-driven NSCCUP or disruptive mutation. Regarding age at diagnosis, gender, treatment, 
tobacco and alcohol consumption, no statistically significant differences were observed 
(Table 20).  
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Table 20: Characteristics of NSCCUP patients in relation to TP53 mutation status. 
  
Total
 
(n=48)
 
HPV+ TP53 wt 
(n=17) 
HPV- TP53 wt 
(n=15) 
HPV- TP53 mut
 
(n=16) 
p† 
 
Age, years (median) 39-85 (58) 39-79 (62) 40-85 (56) 42-80 (62) 0.5 
Gender
 
 
 
   
 
 Male 39 (81%) 12 (71%) 12 (80%) 15 (94%) 0.2 
 
 Female   9 (19%)   5 (29%)   3 (20%) 1 (6%) 
 
Tobacco
 
 
 
   
 
 Ever 38 (79%) 11 (65%) 12 (80%) 15 (94%) 0.1 
 
 Never 10 (21%) 6 (35%)   3 (20%) 1 (6%) 
 
Alcohol
 
 
 
   
 
 Ever 32 (67%) 9 (53%) 12 (80%) 11 (69%) 0.3 
 
 Never 16 (33%) 8 (47%)   3 (20%)   5 (31%) 
 
N stage
 
 
 
   
 
 1, 2a 19 (40%) 9 (53%) 3 (20%) 7 (44%) 0.04 
 
 2b 20 (42%) 8 (47%) 6 (40%) 6 (38%) 
 
 
 
 2c, 3   9 (19%) 0 6 (40%) 3 (19%) 
 
Extracapsular spread
 
 
 
   
 
 Yes 26 (58%) 11 (65%) 5 (36%) 10 (71%) 0.2 
 
 No 19 (42%) 6 (35%) 9 (64%)   4 (29%) 
 
  N/A 3  1 2  
Treatment
 
 
 
   
 
 Surgery only   9 (20%) 4 (24%) 1 (8%) 4 (25%) 0.1 
 
 +RT 18 (39%) 4 (24%)   5 (38%) 9 (56%) 
 
  +CRT 19 (41%) 9 (53%)   7 (54%) 3 (19%)  
  N/A 2  2   
HPV+=HPV-driven; HPV-=non-HPV-driven; wt=wild-type sequence or non-disruptive mutation; mut=disruptive 
mutation; N/A=not available 
†Fisher’s exact test (age categories: ≥62 vs. <62) 
Statistically significant values are displayed in bold. 
 
4.3.3 Prognostic value of TP53 mutations 
TP53 mutation status and HPV status were correlated with survival. Patients with HPV-driven 
NSCCUP without disruptive TP53 mutation (n=18) had the highest overall and progression-
free survival rate (Figure 17). A significant difference was revealed for progression-free 
survival (p=0.04, log-rank test). Among the patients with non-HPV-driven NSCCUP (n=30), 
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those with disruptive TP53 mutation (n=15) showed slightly better survival than the patients 
without disruptive mutation within the first six years after diagnosis, but the difference was 
not statistically significant. 
 
Figure 17: Survival of NSCCUP patients in relation to TP53 mutation status and HPV. Kaplan–Meier curves 
for overall (left) and progression-free survival (right) are compared for patients with non-HPV-driven NSCCUP 
with (TP53 mut HPV-, red) or without disruptive TP53 mutation (TP53 wt HPV-, black) and patients with HPV-
driven NSCCUP without disruptive mutation (TP53 wt HPV+, blue). The numbers at risk are depicted below the 
graph. Log-rank test was used to calculate p values. 
 
4.4 Methylation analysis of NSCCUP 
4.4.1 HPV-associated methylation signature 
In order to assess epigenetic differences between HPV-driven and non-HPV-driven 
NSCCUP as another potential prognostic marker, a pre-defined methylation signature was 
analyzed in metastatic lymph nodes from 103 NSCCUP patients, a subset of the series from 
Heidelberg, Barcelona and Treviso, in collaboration with Dr. Dieter Weichenhan (DKFZ). The 
methylation signature was defined by low methylation in the promoters of the genes ALDH1 
and OSR2 and high methylation in the promoters of GATA4, GRIA4 and IRX4 and was 
previously shown to be associated with HPV-driven HNSCC and to predict better survival 
[76, 77]. Based on the methylation levels in those five promoters, a methylation score (MS, 
number of promoters with methylation level according to this signature, range 0-5) was 
calculated to group patients accordingly. 
Tumor DNA from HPV-driven compared to non-HPV-driven NSCCUP was characterized by 
lower methylation levels in ALDH1 and OSR2 (p=0.4 and p=0.09, respectively; Mann-
Whitney U test) and significantly higher methylation levels in GATA4, GRIA4 and IRX4 
(p=0.0008, p=0.0005 and p=0.01, respectively, Figure 18). Of the HPV-driven NSCCUP, 
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76% (16/21) had a MS of ≥3, compared to only 32% (26/82) of the non-HPV-driven NSCCUP 
(p=0.0002, Pearson chi squared test). Thus, the methylation signature was significantly 
associated with HPV. 
 
Figure 18: Methylation levels in five gene promoters of HPV-driven vs. non-HPV-driven NSCCUP. The 
percentage of methylation in the promoters of the five genes included in the pre-defined methylation signature is 
compared for non-HPV-driven (HPV-, open circles) vs. HPV-driven (HPV+, filled triangles) NSCCUP, defined by 
molecular HPV status (HPV+: presence of HPV16 mRNA together with HPV DNA and/or p16INK4a 
overexpression). The median methylation level is depicted for each group (red bar). An asterisk (*) indicates a 
significant difference (Mann-Whitney U test). 
 
4.4.2 Prognostic value of methylation signature and HPV 
Although the methylation signature was associated with HPV-driven NSCCUP, patients with 
MS≥3 did not have a significantly better overall or progression-free survival (p=0.6 and 
p=0.1, respectively, log-rank test; Figure 19, upper part) compared to patients with MS<3. 
But a survival benefit of patients with HPV-driven NSCCUP was observed (Figure 19, lower 
part), especially for the five patients presenting with NSCCUP with MS<3. However, when 
patients were regrouped into those with low (0-1), intermediate (2-3) or high MS (4-5), a 
trend for better overall and progression-free survival with increasing MS was observed 
(p=0.07 and p=0.03, respectively, Appendix, Figure A-2). 
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Figure 19: Survival of NSCCUP patients in relation to MS and HPV. Kaplan–Meier curves for overall (left) and 
progression-free survival (right) are compared for NSCCUP patients with at least three gene promoters (MS≥3, 
MS+, red) versus less than three promoters (MS<3, MS-, black) according to the pre-defined methylation 
signature (low methylation in the promoters of ALDH1 and OSR2, and high in GATA4, GRIA4 and IRX4). The 
lower panel shows survival of NSCCUP patients with MS≥3 (MS+) and MS<3 (MS-) by HPV status, meaning 
further subdivided into patients with HPV-driven (HPV+) and non-HPV-driven (HPV-) NSCCUP. The numbers at 
risk are depicted below the graph. Log-rank test was used to calculate p values. The time axis has been adapted 
to [76] for better comparison. 
 
 
4.5 Paired analysis of OPSCC primary tumors and metastases 
In order to assess potential heterogeneity between HPV-driven primary tumors and their 
corresponding lymph node metastases regarding HPV status and HPV-associated markers, 
pairs of primary tumors and metastases were compared. In particular, HPV-driven OPSCC 
were investigated, since those are the suspected source of HPV-driven lymph node 
metastases in NSCCUP patients. 
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4.5.1 HPV markers in primary tumors vs. metastases 
Twelve HPV16-driven OPSCC primary tumors and corresponding lymph node metastases 
(n=20, 1-4 per patient) were available for paired HPV marker comparison. The three 
analyzed markers, HPV16 DNA (detected by MPG, and additionally by qPCR in frozen 
biopsies, if available), HPV16 mRNA (detected by E6*I assay and additionally by RNA 
pattern analysis in frozen biopsies, if available) and p16INK4a (only tested in five metastases 
with FFPE tissue available), were concordantly present in primary tumors and corresponding 
metastases.  
However, the viral load (HPV16 E6 copies per tumor cell, assessed in frozen biopsies only) 
varied between primary tumors and corresponding metastases, as well as between 
metastases from the same patient (Table 21). Of the five analyzed metastases, two had a 
higher viral load compared to the primary tumor (factor 2-4) and three had a lower viral load 
(factor 2-6), while the intra-experimental and inter-experimental coefficient of variation, the 
ratio of standard deviation to mean, were very low (range: 0.1-2.2%). 
Table 21: Viral load in primary tumors vs. corresponding metastases. 
Patient HPV16 E6 copies / tumor cell 
 Primary Tumor Metastasis 1 Metastasis 2 
661   1.6 3.2 - 
993 12.6 2.2 - 
1449   4.8 2.1 - 
1553   0.2 0.8 0.1 
 
 
4.5.2 HPV16 integration status in the primary tumors 
The integration status of HPV16 DNA in the twelve primary tumors had been assessed in a 
previous study by TEN16 analysis (Tagging, Enrichment and Next-generation sequencing of 
HPV16, TEN16_2013, Holzinger et al, in preparation). In eight of the twelve primary tumors, 
a single (n=5), two (n=2), or four (n=1) viral-cellular junctions (VCJs) were identified, while 
four primary tumors had no integration. Since HPV16 DNA was concordantly present in the 
pairs, viral integration was assessed in lymph node metastases for comparison with the 
primary tumor. 
4.5.3 Presence of viral-cellular junctions of the primary tumors in the metastases 
Presence of all VCJ (n=13) previously identified in the eight primary tumors was assessed by 
VCJ-PCR in all available lymph node metastases (n=14, 1-4 per patient) from the same 
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patients. VCJs of the primary tumors were present in only 6/14 (43%) metastases (Table 22). 
In three patients (1425, 1464, 1650) all VCJ (four, two and two, respectively) were detected 
in their single metastasis, while the single VCJ of patient 1553 was detectable in only three 
out of four metastases (Figure 20, upper panel). The VCJs identified in the primary tumors of 
patients 661, 993, 1529 and 1643 were undetectable in all corresponding metastases (three, 
one, two and one, respectively).  
Table 22: Validation of viral-cellular junctions of the primary tumors in corresponding metastases. 
Patient VCJ Primary Tumor  VCJ Metastasis 
 
TEN16_2013  M1 M2 M3 M4 
1425 1, 2, 3, 4  1,2,3,4 - - - 
1464 1, 2  1,2 - - - 
1553 1  no 1 1* 1* 
1650 1, 2  1, 2 - - - 
993 1  no - - - 
661 1  no no no - 
1529 1  no no - - 
1643 1  no - - - 
VCJ=viral-cellular junction, TEN16=Tagging, Enrichment and Next-generation sequencing of HPV16  
*FFPE biopsies, in which integration sites were validated by VCJ-PCR  
 
4.5.4 Identification of new viral-cellular junctions 
A new TEN16 analysis (TEN16_2016) was performed in order to search for other VCJs that 
might be present only in the metastases. In addition, four previously assessed primary 
tumors, of which frozen biopsies were available for new sectioning, were re-analyzed to 
search for VCJs that might have been missed in the previous analysis (TEN16_2013, 
Holzinger et al, in preparation), since the processing of sequencing data has been further 
optimized. Furthermore, analysis of new sections from the same biopsy enables investigation 
of potential intratumoral heterogeneity. 
All previously identified VCJs were confirmed in the re-analyzed primary tumors (Table 23). 
Additional 19 candidates for new VCJs were selected based on at least 20 read pairs from 
sequencing analysis. Validation VCJ-PCRs were performed for all 19 candidates, but only six 
(32%) could be confirmed, of which four were identified in primary tumors. In the primary 
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tumor of patient 1529, two additional VCJ were identified that were missed in the previous 
analysis (TEN16_2013), but were validated by VCJ-PCR using the DNA aliquot prepared for 
that analysis (Table 23). Additional two VCJ were identified in the primary tumor of patient 
993 that could be validated by VCJ-PCR using the DNA extracted from the section prepared 
in 2016, but not in the DNA from the section prepared from the same biopsy in 2013, 
indicating intratumoral heterogeneity (Table 23). 
Table 23: Identification of new viral-cellular junctions in primary tumors and metastases. 
Patient VCJ Primary Tumor  VCJ Metastasis 
 
TEN16_2013 TEN16_2016  M1 M2 M3 M4 
1553 1 1  2 1 1* 1* 
1529 1, 2, 3 1, 2, 3  2, 4 w/o* - - 
993 1 1, 2, 3  w/o - - - 
661 1 1  w/o w/o* w/o* - 
339 w/o na  w/o w/o - - 
1449 w/o na  w/o - - - 
1639 w/o na  w/o - - - 
1641 w/o na  w/o w/o - - 
VCJ=viral-cellular junction, na=not assessed, w/o=without integration, TEN16=Tagging, Enrichment and Next-
generation sequencing of HPV16, *FFPE biopsies, in which integration sites were validated by VCJ-PCR 
New VCJ are displayed in bold. 
 
However, new VCJs were identified in single metastases from two patients with known VCJ 
in their primary tumor. Metastasis 1 from patient 1529 had only one of the three VCJs 
present in the primary tumor, but one additional VCJ, that was exclusively present in this 
metastasis (Table 23). Metastasis 1 from patient 1553 was negative for the VCJ present in 
the primary tumor and in all three other metastases, but had another VCJ, which was not 
found in the primary tumor and in the other metastases by VCJ-PCR (Table 23, Figure 20). 
In four patients without VCJ in the primary tumor (339, 1449, 1639 and 1641), no VCJs were 
found in their corresponding metastases (Table 23).  
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Figure 20: Validation of viral-cellular junctions by PCR (VCJ-PCR) in patient 1553. The two viral-cellular 
junctions identified by sequencing were validated by PCR in the primary tumor (PT2: DNA from frozen sections 
prepared for TEN16_2016; PT1: TEN16_2013) and metastases (M1-M4). VCJ primers (■) were re-designed to 
shorten the amplicons (□) for DNA from FFPE tissue (M3 and M4). HPV primers amplifying HPV16 E6/E7 (▲, for 
frozen biopsies) and L1 (▼, for FFPE tissues) were used as positive controls. In the upper right panel showing 
VCJ1 detection in M3 and M4, PCR products were reamplified in a second PCR using the same primers.  
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4.5.5 Localization of viral 3’-breakpoints 
Sequence analysis of the VCJs revealed that most HPV16 3’-breakpoints were located in the 
HPV E1 gene (Figure 21). All patients had at least one 3’-breakpoint in E1 except for patient 
1553, who had both 3’-breakpoints in E2. Four of eight patients (1464, 993, 1425, 1529) had 
additional 3’-breakpoints in the genes E4, E5 or L2 (Figure 21).  
The localization of 3’-breakpoints affected viral transcription. Splicing of the transcripts E1C 
and E1^E4 was impaired in cases with VCJs located only upstream of the splice acceptor 
sites (at N2582 and N3358, respectively). Loss of those transcripts indicated absence of 
complete transcriptionally active HPV genomes in the tumors (primary tumor of 661, primary 
tumor and metastasis 2 of 1553), while detection of E1^E4 despite of upstream VCJs 
indicated presence of truncated and additional complete transcriptionally active HPV 
genomes (primary tumor of 1529, Table 24). 
 
Figure 21: Localization of HPV16 3’-breakpoints. The localization of the viral 3’-breakpoints is represented for 
every patient. The early region of the HPV16 genome (N0-N4500) is depicted with the open reading frames of the 
early genes and the positions of the primers (arrows) used for the TEN16 analysis. The HPV16 E1C and E1-E4 
splice acceptor sites (at N2582 and N3358, respectively) are depicted as dotted lines. Viral-cellular junctions 
(VCJs) were present in the pairs of primary tumor (PT) and metastasis (M, blue), only in the primary tumor 
(black), only in a part of the primary tumor (green) or only in the metastasis (red). The nucleotide positions refer to 
the HPV16 reference genome NC_001526.3 (National Center for Biotechnology Information). 
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Table 24: Detection of viral transcripts in relation to viral 3’-breakpoints. 
Patient Tissue Viral 3‘-breakpoint (bp)  HPV Transcripts 
 
 N0-2582 N2583-3358 N3359-4500  E6*I E1C E1^E4 
661 Primary Tumor VCJ1 - -  + - - 
 Metastasis - - -  + + + 
1529 Primary Tumor VCJ2, 3 VCJ1 -  + + + 
 Metastasis 1 VCJ2 - VCJ4  + + + 
1553 Primary Tumor - VCJ1 -  + + - 
 Metastasis 1 - - VCJ2  + + + 
 Metastasis 2 - VCJ1 -  + - - 
993 Primary Tumor VCJ1 VCJ2 VCJ3  + + + 
 Metastasis - - -  + + + 
VCJ=viral-cellular junction, 2582=E1C splice acceptor site, 3358=E1^E4 splice acceptor site 
 
 
4.5.5 Cellular localization of HPV16 integration sites 
Regarding the cellular localization of the integrated HPV, clusters of up to three VCJs within 
3 Mb of the cellular sequence were observed in 5/8 (63%) primary tumors. Those clustered 
VCJs were all (1650, 1425, 1464), partly (1529) or not (993) present in the corresponding 
lymph nodes (Table 25, further details in Appendix Table A-1). In four (66%) out of six 
patients with multiple VCJs, all VCJs were located on the same chromosome. In contrast, 
patient 1553 had VCJs on chromosomes 1 and 22, and patient 993 had two VCJs in close 
proximity on chromosome 9 and another one on chromosome 1 (Table 25).  
While HPV16 integration occurred in most cases within the non-coding region upstream or 
downstream of cellular genes, the viral genome integrated in two patients within a cellular 
gene (CD24 in patient 1529 and RERE in patient 993, Table 25). Eleven (58%) out of  
19 localized VCJs were in close proximity to cancer-related genes defined by the COSMIC 
database (catalogue of somatic mutations in cancer) and GeneRIF (Gene Reference into 
Function) in the NCBI (National Center for Biotechnology Information) database. Of those 
eleven VCJs, five (45%) were detectable in the primary tumor and in all metastases from the 
patient and seven (63%) at least in half of the metastases. In contrast, only two (25%) out of 
eight VCJs that were not located in proximity to cancer-associated genes were present in 
both the metastasis and the primary tumor (Table 25). 
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Table 25: Cellular localization of HPV16 integration sites in OPSCC primary tumors and metastases. 
Patient 
 
Chromosome 
Position 
VCJ position in relation to cellular genes 
 
1650 8q24.21 POU5F1B(+)__VCJ1(-)__VCJ2(+)__MYC(+) 
1425 9q22.3 XPA(-)__VCJ1(+)__VCJ2(+)__FOXE1(+)__VCJ3(+)__C9orf156(-) 
1553 1p13.3 DENND2D(-)__VCJ1(+)__CHI3L2(+) 
 22q12.3 CSF2RB(+)__VCJ2(+)__TEX33(-) 
1529 6q21 QRSL1(+)__VCJ1(+)__VCJ2(+) within CD24(-)__VCJ3(+)__VCJ4(+)__C6orf203(+)  
661 5q14.3 ARRDC3(-)__VCJ1(-)__NRSF1(+) 
993 1p36.23 VCJ1(-) within RERE(-) 
 9p24.1 TMEM261(-)__VCJ2(+)__PTPRD(-)__VCJ3(+) 
1643 20q13.13 CEBPB(+)__VCJ1(+)__PTPN1(+) 
1464 1p21.2 GPR88(+)__VCJ1(-)__VCJ2(-)__VCAM1(+) 
VCJ=viral-cellular junction (HPV integration site), (+/-)=DNA plus/minus strand; 
Highlighted genes (bold) are cancer-associated genes defined by the COSMIC database (catalogue of somatic 
mutations in cancer, http://cancer.sanger.ac.uk/cosmic) and GeneRIF (Gene Reference into Function) in the NCBI 
(National Center for Biotechnology Information) database, accessed: 09/12/2016.  
Highlighted VCJ (blue) were present in primary tumor and metastases (1553 VCJ1 in 3/4 metastases, 1529 VCJ2 
in 1/2 metastases), or only in a metastasis (red). 1425 VCJ4 is located in repetitive sequences at several positions. 
 
4.5.1 Methylation levels in primary tumors vs. metastases 
Pairs of known OPSCC primary tumors (n=4) and corresponding neck lymph node 
metastases (n=10, 1-4 per patient) were analyzed to assess potential variability in 
methylation levels of the five gene promoters (described in chapter 4.4) between primary 
tumors and corresponding metastases.  
In three (30%) metastases, methylation levels for all five promoters varied by less than 10% 
from the levels in the primary tumors. However, in other three (30%) metastases a variation 
of more than 25% was observed for the promoters of IRX1 and/or ALDH1 in comparison to 
the primary tumors (Figure 22). Overall, the metastases had significantly lower methylation 
levels compared to primary tumors (p=0.00003, paired student’s t-test). A reproducibility 
analysis of six metastases tested in two independent assays revealed a mean inter-
experimental deviation of only 1%, ranging from 0% to 3% (R²=0.98).  
The single methylation score (0 or 1) calculated for each promoter separately based on a 
promoter-specific cut-off value was identical in 40% (OSR2), 70% (ALDH1 and GRIA4) and 
90% (GATA4 and IRX4) of pairs of primary tumors and metastases. For the total methylation 
score combining all five promoters in a sample the agreement between the pairs was 90%, 
since all primary tumors and all corresponding metastases except for one presented with 
MS≥3. 
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Figure 22: Methylation in the five gene promoters comparing OPSCC primary tumors and corresponding 
metastases. The percentage of methylation in the promoters of the five genes included in the pre-defined 
methylation signature is compared for primary tumors versus corresponding lymph node metastases. Promoter-
specific cut-off values are represented as dotted line. Up to four metastases (M1-M4) are depicted for each 
patient (color). Paired student’s t-test was used to calculate p values. 
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5 Discussion 
5.1 Detection of HPV-driven NSCCUP 
HPV mRNA detection is considered as gold standard to identify HPV-driven OPSCC patients 
[47, 49] and was performed in this study by HPV E6*I mRNA assay [48]. In comparison to 
HPV mRNA, HPV DNA had a sensitivity of 100%, but only 95% specificity (Chapter 4.1.3, 
Table 10). The reduced specificity of HPV DNA alone is supported by p16INK4a IHC data, 
since three out of the four HPV DNA-positive but mRNA-negative NSCCUP did not show 
p16INK4a overexpression. A recently published meta-analysis reported a similar sensitivity 
(98%), but lower specificity (84%) of HPV DNA to identify HPV-driven OPSCC [53]. Low 
specificity might be due to cross-contamination between different samples during sectioning. 
In the present study, the risk of cross-contamination was reduced to a minimum by following 
a very stringent, previously optimized sectioning protocol [49]. Aside from contamination, 
HPV DNA detected in the absence of HPV mRNA might be derived from past infection, or 
from recent oral HPV exposure and is probably biologically non-relevant [52]. As previously 
shown for OPSCC, HPV DNA detection alone is not sufficient to identify HPV-driven tumors 
[49, 51], and should therefore also not be used as a single marker in NSCCUP patients. 
Although HPV16 was the most common HPV type, this study demonstrates the 
appropriateness of broad-range high-risk HPV testing in NSCCUP, because five (13%) of the 
39 overall HPV-driven NSCCUP were driven by non-HPV16 types, including HPV18 (n=1), 
HPV31 (n=1), HPV33 (n=2) and HPV35 (n=1). Previous NSCCUP studies detected HPV18 
(n=2), HPV33 (n=6) and in single cases HPV35, HPV58, HPV73 and HPV82, respectively, 
together with p16INK4a overexpression [95, 109, 114, 119, 123]. 
While frozen biopsies are preferable for the detection of nucleic acids, FFPE tissue is needed 
for p16INK4a expression analysis. In current literature, different cut-off values are applied to 
evaluate p16INK4a overexpression (reviewed in [53]). In the present study, NSCCUP were 
defined p16INK4a-positive, if >25% of tumor cells were stained. Additional evaluation of the 
frequently used more stringent cut-off value of >70% showed that in nine (23%) NSCCUP 
with p16INK4a overexpression, between 25% and 70% of tumor cells were stained. Four of 
those were HPV-driven due to positivity for HPV mRNA and DNA. In comparison to HPV 
mRNA, sensitivity of p16INK4a overexpression using the 25% cut-off value was higher and 
specificity was slightly lower (96% and 89%, respectively) compared to the 70% cut-off value 
(81% and 93%, respectively, Chapter 4.1.3, Table 10).  
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Specificity of p16INK4a overexpression as a surrogate marker to identify HPV-driven HNSCC is 
generally low, because p16INK4a overexpression might be triggered not only by HPV 
transformation, but also by non-viral mechanisms [47]. Beadle and colleagues showed  
strong p16INK4a expression in 12.5% (3/24) of lymph node metastases from cutaneous 
HNSCC that were unassociated with HPV, since all three metastases were HPV  
DNA-negative [142]. Thus, assuming oropharyngeal localization of primary tumors only 
based on p16INK4a overexpression in the metastases might be misinterpretation [142]. In the 
present study, 14 (36%) of the 39 p16INK4a-positive cases were HPV mRNA-negative. 
Therefore, p16INK4a overexpression should not be used as a single marker in NSCCUP 
patients.  
From the three markers analyzed in this study, we can conclude that p16INK4a overexpression 
together with presence of HPV DNA [51] would be the best alternative to identify HPV-driven 
NSCCUP cases, if RNA analysis cannot be performed. This marker combination would 
increase specificity in the present study to 99% while maintaining 96% sensitivity, if applying 
the 25% p16INK4a cut-off value (Chapter 4.1.3, Table 10). With the 70% cut-off value 
specificity would further increase to 100%, but sensitivity would be reduced to 81%.  
5.2 Nucleic acid detection in FFPE tissue  
While HPV DNA could be easily detected in DNA extracted from frozen biopsies, FFPE 
samples turned out to be challenging. By MPG, neither HPV nor the cellular control gene 
beta-globin could be detected in 36% of FFPE samples included in the multicenter study 
even after improved DNA extraction. This high percentage of invalid samples demonstrates 
the importance of internal controls for DNA integrity to avoid false-negative results. The 
amplicon size is crucial for DNA detection. Of the DNA samples extracted from FFPE tissue, 
59 were MPG-invalid, meaning negative for HPV (amplicon sizes around 150 bp) and  
beta-globin (208 bp amplicon), but in 22 (38%) of them between 100 and 1300 copies of 
beta-globin were detected by real-time qPCR using a 110 bp amplicon. Taking this into 
account, short amplicons (<200 bp) were designed for methylation analyses and for 
validation PCRs of viral-cellular junctions in HPV16 integration analyses in this study.  
The HPV E6*I mRNA assay had been developed especially for RNA samples extracted from 
FFPE tissue and uses an amplicon of around 65 bp for HPV mRNA and a cellular ubiquitin C 
amplicon of 85 bp for validity analysis [48]. In this study, all samples were mRNA-valid, 
indicating a high technical sensitivity of the mRNA detection assay. 
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5.3 Prevalence of HPV-driven NSCCUP 
5.3.1 Geographical differences 
The prevalence of HPV-driven NSCCUP revealed by the multicenter retrospective study 
ranged from 10% to 20% and reached 28% in the HPV serology study. The lowest 
prevalence was measured in Barcelona (10%), which is in line with a previously reported  
low HPV prevalence in OPSCC patients. In another retrospective study, only 3% of  
OPSCC patients diagnosed between 1990 and 2009 in northern Spain were HPV 
DNA/p16INK4a-positive [143]. Systematic reviews and a large international study report that 
Spain is among the countries with the lowest HPV prevalence (6-9%) in OPSCC [65, 67, 
144].  
The prevalence of HPV-driven NSCCUP was higher in the Treviso region (17%) and in 
Heidelberg (20%), but lower than reported by previous Italian (45%) and German studies 
(22%-85% DNA/p16INK4a-positive) [118, 120, 123, 124]. This might be due to (i) early 
sampling in this study (starting 1988), (ii) identification of truly HPV-driven NSCCUP cases 
and (iii) the low proportion of patients initially presenting as NSCCUP, but later being 
diagnosed with tonsillar or base of tongue carcinoma. Those patients were overrepresented 
(60%, 100% and 100%, respectively) in two German studies reporting 81% and 85%  
HPV DNA/p16INK4a-positivity, respectively [95, 120], as well as in an US study with  
69 patients reporting the highest HPV prevalence (91% p16INK4a overexpression and/or  
HPV ISH) [145]. The only previous study detecting HPV mRNA revealed a prevalence of 
45% in 22 NSCCUP diagnosed between 2010 and 2012 in Rome [146]. Another German 
study analyzed 63 recently diagnosed NSCCUP patients (2002-2011), of which 37% were 
HPV DNA/p16INK4a-positive [123]. The increased HPV prevalence in those studies compared 
to the present study might result from differences in the sampling period, since beside 
regional differences in the prevalence of HPV-driven NSCCUP also a time trend was 
observed in the present study (Chapter 4.1.2, Figure 8).  
5.3.2 Increase in prevalence of HPV-driven NSCCUP over time 
The relative prevalence of HPV-driven NSCCUP in recently diagnosed patients (2005-2014) 
was 2.5-fold increased, compared to those diagnosed earlier (1988-2004). The increase was 
observed for all three study centers ranging from 1.6-fold in Barcelona, to 2.8-fold in 
Heidelberg and up to 3.3-fold in Treviso, ruling out regional bias. This time trend might at 
least partly explain the regional differences observed in this study, because cases from 
Barcelona with the lowest HPV prevalence were diagnosed longer ago (median year of 
diagnosis: 2002), while cases from Heidelberg with the highest HPV prevalence were 
diagnosed more recently (median: 2008). The highest HPV prevalence (28%) was measured 
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by HPV serology in NSCCUP patients from Leipzig, who were diagnosed even more recently 
(2008-2016, median: 2011).  
The increase in prevalence of HPV-driven NSCCUP in recent decades is in line with the 
increase observed for HPV-driven OPSCC [147]. A systematic review reported a steady 
increase of HPV prevalence in OPSCC from pre-1995 till 2013, more precisely from 28% to 
50% (1.8-fold) in Europe, that was independent of the HPV detection method and whether 
FFPE or frozen tissue was analyzed [144]. However, it is discussed whether the HPV 
prevalence is absolutely increasing, or relatively increasing due to the decreasing proportion 
of smoking- and alcohol-related cancers in men in Western countries [68]. While the relative 
prevalence of HPV-driven NSCCUP cases increased in the present study (p=0.004), the 
proportion of tobacco and alcohol consumers among NSCCUP patients decreased in the 
same period (p=0.008 and p=0.006, respectively) [88]. However, even in the late sampling 
period, smoking was still very common (77%), and in both sampling periods the majority of 
patients with HPV-driven NSCCUP were also smokers (64%), pointing at a potential 
interaction between HPV and smoking [60].   
5.4 Survival benefit of patients with HPV-driven NSCCUP 
Although statistical power was limited due to the low number of events (death or progression) 
among patients with HPV-driven NSCCUP, the multicenter and the serology study revealed 
both a significantly better overall (p<0.004) and progression-free survival (p<0.02,  
Chapter 4.1.5, Figure 12 and Chapter 4.2.4, Figure 15) of patients with HPV-driven or  
HPV-seropositive NSCCUP, emphasizing the clinical relevance of the HPV status. This is in 
line with previous NSCCUP studies reporting significantly better 4-year or 5-year overall and 
progression-free survival rates (Chapter 1.3.5, Table 4) for HPV-positive patients defined by 
presence of HPV DNA and/or p16INK4a overexpression [109, 115, 121]. 
The survival benefit observed in the multicenter and the HPV serology study remained 
significant even after adjusting for potential confounders (Chapter 4.1.5, Table 12 and 
Chapter 4.2.4, Table 17) taking into consideration that patients with HPV-driven NSCCUP 
presented with significantly less risk factors, meaning less alcohol and tobacco consumption 
and less advanced N stage (Chapter 4.1.4, Table 11 and Chapter 4.2.1, Table 14). The 
hazard ratios calculated in both studies for overall survival (0.30 and 0.09, p≤0.001, 
respectively) and progression-free survival (0.27 and 0.03, p≤0.003, respectively) were 
similar or lower compared to previous studies. For overall survival, a Swedish study including 
50 NSCCUP patients revealed a similar hazard ratio of 0.29 (p=0.03) for p16INK4a-positive 
patients after adjusting for age at diagnosis, gender, tobacco consumption and p53 
expression [109], while in a Danish study with 60 patients the hazard ratio was 0.71 
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(p=0.009) for p16INK4a-positive patients after adjusting for age at diagnosis, tobacco and 
alcohol consumption and non-keratinizing morphology [122]. For disease-free survival, a 
Korean study analyzing 58 NSCCUP patients revealed for p16INK4a-positive patients a hazard 
ratio of 0.29 (p=0.03) after adjusting for extracapsular spread and p53 expression, which is 
similar to the hazard ratio for progression-free survival in the presented multicenter study 
[115]. However, comparison to previous studies is limited due to the lack of HPV mRNA 
assessment. 
5.5 Additional factors influencing survival of NSCCUP patients 
Besides HPV status, multimodal treatment was revealed as independent prognostic factor, 
although in the multicenter study interpretation is complicated by the time-dependent effect 
implying that the hazard ratio varies over time. But also in the HPV serology study, a 
significant survival benefit of NSCCUP patients receiving postoperative chemoradiotherapy 
was observed (Chapter 4.2.4, Table 17).  
Increased age at diagnosis, presence of extracapsular spread and advanced nodal stage 
were revealed as independent unfavorable prognostic factors (Chapter 4.1.5, Table 12 and 
Chapter 4.2.4, Table 17). Regarding prognosis, those should be considered in addition to 
HPV. This is in concordance with previous studies confirming age at diagnosis and 
extracapsular spread as unfavorable prognostic factors [115, 122]. In the updated TNM 
staging system (AJCC Cancer Staging Manual, 8th edition, January 2017) extracapsular 
spread is taken into consideration, since NSCCUP patients with extracapsular spread are 
classified into the highest nodal stage (N3b). 
In addition, increased p53 expression was reported to be an unfavorable prognostic factor in 
NSCCUP patients [109, 115]. Expression levels were shown to be increased in HNSCC 
patients with missense TP53 mutations and reduced in patients with nonsense mutations 
[148]. TP53 mutation status was assessed in the multicenter study, but only in 70 patients 
and was therefore not included in the multivariate analysis. As described for OPSCC [72, 73], 
all HPV-driven NSCCUP presented without disruptive TP53 mutation, which might explain 
their survival benefit due to an increased radiosensitivity [149]. However, in the absence of 
HPV, patients with disruptive TP53 mutation showed a slightly better survival than those 
without disruptive mutation (Figure 17, Chapter 4.3.3), which might be due to the fact that 
patients without disruptive mutation presented with significantly advanced N stage. 
Sequencing of additional samples and multivariate survival analysis is required and the effect 
of the identified mutations on p53 expression levels should be investigated in order to get 
more insights into the role of TP53 in NSCCUP patients. 
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For gender, tobacco and alcohol consumption no significant effect on survival was observed 
(Chapter 4.1.5, Table 12 and Chapter 4.2.4, Table 17), which might be due to limited 
statistical power of the two studies. Although the multicenter study is the largest NSCCUP 
study published so far, confidence intervals are still large due to low number of events (death 
or progression) among females, never smokers and never drinkers with HPV-driven 
NSCCUP in the multicenter study (n=2, 2 and 4, respectively) and the HPV serology study 
(n=0, 1 and 0, respectively).  
5.6 Epigenetic characteristics of HPV-driven lymph node metastases 
The survival benefit of HPV-driven HNSCC is linked to epidemiological, molecular and 
clinical differences compared to non-HPV-driven HNSCC. On the molecular level, Kostareli 
et al. reported epigenetic differences in HPV-driven vs. non-HPV-driven HNSCC and 
identified a prognostic methylation signature [76, 77]. A survival benefit has been reported for 
OPSCC and other HNSCC patients presenting with high agreement to the signature [76, 77], 
but tumors outside the head and neck have not yet been studied. The multicenter study 
showed that this methylation signature is also present in HPV-driven NSCCUP (Chapter 
4.4.1, Figure 18). However, it did not seem to have a prognostic role in NSCCUP patients. 
Among the analyzed NSCCUP, an unknown proportion of metastases might originated from 
primary tumors outside the head and neck region, such as from the lung. In those patients, 
the prognostic value of the methylation signature might be different.  
Furthermore, a technical issue should be considered to influence the methylation analysis. 
Since methylation levels are measured in all cells of the tissue section, the tumor content 
should ideally approach 100%. Some samples had a lower tumor content (range: 10-100%), 
although the median was 90%. Non-malignant cells such as lymphocytes present in the 
section might change the percentage of methylation measured in the samples. 
It has not been investigated before, whether the methylation signature and its prognostic 
value observed in OPSCC also apply to lymph node metastases from oropharyngeal primary 
tumors. In the present study, paired analysis of HPV-driven OPSCC and corresponding 
metastases revealed significantly reduced methylation levels in metastases (Chapter 4.5.1, 
Figure 22). This implies that the methylation score might not be directly transferable from 
primary tumors towards metastases. Instead, adjustment of the cut-off values might be 
necessary. Lower methylation might result in higher expression levels. For the gene ALDH1, 
lower methylation might explain the previous observation that in OPSCC ALDH1 expression 
was associated with advanced nodal stage (p=0.02) and was significantly increased in 
metastases compared to primary tumors (p=0.01) [150].  
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Taking into consideration those limitations of the analysis, in particular potentially imprecise 
cut-off values, we regrouped NSCCUP in those with high agreement to the pre-defined 
methylation signature (methylation in 4-5 promoters accordingly), low agreement (0-1 
promoters) and an intermediate group (2-3 promoters) in order to assess differences 
between the two extremes (Appendix, Figure A-2). Indeed, separation of the curves was 
visible and a statistically significant difference for progression-free survival was revealed by 
log-rank test. Therefore, the intermediate group that is close to the applied cut-off value (≥3 
promoters) might be at least partly misclassified in this study and might distort the survival 
analysis. However, HPV will probably remain the stronger prognostic marker in NSCCUP 
patients. 
5.7 Stability of HPV markers and integration upon metastasis formation 
While methylation levels might vary between primary tumors and metastases, presence of 
HPV DNA and E6*I mRNA was consistent between all pairs analyzed in this study. However, 
the viral load differed between primary tumors and corresponding metastases (Chapter 4.5.1, 
Table 21), but this might be biased by the tumor content, since an overestimated tumor 
content would result in underestimated viral load and vice versa. Although the tumor content 
was determined by an experienced pathologist, this is challenging due to presence of small 
lymphocytes in the lymph node metastases. 
HPV integration site analysis revealed differences, since not all integration sites found in the 
primary tumors were present in the corresponding metastases (Chapter 4.5.4, Table 22). The 
fact that in one primary tumor two integration sites were only found in one, but not in another 
section of the same tumor, indicates intratumoral heterogeneity (Figure 23). A primary tumor 
might consist of several distinct subclones with different HPV integration sites, but metastatic 
cells would disseminate and expand from one subclone.  
In patients with NSCCUP and HPV-driven OPSCC patients, metastasis formation is 
assumed to be an early event, as described for breast cancer by the early dissemination and 
parallel progression model [151]. If the HPV integration site of the primary tumor is not 
present in the corresponding metastasis, integration might either be a rather late event 
occurring after early formation of metastases, or more likely it might be unstable over time 
(Figure 23). If a random integration event was not beneficial for the viral transformation or 
proliferation of the cell, this specific integration site might get lost in the metastasis and even 
in the primary tumor over time. This hypothesis is supported by the observation that VCJs in 
close proximity to cancer-related genes were more stable than others (Chapter 4.5.5, Table 
25). Further studies are needed in order to investigate, how HPV integration affects the 
neighboring cellular genes. 
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Specific HPV integration sites might be used to confirm origination of a metastasis from a 
primary tumor harboring the same integration site. However, different HPV integration status 
cannot exclude that the metastasis originated from that particular primary tumor. 
 
Figure 23: Scenarios for presence or absence of viral-cellular junctions in primary tumors and 
corresponding lymph node metastases. Three possible scenarios (A, B, C) might explain presence of viral-
cellular junctions (blue, green, grey) only in the primary tumor (PT), but not in the corresponding lymph node 
metastasis (M). Scenario C assumes heterogeneity regarding HPV integration within the primary tumor and 
explains detection of another viral-cellular junction (red) only in the lymph node metastasis. 
5.8 HPV detection methods suitable for clinical settings 
With regard to the rising prevalence of HPV-driven NSCCUP and the prognostic value, HPV 
assessment is worthwhile to be included in the standard diagnostic work-up of NSCCUP 
patients. This requires a cost-effective, time-saving and easy-to-perform assay for clinical 
settings that is validated against the gold standard to identify HPV-driven HNSCC accepted 
in research settings, which is the detection of HPV mRNA. 
5.8.1 Serological HPV status assessment 
HPV serology might be particularly suitable for HPV status diagnostics in NSCCUP patients 
in clinical settings, because the HPV antibodies can be detected in few microliters of serum 
or plasma, which is routinely drawn for clinical purposes. Since the complex serological  
high-throughput assay used in this study needs to be further adapted for clinical settings, an 
HPV16 E6 antibody ELISA (enzyme-linked immunosorbent assay) has been developed 
aiming at comparable performance with more convenient handling in less specialized clinical 
laboratories [Viarisio et al, oral communication]. 
In the HPV serology study, it was demonstrated for the first time that HPV-driven NSCCUP 
patients produce HPV antibodies. Ten (22%) of the 46 NSCCUP patients had high  
B) Late Integration
C) Heterogeneity
A) Instable Integration
P
Migrating cell
P
M
D) Heterogeneity + Late Integration
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HPV16 antibody levels, which were in all cases in agreement with presence of HPV16 DNA, 
mRNA and p16INK4a overexpression. This is in line with the high sensitivity and specificity 
(96% and 98%, respectively) previously determined for HPV16 serology to identify  
HPV16-driven OPSCC and with the HPV16 antibody patterns observed in patients with 
HPV16-driven OPSCC [54].  
For other high-risk HPV types, the serological HPV status was at least partly discordant in 
comparison to the molecular HPV status. One case with HPV31-driven metastasis had high 
antibody levels against HPV31 E6 and E7, but also showed cross-reactivity with HPV35 E6 
and E7. Cross-reactivity was also seen for the ten HPV16-seropositive cases in this study 
against E7 of HPV31 (n=7), HPV33 (n=7) and HPV35 (n=6) and is expected due to the close 
phylogenetic relationship between those HPV types [152]. Another case with HPV33-driven 
metastasis had high antibody levels against HPV33 E7 but not against E6, and was thus 
defined HPV-seronegative. Absence of antibodies against HPV16 or HPV18 E6 despite of 
presence of antibodies against the other early proteins E7, E1 and E2, was shown for single 
patients with HPV-driven NSCCUP in this study (Chapter 4.2.1, Figure 13) and in a previous 
OPSCC study [54]. Analysis of further NSCCUP and OPSCC cases is required in order to 
optimize cut-off values and to better define the serology algorithms to identify cases driven 
by HPV types other than HPV16. 
5.8.2 HPV E6 protein detection in FNAB 
Another promising candidate for HPV status diagnostics in NSCCUP patients is the 
commercially available OncoE6TM Oral Test, which was tested in this study. The fast and 
simple procedure compared to other HPV detection methods makes it suitable for clinical 
settings. In HPV16-driven frozen biopsies from two NSCCUP patients, detection of the 
HPV16 E6 protein using the OncoE6TM Oral Test was demonstrated. A result could be 
obtained within three hours after sampling.  
In a previous study, the assay detected HPV16 E6 in 32 (97%) out of 33 HPV16-driven 
OPSCC, but in none of the 24 non-HPV-driven OPSCC [Holzinger et al., in preparation]. In 
an ongoing study with the collaborators Dr. Paolo Boscolo-Rizzo and Dr. Elisa Dal Cin in 
Treviso, we are currently investigating, whether the OncoE6TM Oral Test might be used to 
detect HPV16/18 E6 in fine-needle aspiration biopsies (FNAB) from lymph node metastases 
in OPSCC and NSCCUP patients with good concordance to molecular HPV markers and 
HPV antibodies. FNAB are routinely taken from patients with NSCCUP in most institutions 
and would represent a minimally invasive diagnostic method to identify patients with  
HPV-driven NSCCUP, which might be useful for guiding diagnostic work-up and treatment 
[110]. A previous study demonstrated detection of HPV16 by ISH together with  
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p16INK4a overexpression in FNAB from 10/19 (53%) metastases from oropharyngeal tumors, 
0/46 (0%) from other primary sites and from 3/10 (30%) patients with NSCCUP, in which 
HPV might be an indicator for oropharyngeal primary tumor [116]. The HPV status in the 
FNAB of NSCCUP patients was reported to predicted an oropharyngeal primary tumor with 
90-100% specificity, but only 50-70% sensitivity [110]. 
5.9 Potential clinical implications of HPV detection in NSCCUP 
HPV status assessment might become clinically relevant, as it may help to target the search 
for the primary tumor and to target therapy in patients with HPV-driven NSCCUP, which may 
result in better prediction of the clinical course and may improve quality of life [88, 115-120].  
5.9.1 Localization of the primary tumor 
The multicenter study included 13 patients, in which a potential primary tumor was identified 
within three years after initial NSCCUP diagnosis (Chapter 4.1.6, Table 13), including two 
cases with an HPV-driven metastasis. One patient had an occult HPV-driven base of tongue 
carcinoma, which probably was missed when taking biopsies at the time of NSCCUP 
diagnosis, but was identified 18 months later. The other patient had an occult 
nasopharyngeal carcinoma diagnosed 14 months later (Chapter 4.1.6, Table 13). While the 
metastasis was EBV-negative, no tissue was available to determine the HPV or EBV status 
of the nasopharyngeal carcinoma. Although nasopharyngeal carcinomas are mainly 
associated with EBV, also HPV16 or HPV18 DNA/p16INK4a-positive cases were reported in 
recent studies [153-156]. A large international archival HNSCC tissue study identified  
5.9% (6/101) HPV-driven nasopharyngeal carcinomas [67]. However, oropharyngeal 
carcinomas might also extend to the nasopharynx due to close proximity, and might be 
wrongly diagnosed as nasopharyngeal carcinomas [156]. 
While in previous studies, patients initially presenting with HPV DNA/p16INK4a-positive 
NSCCUP likely had primary tumors in the oropharynx [115, 118, 120], those occult  
HPV-driven OPSCC were underrepresented in this study. This might be due to the difficulty 
of identifying initial NSCCUP patients from clinic databases and the NCT cancer registry, 
since patients are reclassified after primary tumor diagnosis changing the ICD code 
(International Classification of Diseases) from C80 towards the ICD code describing the 
localization of the primary tumor. Nevertheless, an extended diagnostic work-up of the 
oropharynx might be indicated for patients with HPV-driven metastasis [114].  
While occult tonsillar carcinomas can be efficiently resected by diagnostic tonsillectomy, 
even when histopathological analysis does not identify the primary tonsillar carcinoma, small 
occult base of tongue carcinomas can be frequently missed by routinely performed biopsies. 
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Resection of the base of tongue is hardly performed without complications and functional 
loss, such as impaired ability to swallow. Recently, an innovative tool, transoral robotic 
surgery (TORS), has been developed that facilitates resection of the base of tongue. The 
surgeon controls the instruments at a console allowing precise freedom of motion and 
improved video-assisted visualization [157]. In a US study, small occult base of tongue 
carcinomas were identified by TORS in nine (90%) out of ten NSCCUP patients [158]. The 
mean diameter of the carcinomas was 0.9 cm, the smallest was only 0.2 cm. Eight of the 
nine occult carcinomas were HPV16-positive, suggesting that this tool might be in particular 
beneficial for patients with HPV-driven NSCCUP. 
5.9.2 De-intensified treatment 
Besides indicating extended diagnostic work-up of the oropharynx, HPV status might also 
guide treatment decisions in NSCCUP patients. With regard to the significant survival benefit 
observed in the present study but also in published studies [90, 109, 115, 118, 121, 122] and 
taking into account the rather broad treatment and treatment-associated toxicity, it is 
discussed whether patients with HPV-driven NSCCUP might benefit from treatment  
de-intensification. In is currently assessed in patients with HPV-driven HNSCC, whether 
similar effects might be achieved with de-intensified treatment, while improving tolerance and 
post-treatment quality of life [81]. Toxicity might be minimized by focusing treatment to the 
oropharynx, or by reducing the radiation dose based on the increased radiosensitivity of 
HPV-driven HNSCC [159]. The phase II trial NCT01530997 found that de-intensification of 
chemoradiotherapy by using intensity-modulated radiation therapy and reducing the dose 
from 70 Gy to 60 Gy decreased toxicity, while maintaining a high pathologic complete 
response rate in HPV DNA-positive or p16INK4a-positive OPSCC [160]. Randomized 
prospective treatment studies including NSCCUP patients have not yet been performed and 
will be difficult to conduct because of the low incidence. But since patients with HPV-driven 
NSCCUP can be strongly suspected to harbor occult OPSCC, evidence can be extrapolated 
from those studies.  
The challenge of de-intensification treatment is to choose the appropriate subset of patients. 
Selecting patients with truly HPV-driven NSCCUP is essential. However, for several recent 
de-intensification trials patients were selected based on p16INK4a overexpression alone [81], 
which in the present study and in many OPSCC studies showed a rather low specificity 
involving the risk of undertreating the subgroup of patients with non-HPV-driven NSCCUP 
overexpressing p16INK4a. Not only HPV status, but also unfavorable prognostic factors, such 
as extracapsular spread and advanced nodal stage, should be considered, as indicated in 
this study and in a few small published series [115, 122]. In patients with HPV-driven 
NSCCUP presenting with those characteristics, rather intensive treatment might be indicated.  
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5.10 HPV serology as follow-up marker 
After treatment, patients are regularly invited for follow-up visits in order to check for relapse 
and particularly for outgrowth of a primary tumor not eradicated by treatment. The specific 
detection of HPV antibodies in patients with HPV-driven NSCCUP raised the interest in 
assessing whether kinetics of HPV antibody levels might be used as a marker to monitor 
successful tumor resection versus recurrence in NSCCUP patients with HPV-driven 
metastases. Indeed, in all five analyzed NSCCUP patients antibody levels decreased within 
the first 6-18 months after surgical removal of the metastasis by neck dissection and 
increased again in the single patient at the time of relapse (Chapter 4.2.5, Figure 16). This 
was consistent to the results obtained for patients with HPV-driven OPSCC, in which the 
main decrease in HPV16 antibody levels was observed within the first six months after 
treatment [Broglie et al., oral communication]. In the present study, follow-up serum samples 
drawn between three to nine months after treatment were only available for three patients, of 
which two showed a strong decrease in antibody levels (Chapter 4.2.5, Figure 16). 
However, in patients with HPV-driven NSCCUP, antibodies to HPV early proteins are 
generally produced at high levels and in patients followed-up over years after removal of the 
metastasis, antibody levels seem to be stable after the initial drop (Chapter 4.2.5, Figure 16). 
The patient with occult HPV-driven base of tongue carcinoma showed a decrease of  
HPV antibody levels during the first year after diagnosis and initial treatment that was similar 
to two patients without subsequent discovery of the primary tumor (Chapter 4.2.5, Figure 16). 
This is probably due to the fact that multiple metastatic ipsilateral lymph nodes (N stage 2b) 
were removed by neck dissection, while the occult base of tongue carcinoma must have 
been so small at that time that it was not detected by PET/CT and base of tongue biopsies. 
Together with the lymph nodes also plasma cells producing HPV antibodies might have been 
removed, resulting in a decrease in HPV antibody production despite presence of the  
HPV-driven base of tongue carcinoma.  
While giving insights into HPV immune response and antibody stability, the results from the 
few cases analyzed are not strong enough to suggest the use of HPV antibody levels as 
follow-up marker in patients with HPV-driven NSCCUP. Analysis of additional cases and with 
closer follow-up time points is required to better characterize the HPV antibody decay. In 
particular, HPV antibody kinetics between treatment and relapse should be further studied. 
5.11 Immune response against HPV 
Presence of HPV antibodies indicates existence of an adaptive, HPV-induced immune 
response, which is discussed as one of the explanations for the better prognosis of patients 
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with HPV-driven HNSCC [19]. On the one hand, CD4+ and CD8+ T cells reacting to HPV16 
E6 and E7 were previously found in six out of eight HPV DNA-positive OPSCC, in one out of 
two analyzed tumor-draining lymph nodes, and in the peripheral blood [161]. Furthermore, 
Ward et al. showed that the majority (84%) of 149 patients with HPV DNA/p16INK4a-positive 
OPSCC had moderate or high levels of tumor-infiltrating lymphocytes, which were associated 
with a better disease-specific survival [162]. 
On the other hand, several immune escape strategies were described [19]. Critical 
components of the HLA class I antigen-processing machinery were shown to be 
downregulated in HPV-driven HNSCC tissue compared to adjacent normal squamous 
epithelium [163]. Moreover, the immune checkpoint regulator PD-L1 seems to play a role, but 
published results are controversial. While Lyford-Pike et al found significantly higher  
PD-L1 expression levels in HPV DNA/p16INK4a-positive compared to HPV-negative HNSCC 
tissues (70% vs. 29%), a recent study reported similar PD-L1 expression in p16INK4a-positive 
compared to p16INK4a-negative OPSCC (71% and 61%, p=0.274) without significant 
association with survival [164]. Blockade of the PD-1/PD-L1 pathway is currently evaluated 
as promising strategy for immunotherapy [165]. In a pilot study in collaboration with Prof. Dr. 
Jochen Hess, PD-L1 expression levels will be analyzed in a subset of NSCCUP patients 
from the present study and will be correlated with HPV status in order to evaluate the 
potential use of immunotherapy in NSCCUP patients. A better understanding of the  
HPV immune response and immune escape mechanisms in NSCCUP patients is necessary 
in order to define prognostic markers and potential targets for immunotherapy.  
5.12 Conclusion and outlook 
The increasing HPV prevalence in NSCCUP patients suggests inclusion of HPV status 
assessment in the standard diagnostic work-up. If HPV mRNA detection is not feasible in 
clinical settings, detection of HPV DNA should be combined with p16INK4a expression, since 
the single markers showed low specificity and sensitivity to identify patients with HPV-driven 
NSCCUP. HPV serology might be a promising alternative, since the detection of HPV 
antibody patterns in serum from NSCCUP patients showed high sensitivity and specificity 
compared to the molecular HPV status in the metastasis. There is a need for simple and 
cost-effective assays particularly suited for clinical settings, which however need careful 
validation against the gold standard in prospective studies. 
NSCCUP patients with HPV-driven lymph node metastases showed a better prognosis, 
which might at least partly be due to an HPV-induced immune response, absence of 
mutations in the TP53 tumor-suppressor gene and altered promoter methylation levels. 
Those patients should undergo an extended work-up of the oropharynx to reveal occult 
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primary tumors and they might benefit from de-intensified treatment, which needs to be 
investigated in clinical trials.  
Although HPV markers were concordantly present in pairs of oropharyngeal primary tumors 
and lymph node metastases, differences were observed regarding HPV integration sites and 
promoter methylation levels, indicating potential changes upon metastasis formation. Further 
analysis would be necessary to investigate heterogeneity between primary tumors and 
corresponding metastases, as well as intratumoral heterogeneity. 
, 
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Abbreviations 
ATP   adenosine triphosphate 
bp   base pairs 
BS   broad-spectrum 
°C   degree Celsius 
CDK   cyclin-dependent kinase 
CI   confidence interval 
cm   centimeter 
CT   computed tomography 
DAB   3,3'-diaminobenzidine 
DFS   disease-free survival 
DKFZ   Deutsches Krebsforschungszentrum 
DNA   deoxyribonucleic acid 
DSS   disease-specific survival 
E1C   N-terminal truncated E1 
E6AP   E6-associated protein 
EBV   Epstein-Barr virus 
EDTA   Ethylenediaminetetraacetic acid 
ELISA    enzyme-linked immunosorbent assay 
ENT   Ear-Nose-Throat 
FFPE   formalin-fixed paraffin-embedded 
FNAB   fine-needle aspiration biopsy 
g   gram 
HE   hematoxylin and eosin 
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HNSCC  head and neck cancers are squamous cell carcinomas 
HPV   human papillomavirus 
HR   hazard ratio 
HSV   herpes simplex virus 
hTERT  human telomerase reverse transcriptase 
IARC   International Agency for Research on Cancer 
ICO   Institut Català d'Oncologia (Catalan Institute of Oncology) 
IHC   immunohistochemistry 
ISH   in situ hybridization 
LCR   long control region 
M   molar 
MCV   Merkel cell polyomavirus 
MFI   median fluorescence intensity 
min   minutes 
ml   milliliter 
mM   millimolar 
MP96   MagNA Pure 96 
MPG   multiplex HPV genotyping assay 
MRI   magnetic resonance imaging 
mRNA   messenger ribonucleic acid 
µl   microliter 
µm   micrometer 
n   number 
N1234   Nucleotide sequence position 1234 
N/A   not available 
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NCBI   National Center for Biotechnology Information 
NCT   National Center of Tumor Diseases 
ng   nanogram 
nm   nanometer 
NSCCUP  neck squamous cell carcinoma from unknown primary 
OPSCC  oropharyngeal squamous cell carcinomas 
ORF   open reading frame 
OS   overall survival 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PD-L1   programmed death-ligand 1 
PET   positron emission tomography 
PFS   progression-free survival 
pRb   retinoblastoma protein 
qPCR   quantitative PCR 
RNA   ribonucleic acid 
RT-qPCR  reverse transcription quantitative PCR analysis 
SDS   sodium dodecyl sulfate 
sec   seconds 
Strep-PE  Streptavidin-R-Phycoerythrin 
TEN16   Tagging, Enrichment and Next-generation sequencing of HPV16 
TMAC   tetramethylammonium chloride 
TORS   transoral robotic surgery 
TP53   Tumor suppressor protein p53 
Tris   tris(hydroxymethyl)aminomethane 
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URR   upstream regulatory region 
US, USA  United States (of America) 
VCJ   viral-cellular junction 
vs   versus 
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Figure A-1: HPV16 E6 protein detection  
The commercially available OncoE6TM Oral Test (Arbor Vita Corporation, Fremont, CA, USA) was used to detect 
HPV16 E6 in two HPV16-driven (HPV16+) frozen biopsies from NSCCUP patients (ID 101, ID 105). A lysate from 
a non-HPV-driven (HPV-) oropharyngeal squamous cell carcinoma (OPSCC) was included as negative control. 
Assay validity is indicated by visibility of the internal positive control line (C) at the top. The lowest purple line (16) 
indicates presence of the HPV E6 protein in the lysate. Signal strength was evaluated based on the reading guide 
template shown at the right. 
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Figure A-2: Survival of NSCCUP patients in relation to MS (high vs. intermediate vs. low)  
Methylation levels were measured in NSCCUP to group patients according to presence of a pre-defined promoter 
methylation signature (low methylation in the promoters of ALDH1 and OSR2, and high in GATA4, GRIA4 and 
IRX4 based on pre-defined cut-off values). Of the five promoters analyzed, 0-1 (MSlow, black), 2-3 (MSmedium, 
grey), or 4-5 (MShigh, red) were according to the methylation signature. Kaplan–Meier curves for overall (upper 
panel) and progression-free survival (lower panel) are compared for NSCCUP patients grouped accordingly. Log-
rank test was used to calculate p values. 
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Table A-1: Structural organization of viral-cellular junctions in OPSCC patients. 
Patient VCJ 3'-breakpoint HPV16  Chromosome Position (Strang) GRCh38 
661 VCJ1 2323 5 91,997,752 (-) 
993 VCJ1 1065 1 8,774,749 (-) 
 VCJ2 2661 9 10,958,578 (-) 
 VCJ3 3462 9 7,855,857 (+) 
1425 VCJ1 3488 9 97,700,482 (+) 
 
VCJ2 1014 9 97,845,247 (+) 
 
VCJ3 1122 9 97,872,724 (+) 
 
VCJ4 2376 (21) repetitive sequences at several positions 
1464 VCJ1 4303 1 100,621,391 (-) 
 
VCJ2 2348 1 100,626,755 (-) 
1529 VCJ1 2829 6 106,803,339 (+)  
 VCJ2 1974 6 106,975,053 (+) 
 VCJ3 2158 6 106,995,226 (-) 
 VCJ4 3992 6 107,020,172 (+) 
1553 VCJ1 3108 1 111,211,650 (+) 
 VCJ2 3768 22 36,946,938 (+) 
1643 VCJ1 2581 20 50,301,639 (+) 
1650 VCJ1 1247 8 127,680,237 (-) 
 
VCJ2 2821 8 127,680,288 (+) 
VCJ=viral-cellular junction, GRCh38=human reference genome (NCBI) 
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Table A-2: Characteristics of 180 NSCCUP patients included in the multicenter study. 
  HPV Marker         OS PFS   
ID Center Driven DNA RNA p16 Diagnosis Age Gender Tob Alc Treat ECS N Years Status Years Status TP53 MS 
1 B 0 0 0 0 13.09.90 62 0 1 1 S+R+C 1 3 1.37 1 1.37 1 N/A N/A 
2 B 0 invalid 0 0 20.03.91 56 0 1 1 S+R+C 1 3 0.99 1 0.99 1 N/A N/A 
3 B 0 invalid 0 0 27.08.91 81 0 1 1 S+R+C 1 2b 3.34 1 3.34 1 N/A N/A 
4 B 0 invalid 0 1 25.08.92 52 0 1 1 S+R+C 1 3 1.88 1 1.88 1 N/A N/A 
5 B 0 invalid 0 invalid 20.12.93 51 0 1 1 S+R+C 1 2b 4.60 1 4.60 1 N/A 4 
6 B 0 invalid 0 0 03.01.94 44 1 0 0 R 0 3 22.04 0 19.77 0 N/A N/A 
7 B 0 invalid 0 0 15.10.93 61 0 1 1 S+R+C 1 3 5.56 1 5.56 1 N/A N/A 
8 B 0 invalid 0 0 02.11.94 67 0 1 0 S+R+C 0 1 3.27 1 3.27 1 N/A N/A 
9 B 1 1 1 1 10.02.94 55 0 1 1 S+R+C 1 2b 2.08 1 1.19 1 N/A N/A 
10 B 0 invalid 0 0 16.03.94 68 0 1 1 S+R+C 1 2b 2.01 1 1.25 1 N/A N/A 
11 B 0 invalid 0 0 28.07.95 66 0 1 0 S+R+C 0 2a 15.15 1 15.09 1 N/A 2 
12 B 0 invalid 0 0 20.10.96 56 0 1 1 S+R+C 0 1 8.97 1 8.82 1 N/A N/A 
13 B 0 invalid 0 0 23.04.96 77 0 1 1 S 0 1 5.98 1 3.43 1 N/A N/A 
14 B 0 invalid 0 1 07.10.97 66 0 1 1 S+R+C 1 2b 1.02 1 0.92 1 N/A N/A 
15 B 0 invalid 0 0 30.03.98 56 0 1 1 S+R+C 1 2a 17.27 0 15.22 0 N/A N/A 
16 B 0 invalid 0 0 19.02.98 60 0 1 1 S+R+C 1 2b 0.82 1 0.82 1 N/A N/A 
17 B 0 invalid 0 0 25.02.98 42 1 1 0 S+R+C 1 3 17.33 0 15.27 0 N/A N/A 
18 B 0 invalid 0 0 11.05.98 65 0 1 0 S+R+C 1 1 7.42 0 7.42 0 N/A N/A 
19 B 0 invalid 0 0 18.11.98 44 0 1 1 S+R+C 1 2b 16.93 0 5.52 1 N/A N/A 
20 B 0 invalid 0 0 13.01.99 57 0 1 1 S+R+C 1 2b 0.91 1 0.91 1 N/A N/A 
21 B 0 invalid 0 0 29.03.99 63 0 1 1 S+R+C 1 2b 1.94 1 1.94 1 N/A N/A 
22 B 0 invalid 0 0 20.04.99 79 0 1 0 S 0 1 8.48 1 8.48 1 N/A 1 
23 B 0 invalid 0 0 13.07.99 61 0 1 1 S 0 2b 16.56 0 13.33 0 N/A 3 
24 B 0 invalid 0 0 21.06.99 62 0 1 1 S+R+C 1 2b 1.15 1 1.15 1 N/A N/A 
25 B 1 1 1 1 09.11.99 43 0 1 1 S 1 3 1.39 1 1.39 1 N/A N/A 
26 B 0 invalid 0 0 23.08.00 60 0 1 1 S+R+C 1 2b 3.04 1 3.04 1 N/A 0 
27 B 0 invalid 0 0 06.06.01 72 0 1 1 S 1 3 0.18 1 0.18 1 N/A N/A 
28 B 0 invalid 0 invalid 26.09.02 68 0 1 1 S+R+C 1 2b 1.87 1 1.55 1 N/A N/A 
29 B 0 invalid 0 0 21.03.02 71 0 1 1 S+R+C 1 3 8.32 1 5.99 1 N/A N/A 
30 B 0 invalid 0 0 26.06.02 52 0 1 1 S+R+C 1 1 13.38 0 11.37 0 N/A N/A 
31 B 0 0 0 0 01.12.03 51 0 1 1 S+R+C 0 2b 4.02 1 2.40 1 N/A N/A 
32 B 0 invalid 0 0 13.09.04 62 0 1 1 S 1 2b 2.39 1 2.39 1 N/A N/A 
33 B 1 1 1 1 27.10.04 69 0 1 0 S+R+C 1 1 10.62 1 6.32 1 wt 3 
34 B 0 invalid 0 0 29.10.03 68 0 0 1 S 1 3 0.44 1 0.44 1 N/A N/A 
35 B 0 invalid 0 0 07.02.05 77 0 1 0 S+R+C 1 2a 0.56 1 0.56 1 N/A N/A 
36 B 0 invalid 0 0 25.07.05 80 0 0 0 S+R+C 1 3 0.75 1 0.75 1 N/A 1 
37 B 0 invalid 0 invalid 27.07.04 78 0 0 1 S+R+C 1 3 0.95 1 0.95 1 N/A N/A 
38 B 0 invalid 0 0 02.09.04 65 0 1 1 S+R+C 0 2b 5.81 1 5.12 1 N/A N/A 
39 B 0 0 0 0 25.02.05 58 0 1 1 S+R+C 1 3 1.95 1 1.95 1 N/A N/A 
40 B 1 1 1 1 21.05.05 47 1 1 0 S+R+C 1 2b 7.53 1 5.25 1 wt N/A 
41 B 0 1 N/A 0 02.08.06 70 0 0 1 N/A N/A 2c 0.68 1 0.68 1 wt N/A 
42 B 0 invalid 0 0 04.04.06 36 0 1 1 S N/A 3 1.28 1 1.28 1 N/A N/A 
43 B 0 1 0 0 19.04.06 61 0 1 1 S+R+C 1 3 1.12 1 1.12 1 N/A N/A 
44 B 0 0 0 0 11.04.06 65 0 1 1 S+R+C 1 2b 6.29 1 5.83 1 N/A N/A 
45 B 0 0 0 0 21.08.06 56 0 1 1 S+R+C 1 3 4.09 1 2.65 1 N/A N/A 
46 B 0 0 0 0 17.05.07 71 0 1 1 S+R+C 1 3 8.44 0 5.53 1 N/A N/A 
47 B 0 invalid 0 0 28.07.08 61 0 1 0 S+R+C 1 3 0.79 1 0.79 1 N/A N/A 
48 B 0 0 0 0 04.12.08 42 0 1 1 S+R+C 1 3 2.67 1 2.01 1 mut N/A 
49 B 0 0 0 0 23.02.09 60 0 1 1 S+R+C 1 3 5.84 1 5.84 1 N/A N/A 
50 B 0 0 0 0 29.04.09 56 1 1 1 S+R+C 0 1 6.58 0 4.83 0 wt 2 
51 B 0 0 0 0 30.12.09 42 0 1 1 S+R+C 0 2b 5.31 0 3.50 0 wt N/A 
52 B 1 1 1 1 02.02.10 58 1 0 0 S+R+C 0 2a 5.25 0 3.79 0 wt 3 
53 B 0 0 0 0 03.02.10 40 1 0 0 S+R+C 0 2b 5.70 0 4.06 0 wt 3 
54 B 0 1 0 1 10.05.10 55 1 1 0 S+R+C 0 2b 5.69 0 3.42 0 N/A 2 
55 B 0 0 0 0 08.09.10 75 0 1 0 S 1 3 0.07 1 0.07 1 N/A 3 
56 B 0 0 0 0 02.07.10 73 0 1 1 S 1 2b 0.29 1 0.29 1 N/A 1 
57 B 1 1 1 1 24.02.11 67 0 1 1 S+R+C 1 2b 4.56 1 3.63 1 wt 3 
58 B 0 0 0 0 02.06.11 71 0 1 1 S+R+C 1 2b 4.42 1 0.69 1 N/A 2 
59 B 0 0 0 0 06.03.12 75 0 1 0 S+R+C 1 3 2.00 1 0.52 1 N/A 3 
60 H 1 1 1 1 17.03.09 67 0 1 1 S+R+C 1 2b 5.58 0 0.42 0 wt 3 
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  HPV Marker         OS PFS   
ID Center Driven DNA RNA p16 Diagnosis Age Gender Tob Alc Treat ECS N Years Status Years Status TP53 MS 
61 H 0 0 0 0 15.06.09 70 0 1 0 S+R+C 0 2b 2.24 1 2.24 1 wt 3 
62 H 1 1 1 1 25.09.09 52 0 0 0 S+R+C 1 2a 3.59 0 3.59 0 wt 5 
63 H 0 0 0 0 03.12.09 50 0 1 0 S+R+C 1 2b 5.77 0 5.77 0 N/A 2 
64 H 0 0 0 0 02.06.10 68 0 1 1 S+R 1 1 2.05 0 2.05 0 mut 2 
65 H 0 0 0 0 08.06.10 66 0 1 0 S+R 0 2b 2.09 0 2.09 0 mut 2 
66 H 0 0 0 0 12.05.10 65 0 1 1 S+R+C 1 2a 0.56 0 0.47 1 N/A N/A 
67 H 1 1 1 1 08.11.10 58 0 0 1 S 0 2a 5.09 0 5.09 0 wt 1 
68 H 0 invalid 0 0 18.01.11 61 0 0 0 S+R+C 0 1 4.53 0 4.53 0 N/A 3 
69 H 0 invalid 0 0 02.02.11 61 0 1 0 S 1 2a 1.24 1 1.24 1 N/A N/A 
70 H 1 1 1 1 15.02.10 55 0 0 N/A S 0 2b 4.66 0 4.66 1 N/A 3 
71 H 0 0 0 0 15.04.11 59 0 N/A N/A S+R 1 1 1.29 0 1.29 0 N/A 1 
72 H 0 0 0 0 09.06.11 85 0 0 1 S+R+C 0 1 1.19 1 0.09 1 wt 1 
73 H 0 0 0 0 12.07.11 69 0 1 1 S 1 2b 0.60 0 0.60 0 N/A 2 
74 H 1 1 1 1 27.07.11 56 1 1 1 S+R+C 0 1 4.46 0 4.46 0 wt 5 
75 H 1 1 1 1 08.08.11 56 0 0 0 S+R 0 2b 0.92 0 0.92 0 N/A 3 
76 H 1 1 1 1 20.09.11 62 1 0 0 S+R 0 1 3.57 0 3.57 0 wt 2 
77 H 0 invalid 0 0 25.08.11 51 0 1 1 S+R+C 1 2c 2.58 0 2.58 0 N/A N/A 
78 H 0 0 0 0 13.09.11 75 0 1 0 S+R+C 1 2b 0.31 0 0.31 0 N/A N/A 
80 H 0 invalid 0 0 22.08.97 53 0 0 1 S+R+C 1 3 1.49 1 1.49 1 N/A 4 
81 H 0 invalid 0 1 01.02.99 62 0 1 1 S+R 1 2a 0.04 0 0.04 0 N/A 1 
82 H 0 0 0 0 18.02.99 58 0 1 0 S+R+C 1 3 0.78 1 0.78 1 wt 1 
83 H 0 invalid 0 0 19.10.05 55 0 1 1 S+R 1 2b 0.61 1 0.61 1 N/A 1 
84 H 0 0 0 1 04.05.06 64 1 1 1 R+C 0 2c 1.21 1 1.21 1 N/A 2 
85 H 0 invalid 0 0 16.10.06 48 1 1 1 S+R+C 0 2b 2.64 1 1.54 1 N/A 1 
86 H 1 1 1 1 15.01.07 68 0 0 0 S 1 2a 8.64 0 1.52 1 N/A N/A 
87 H 0 invalid 0 0 08.02.08 69 0 1 1 S+C 1 3 2.06 0 2.06 0 N/A 4 
88 H 0 invalid 0 0 18.06.08 83 1 0 0 S 0 2a 2.15 0 2.15 0 N/A 2 
89 H 0 0 0 0 15.11.10 54 0 1 0 S+C 0 3 0.38 1 0.38 1 N/A 1 
90 H 0 invalid 0 0 18.04.11 60 0 0 1 S+R+C 1 2c 0.41 1 0.16 1 N/A 1 
93 H 0 0 N/A N/A 19.05.93 53 0 1 1 R N/A 2a 21.47 0 6.87 1 N/A 1 
94 H 0 0 0 N/A 28.04.93 60 0 1 1 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
95 H 0 0 0 N/A 15.06.95 72 0 1 1 N/A 1 2a 7.76 0 3.71 1 N/A 2 
96 H 0 0 0 N/A 20.06.95 66 0 1 1 N/A 1 3 0.14 0 0.14 0 N/A 2 
97 H 0 0 N/A N/A 22.01.96 59 0 1 1 S+R 1 2a 4.94 0 4.94 1 N/A 2 
98 H 0 0 N/A N/A 25.01.96 64 0 N/A N/A S+R 1 3 0.59 0 0.35 1 N/A 1 
99 H 0 0 N/A N/A 15.08.96 65 0 1 1 N/A 1 3 0.26 1 0.26 1 wt 3 
101 H 1 1 1 N/A 04.09.97 77 0 0 0 S 1 2a 14.29 1 14.29 1 wt 4 
102 H 0 0 N/A N/A 27.01.98 43 0 1 1 S+R 0 2b 16.98 0 1.09 1 wt 2 
103 H 0 0 N/A N/A 06.03.98 75 0 N/A N/A R+C N/A 2a 0.10 0 0.10 0 N/A 4 
104 H 0 0 N/A N/A 06.08.98 59 0 1 1 S+R 1 N/A N/A N/A N/A N/A N/A N/A 
105 H 1 1 1 N/A 01.12.99 70 1 1 1 R+C 1 2b 1.35 1 1.35 1 wt 4 
106 H 0 0 N/A N/A 31.03.00 51 0 1 1 S+R N/A 2a 2.83 0 2.83 0 mut 2 
107 H 0 0 N/A N/A 03.05.00 45 0 1 1 S+R N/A 3 0.77 1 0.77 1 N/A N/A 
108 H 0 0 N/A N/A 02.05.01 63 0 N/A N/A N/A N/A 2a 0.03 1 0.03 1 N/A N/A 
109 H 0 0 N/A N/A 28.07.04 55 0 1 1 S+R 1 2a 10.16 1 4.84 1 N/A 4 
110 H 0 0 N/A N/A 23.06.10 73 0 1 1 S 0 3 3.62 0 3.62 0 N/A 3 
111 H 0 0 N/A N/A 13.07.11 49 0 1 1 S+R+C 1 2b 0.04 0 0.04 0 wt 1 
112 H 0 0 0 N/A 16.07.90 56 0 1 1 S+R+C 0 2b 15.29 1 6.10 1 N/A N/A 
116 Tre 0 invalid 0 1 15.08.98 70 0 1 1 S+R 1 2b 7.25 1 6.60 1 N/A N/A 
117 Tre 0 invalid 0 0 04.07.95 68 0 1 1 S 0 2b 13.68 1 11.50 1 N/A 4 
118 Tre 0 invalid 0 0 12.05.98 62 0 1 1 S+R 1 2b 6.65 1 2.80 1 N/A N/A 
119 Tre 0 0 0 0 28.02.92 64 0 1 1 S+R 1 3 22.44 0 1.93 1 N/A 2 
120 Tre 0 0 0 0 21.07.09 77 0 1 1 S+R 1 2b 5.04 0 5.04 0 mut N/A 
121 Tre 0 invalid 0 0 01.09.00 88 1 0 0 S+R 0 2b 13.62 1 13.62 1 N/A 0 
122 Tre 0 0 0 0 01.08.00 56 0 1 1 S+R 1 3 1.54 1 0.08 1 wt 2 
123 Tre 1 1 1 1 16.10.12 79 0 1 0 S+R+C 1 2a 3.30 0 3.30 0 wt 3 
124 Tre 0 0 0 0 24.08.07 76 0 1 1 S+R 1 2b 3.15 1 0.60 1 N/A 1 
125 Tre 0 0 0 0 13.03.89 72 0 1 1 S 1 3 1.99 1 0.89 1 N/A 2 
126 Tre 0 0 0 0 31.08.06 76 0 1 0 S+R 1 2b 1.96 1 1.96 1 mut 3 
127 Tre 1 1 1 1 20.07.88 57 0 1 1 S+R 1 2b 27.27 0 27.27 0 wt 4 
128 Tre 0 0 0 0 10.09.89 48 0 1 0 S 0 2a 24.83 0 24.83 0 mut 2 
129 Tre 1 1 1 1 23.05.08 51 0 1 0 S+R 1 2b 7.60 0 7.60 0 wt N/A 
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  HPV Marker         OS PFS   
ID Center Driven DNA RNA p16 Diagnosis Age Gender Tob Alc Treat ECS N Years Status Years Status TP53 MS 
130 Tre 1 1 1 0 09.03.10 48 0 1 0 S+R+C 1 2b 5.18 0 5.18 0 N/A N/A 
131 Tre 0 0 0 0 01.03.98 71 0 1 1 S+R 1 2b 7.17 1 7.17 1 mut 2 
132 Tre 0 0 0 1 28.01.97 65 0 1 0 S+R 1 3 1.61 1 1.61 1 N/A 1 
133 Tre 1 1 1 1 01.06.03 61 0 1 0 S 1 2a 12.72 0 12.72 0 N/A 2 
134 Tre 0 invalid 0 0 11.08.98 67 0 1 1 S+R 1 3 1.52 1 1.22 1 N/A 2 
135 Tre 0 0 0 0 08.09.92 58 0 1 1 S+R 1 3 7.38 1 6.23 1 mut 3 
136 Tre 0 0 0 1 02.02.10 61 0 1 1 S+R+C 1 2b 4.97 0 4.97 0 N/A N/A 
137 Tre 0 0 0 0 27.08.13 57 1 1 0 S+R+C 0 2b 1.13 0 1.13 0 N/A 0 
138 Tre 0 invalid 0 0 01.05.02 63 0 1 1 S 1 2b 1.61 1 1.61 1 N/A N/A 
139 Tre 0 0 0 0 18.12.89 68 0 1 1 S 1 2a 1.38 1 0.20 1 mut N/A 
140 Tre 0 0 0 0 21.08.07 53 1 1 0 S+R 1 2a 7.05 0 7.05 0 mut N/A 
141 Tre 0 0 0 0 05.01.89 47 0 1 1 S 1 2c 0.83 1 0.57 1 N/A N/A 
142 Tre 0 1 0 0 22.07.02 79 0 1 1 S+R 1 2b 2.02 1 0.94 1 N/A N/A 
143 Tre 0 invalid 0 1 16.07.01 60 0 0 0 S 0 2c 5.17 1 1.96 1 N/A 3 
144 Tre 0 invalid 0 0 03.05.89 77 0 1 1 S 0 2a 0.48 1 0.48 1 N/A N/A 
145 Tre 0 0 0 0 06.03.01 52 0 1 0 S+R 0 2b 6.58 1 6.58 1 N/A N/A 
146 Tre 0 0 0 0 03.08.99 71 0 1 1 S 1 3 0.63 1 0.41 1 N/A N/A 
147 Tre 0 0 0 0 19.06.96 73 0 1 1 S+R 1 2b 5.47 1 5.47 1 N/A N/A 
148 Tre 0 0 0 0 01.02.04 56 1 1 1 S+R 1 3 10.61 0 9.24 1 N/A 1 
149 Tre 0 invalid 0 1 01.12.02 72 0 0 0 S+R+C 1 3 3.47 1 0.08 1 N/A N/A 
150 Tre 0 0 0 0 12.09.00 47 0 1 0 S+R 1 2b 0.70 1 0.70 1 N/A N/A 
151 Tre 0 0 0 1 20.10.04 54 0 1 1 S+R 1 2b 0.68 1 0.45 1 N/A 2 
152 Tre 0 0 0 0 19.06.12 77 0 1 0 S+R 1 2b 2.30 0 2.30 0 N/A N/A 
153 Tre 0 0 0 0 25.07.05 59 0 1 1 S+R 1 3 9.55 0 0.68 1 N/A 2 
154 Tre 0 invalid 0 0 01.04.98 67 0 1 1 R+C 1 2c 0.76 1 0.08 1 N/A N/A 
155 Tre 0 0 0 0 08.07.02 67 0 1 0 S+R 1 3 12.08 0 4.48 1 N/A N/A 
156 Tre 0 0 0 0 07.11.90 79 0 1 0 S+R 1 2b 1.04 1 1.04 1 N/A 2 
157 Tre 0 0 0 0 11.09.12 56 0 1 0 S+R+C 1 2b 1.90 0 1.90 0 N/A 1 
158 Tre 0 0 0 0 09.12.92 53 0 1 1 S 0 2a 11.23 1 11.23 1 wt 3 
160 Tre 1 1 1 1 22.01.10 63 0 1 0 S+R 1 2a 5.90 0 5.90 0 N/A 4 
161 Tre 0 0 0 0 11.08.99 50 0 1 1 S 1 2b 1.72 1 1.72 1 N/A 1 
162 Tre 0 invalid 0 0 04.07.03 74 1 1 1 S 1 3 1.42 1 0.58 1 N/A 3 
163 M 0 0 0 0 10.07.06 56 0 1 1 S+R 0 2c 5.76 0 5.76 0 wt 1 
164 M 0 0 0 0 22.07.14 76 0 1 1 S 0 2a 0.16 0 0.11 1 mut 3 
165 M 0 0 0 0 02.08.11 76 0 0 0 S+R 1 2b 1.83 1 1.83 1 N/A 1 
166 M 0 0 0 0 15.07.11 54 0 1 1 S 0 2a 3.02 1 2.70 1 N/A 2 
167 M 0 0 0 1 16.01.08 75 0 1 1 S+R 0 2a 5.74 1 5.74 1 N/A 2 
168 M 0 0 0 0 11.03.04 65 1 1 1 S+R 0 2b 8.06 1 8.06 1 wt 4 
169 M 0 0 0 0 27.02.08 54 0 1 1 S+R 1 3 1.28 1 0.59 1 mut 2 
170 M 0 0 0 0 02.02.04 63 0 1 1 S+R 0 2b 8.52 0 8.52 0 N/A 4 
171 M 0 0 0 0 11.07.11 52 0 1 1 S+R+C 0 1 3.32 0 3.32 0 mut 4 
172 M 0 invalid 0 0 16.02.12 58 0 1 1 S+R+C 1 2b 2.76 0 2.76 0 N/A 3 
173 M 0 0 0 0 01.04.03 59 0 1 1 S+R 1 2c 1.51 1 1.00 1 N/A 1 
174 M 0 0 0 0 07.07.09 58 0 1 1 S+R+C 1 3 4.99 0 4.99 0 wt 1 
175 M 0 invalid 0 0 26.03.08 56 0 0 1 S+R 1 2b 6.05 0 6.05 0 N/A 4 
176 M 1 1 1 1 17.02.12 66 1 0 0 S 0 2b 4.00 0 4.00 0 N/A 2 
177 M 0 0 0 0 09.02.12 80 0 0 0 S+R 1 2b 2.86 0 2.86 0 mut 2 
178 Tri 1 1 1 1 01.12.03 65 0 1 1 S 1 2b 12.22 0 12.22 0 wt N/A 
179 Tri 1 1 1 1 09.06.06 71 1 0 0 S+R 0 2b 9.35 0 9.35 0 wt 3 
180 Tri 0 0 0 1 20.10.09 87 0 1 0 S 1 1 2.07 1 2.07 1 N/A N/A 
181 Tri 0 0 0 1 11.04.12 52 0 1 1 S+R 0 2b 3.39 0 3.39 0 N/A 1 
182 Tri 0 0 0 0 15.10.12 68 0 0 1 S+R+C 1 2b 3.16 0 3.16 0 N/A 1 
183 Tri 0 1 0 0 16.10.12 56 0 1 1 S N/A 2b 0.00 1 0.00 1 mut N/A 
184 Tri 0 0 0 0 05.05.14 65 0 1 1 S+R+C 1 2b 1.27 1 1.27 1 N/A 3 
185 Tri 0 0 0 0 09.05.14 63 1 1 1 S 1 2b 0.45 1 0.32 1 N/A N/A 
186 Tri 1 1 1 1 26.05.14 59 0 1 1 S+R 0 2b 1.70 0 1.70 0 N/A 4 
187 Tri 1 1 1 1 22.08.14 56 0 1 1 S+R+C 1 2b 1.41 0 1.41 0 wt 2 
188 Tri 1 1 1 1 21.10.14 39 0 1 1 S 0 2a 0.10 0 0.10 0 wt 4 
Center: B=Barcelona, H=Heidelberg, Tre=Treviso, M=Montebelluna, Tri=Trieste; Driven: positive for HPV mRNA and HPV DNA and/or p16 overexpression (>25%); 
Age=age at diagnosis; Gender: 1=female, 0=male; Tob=tobacco consumption (1=current or former, 0=never); Alc=alcohol consumption (1=current or former, 0=never); 
Treat=treatment: S=surgery, R=radiotherapy, C=chemotherapy; ECS=extracapsular spread; N=N stage; OS=overall survival; PFS=progression-free survival; TP53: 
wt=wild-type or non-disruptive mutation, mut=disruptive mutation; MS=methylation score (0-5); N/A=not assessed 
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Table A-3: Characteristics of 46 NSCCUP patients from Leipzig analyzed by HPV serology. 
 HPV status         OS PFS 
ID Serum RNA Diagnosis Age Gender Tob Alc Treat ECS N Years Status Years Status 
4 16 16 21.08.08 79 0 1 1 R 1 2b 1.31 1 1.31 1 
5 16 16 19.10.10 67 0 0 1 S 1 2a 5.85 0 1.27 1 
6 0 0 05.11.10 56 0 1 1 S+R+C 1 2a 5.78 0 5.78 0 
7 16 N/A 09.12.10 68 0 0 1 S+R+C 1 2b 4.56 0 4.56 0 
8 0 0 08.06.11 68 0 1 1 S+R+C 1 2b 1.45 1 0.64 1 
10 0 0 22.02.10 38 0 1 1 S+R+C 1 2b 3.90 1 3.38 0 
11 0 N/A 19.07.10 67 0 1 1 N/A 1 1 3.74 0 3.74 1 
12 0 N/A 27.04.15 78 0 1 0 S 1 2b 0.13 1 0.13 1 
13 0 0 25.09.13 52 1 1 1 S+R+C 1 2a 2.93 0 2.93 0 
14 16 16 28.08.13 57 0 1 0 S+R 0 2a 3.15 0 3.15 0 
15 0 N/A 21.06.12 52 0 1 1 S+R+C 1 2b 4.33 0 4.33 0 
16 33 N/A 16.09.10 67 0 0 1 S+R+C N/A 2a 4.85 0 4.85 0 
17 0 N/A 26.05.10 48 0 1 1 S+R+C 1 2b 1.39 1 1.39 1 
18 16 16 19.05.09 68 0 0 1 S+R+C 1 2b 5.08 0 5.08 0 
19 0 0 26.11.08 66 0 0 1 S+R+C 0 2b 4.22 1 4.22 1 
20 0 0 23.07.08 58 0 1 1 S+R+C 1 2b 2.08 1 2.03 1 
23 0 0 07.07.11 48 0 1 1 S+R+C 1 2a 3.10 1 1.52 1 
24 0 0 15.07.09 67 0 1 1 S 1 3 0.59 1 0.35 1 
25 16 16 01.10.08 52 1 0 1 S+R+C 0 1 4.91 0 4.91 0 
29 0 0 03.01.13 60 0 1 1 S 1 2a 0.28 1 0.28 1 
30 0 N/A 31.08.11 53 0 0 1 S+R+C 0 2b 3.93 0 3.93 0 
33 0 N/A 09.11.13 63 0 1 1 S+R+C 0 2b 3.00 0 3.00 0 
34 0 0 03.02.14 59 0 1 1 S 1 2b 0.16 1 0.16 1 
35 0 N/A 17.03.14 56 0 1 1 S+R+C 1 2a 1.97 1 1.81 1 
36 0 N/A 12.06.14 59 1 1 1 S 0 N/A 2.07 0 2.07 0 
37 0 N/A 18.06.14 79 0 1 1 S 1 2b 0.08 1 0.08 1 
38 0 0 10.09.15 55 0 1 1 S+R N/A 3 1.11 0 0.43 1 
40 31/35 31 19.02.16 60 0 1 1 S+R 0 2a 0.61 0 0.61 0 
41 0 N/A 24.02.16 79 0 1 1 S+R 1 2a 0.65 0 0.42 1 
43 0 0 14.12.12 57 0 1 1 S+C 1 2c 3.18 1 1.14 1 
44 16 16 14.03.14 63 0 1 1 S+R 0 1 2.50 0 2.50 0 
45 0 0 03.07.13 59 0 1 1 S 1 2a 1.70 1 1.04 1 
46 16 16 25.02.13 65 0 1 1 S 1 3 3.50 0 2.09 1 
47 0 0 15.11.12 80 0 1 1 S+R 1 2b 0.66 1 0.44 1 
49 18 N/A 16.02.12 57 0 0 0 S N/A 2b 4.59 0 4.59 0 
50 16 16 14.09.11 66 0 0 1 S+R+C 1 2b 5.23 0 5.23 0 
51 0 N/A 13.07.10 79 0 1 1 C N/A 2a 6.28 0 6.28 0 
52 0 N/A 23.09.09 46 1 1 1 S+R+C 1 2b 7.08 0 7.08 0 
53 0 N/A 07.09.09 58 0 1 1 S+R 1 3 0.58 0 0.58 0 
56 0 0 12.08.08 52 0 1 1 N/A 1 3 0.08 1 0.08 1 
57 0 N/A 07.08.08 73 0 0 0 S+R 1 2b 1.20 1 0.61 1 
58 16 16 16.01.14 68 1 1 1 0 0 2a 2.76 0 2.76 0 
59 0 0 13.06.16 55 0 1 0 S+R+C 1 2b 0.41 0 0.41 0 
60 0 N/A 29.07.16 57 0 1 1 R 1 2b 0.03 0 0.03 0 
61 0 0 29.08.16 59 0 1 1 S+R+C 1 2c 0.23 0 0.23 0 
24B 0 33 02.11.09 46 0 1 1 S+R+C 0 1 4.89 0 4.89 0 
Age=age at diagnosis; Gender: 1=female, 0=male; Tob=tobacco consumption (1=current or former, 0=never); 
Alc=alcohol consumption (1=current or former, 0=never); Treat=treatment: S=surgery, R=radiotherapy, 
C=chemotherapy; ECS=extracapsular spread; N=N stage; OS=overall survival; PFS=progression-free survival; 
N/A=not assessed 
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